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ABSTRACT 
Peptide microarrays are to proteomics as sequencing is to genomics. As 
microarrays become more content-rich, higher resolution proteomic studies will parallel 
deep sequencing of nucleic acids. Antigen-antibody interactions can be studied at a much 
higher resolution using microarrays than was possible only a decade ago. My dissertation 
focuses on testing the feasibility of using either the Immunosignature platform, based on 
non-natural peptide sequences, or a pathogen peptide microarray, which uses 
bioinformatically-selected peptides from pathogens for creating sensitive diagnostics. 
Both diagnostic applications use relatively little serum from infected individuals, but each 
approaches diagnosis of disease differently. The first project compares pathogen epitope 
peptide (life-space) and non-natural (random-space) peptide microarrays while using 
them for the early detection of Coccidioidomycosis (Valley Fever). The second project 
uses NIAID category A, B and C priority pathogen epitope peptides in a multiplexed 
microarray platform to assess the feasibility of using epitope peptides to simultaneously 
diagnose multiple exposures using a single assay. Cross-reactivity is a consistent feature 
of several antigen-antibody based immunodiagnostics. This work utilizes microarray 
optimization and bioinformatic approaches to distill the underlying disease specific 
antibody signature pattern. Circumventing inherent cross-reactivity observed in antibody 
binding to peptides was crucial to achieve the goal of this work to accurately 
distinguishing multiple exposures simultaneously. 
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PREFACE 
This dissertation examines fundamental aspects of antibody behavior through the 
observation of their interaction with peptide targets.  Historically, immunodiagnostics 
have fulfilled their role in healthcare by the measurement of the interaction between 
patient antibodies and select targets, whether auto-antigens, or viral, bacterial, or fungal 
antigens.  The sensitivity and specificity of diagnostics is linked to the selection of ligand, 
and the quality of the measuring assay.  The need for high sensitivity originates from the 
need to detect outbreaks, new zoonosis and animal-to-human disease transfer, 
epidemiology, and early detection of disease.  The need for high specificity originates 
from the need to discriminate closely related pathogens, or detection of new disease in 
endemic regions, or areas of numerous commonly acquired infections.  In this tome, there 
was a directed effort to cover a broad landscape of questions that directly address the 
performance of diagnostics for infectious disease, biochemically, informatically, and 
practically. 
Chapter 2 demonstrates a diagnostic application of the Immunosignature non-
natural sequence peptide microarray for diagnosing a single infection, Valley Fever (VF), 
Coccidioidomycosis.  The introduction to this chapter explores the unmet need for a more 
sensitive diagnostic for Valley Fever false-negative individuals.  The Valley Fever patient 
sera were kindly contributed by Dr. John Galgiani from the Valley Fever Center for 
Excellence at the University of Arizona. The work described here includes experimental 
data from 3 sets of non-natural Immunosignature microarrays, and compares the results.  
Experiments were done to assess whether or not Valley Fever could be distinguished 
from other fungal infections such as Aspergillus fumigatus and other confounding 
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community acquired pneumonias such as those cause by Mycoplasma pneumoniae, 
Chlamydia pneumoniae.  Upon establishing a unique signature pattern for Valley fever, 
the sensitivity of this Immunosignaturing assay was tested using serum from patients 
obtained in the early stages of the infection in the form of independent training and test 
serum sample sets. A set of 96 predictor peptides were selected for their high sensitivity 
and tested independently on a smaller ‘VF-diagnostic’ chip to verify sensitivity.  
Chapter 3 evaluates the diagnostic accuracy of using natural antigen epitopes 
peptides versus 96 non-natural VF predictor peptides as diagnostics.  These 96 non-
natural predictor peptides were selected very early in the development of 
Immunosignatures. Although pathogen epitope proteins and never-born/non-natural 
proteins are bioinformatically compared in literature, this is the first study completing 
this comparison in a diagnostic context. From our data, the 96 non-natural VF predictor 
peptides showed higher accuracy at classifying all stages of VF infection over VF-epitope 
peptides.  
Chapter 4 highlights the challenges involved when evolving a single pathogen 
diagnostic assay into a multiplexed immunodiagnostic. The assay was developed for 
simultaneous detection of 5 or more NIAID category A, B, C priority pathogens in 
fulfillment of a project supported by the Chemical Biological Technologies Directorate 
contract HDTRA-11-1-0010 from the Department of Defense Chemical and Biological 
Defense program through the Defense Threat Reduction Agency (DTRA) to Dr. Stephen 
Albert Johnston. My role in this undertaking was to evaluate the feasibility of selecting 
pathogen epitopes, both those known to bind empirically, and those predicted to bind 
from the IEDB (Immune Epitope DataBase). Based on our analysis I designed the 
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pathogen proteome peptide (PPP) microarray to represent immunodominant antigens for 
larger pathogen proteomes and complete proteomes for smaller viruses.  I examined the 
behavior of serum from infected individuals on these peptides while dissecting the effects 
of temperature and time of incubation, concentration of primary, competitors, inter-
peptide spacing on the array surface, peptide linkers, dual and single color scanning, and 
mathematical normalization methods. We developed an assay capable of distinguishing 4 
priority pathogen infections apart with >90% AUC-ROC (Area under a receiver operator 
characteristics curve). Chapter 5 summarizes the bioinformatic efforts implemented to 
circumvent cross-reactivity observed on the multiplexed PPP pathogen epitope peptide 
microarray platform.  We interpreted the cross-reactivity observed on the PPP array using 
an antibody ‘Umbrella Approach’ for bioinformatically re-attributing observed cross-
reactivity.   
The first appendix covers the observation and characterization of globular VF 
spherule-like globular objects within infected individual’s sera. Given the paucity of VF 
diagnostics, this observation might serve to enable diagnostics in this area. The presence 
of such spherule like circulating antigen-antibody complexes might pose significant 
interference on the peptide microarray’s ability to capture antibodies bound to spherules 
as noted in other antigen based diagnostics. The second appendix includes data from VF 
epitope peptides for four immunodominant antigens showing binding of patient sera at 
various IDCF titers (incremental stages) of the infection. The third appendix summarizes 
the ASFV (Pirbright, UK) and Francisella tularensis (University of New Mexico) 
projects. These were applications requiring use of a more sensitive technology such as the 
PPP array as compared to standard ELISA assays to monitoring the antibody response 
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from various genetic immunization regimes.  Serum samples for these two projects were 
contributed by Dr. Kathryn Sykes.  My contribution to the Bead Protein Array project 
originally conceived and developed by Dr. Kathryn Sykes was to experimentally 
optimize this protein microarray system for screening of infectious or vaccinated sera 
using IVTT synthesized proteins on beads.  
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CHAPTER 1 
INTRODUCTION 
Project Overview 
Through this work we explore the use of peptide microarray platforms towards 
diagnostic applications of infectious diseases. In the first phase, of this study we use a 
non-natural sequence peptide microarray platform for diagnosing a single, specific 
infection, Valley Fever caused by Coccidioides. In the second phase, in contrast we used 
a natural sequence peptide array as a multiplexed array platform capable of 
simultaneously discerning 5 or more infections. While most of the work presented in this 
dissertation has diagnostic applications, it answers several fundamental questions about 
antigen-antibody kinetics as observed in the context of an infectious response. 
Peptide microarray as clinical diagnostics 
Peptides are useful reagents for characterizing the humoral immune response to 
disease.  Antibodies respond to a number of different types of antigens including linear 
and non-linear proteinaceous targets, polysaccharides and glycopeptides, phosphorylated 
proteins, and other biological molecules.  Peptides can simulate the physico-chemical 
structure of many of these targets (mimotopes), creating a systematic one-stop-solution 
for probing antibody behavior.  Technologies that rely on proteins as probes are varied 
[1]:  bead based immunoassay (Luminex, Austin, TX), mass spectrometry (Ciphergen, 
Fremont, CA), surface plasmon resonance (Biacore, www.biacore.com), protein 
microarrays (Zeptosens-Witterswil, Switzerland; ProtoArray-Life Technologies), electro-
 2 
 
osmotic micro-fluidic LabChip (Calipertech, Hopkinton, MA), surface acoustic waves 
based micro-fluidic assays (Advalytix, Brunnthal, Germany), micro-cantilever 
measurement (Protiveris, Rockville, MD), but most widely used have been peptide 
microarrays: PEPperPRINT-Heidelberg, Germany; CombiMatrix-Mukilteo, WA; 
Immunosignaturing [2].  Microarrays enable thousands of peptides to be assayed 
simultaneously under identical assay processing conditions. Many groups have developed 
pathogen antigen based peptide microarrays diagnostics for specific infections such as 
Tuberculosis [3,4], Echinococcus spps. [5] and SARS [6,7]. The antibody response 
mapping strategy as outlined by these groups involves testing patient sera in comparison 
to normal donor sera. Using tiled regions of proteins, researchers have precisely 
identified small portions of proteins that correspond to the eliciting antigen [8].  
Immunosignaturing is a novel microarray platform as compared to pathogen antigen 
based peptide microarrays because it uses non-natural peptides to capture antibody 
response [2,9,10]. This technology has led to fundamental breakthroughs in 
understanding antigen-antibody interactions that could potentially be used for medical 
diagnostics [11-13]. 
Advantages of using peptide microarrays 
A significant advantage of using peptide microarrays is their ability to partition 
and measure separately, specific portions of an antibody response. The resolution of these 
responses captured on peptide microarrays can be traced down to the eliciting antigen 
fragments. In comparison, protein based ELISA’s or protein microarrays merely allow 
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capturing a cumulative sum of antibodies against entire proteins. Unlike certain protein 
microarrays another advantage of using peptide microarrays is the minimal test sample 
preparation and lack of complex blocking steps required during sample processing. For 
example, in Escherichia coli based in-vitro translation and transcription (IVTT) protein 
microarrays, test sera is blocked using E. coli lysate to exclude false-positive reactivity to 
E.coli proteins within the IVTT protein mixture [14]. E.coli reside within the human gut 
microbiome comprising a 100 trillion microorganisms [15] classified under phyla: 
Bateriodetes, Firmicutes and Actinobacteria [16]. Golby et al. [17] observed preliminary 
evidence for B-cell development in human fetal intestinal cells using 
immunohistochemistry studies. Additionally, recent evidence in mice suggests that 
bacteria within the gut microbiome might be capable of influencing B-cell development 
and immune response in the mouse intestine [18]. Given that the antibody response to E. 
coli residing in the intestine might be part of the primary immune response in humans, it 
would not be advisable to exclude this anti-E.coli protein lysate signature when 
attempting to capture pathogen specific antibody reactivity using microarrays. Peptide 
microarrays do not require biasing the observable infectious antibody response by 
including such high complexity sample preparation steps. Additional advantages of 
peptide microarrays are their ability to tile continuous fragments of proteins to 
characterize monoclonal antibody reactivity with higher resolution than is possible with 
protein microarrays. Peptides are easier and less expensive to produce in comparison to 
proteins through IVTT. Considering these significant advantages, it would be prudent to 
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apply peptide microarrays to diagnose and distill the complex immune response observed 
in chronic infectious diseases such as Valley fever.  
Project I: Valley Fever Immunosignaturing diagnostic 
Coccidioidomycosis (Valley Fever) is caused by a dimorphic fungus that grows in 
the southwestern desert regions of United States and Central and South Americas. The 
two genotypically variant strains are C. immitis found in California and C. posadasii 
found outside California. The disease is caused by inhalation of the spores called 
Arthroconidia and manifests initially with pneumonia-like symptoms due to the mode of 
entry being lungs. The disease is most prevalent in the states of Arizona, California, 
Nevada and New Mexico and infects more than an estimated 150,000 [19] people in the 
United States every year. 
Symptomatically, Valley Fever (VF) infection is very difficult to diagnose in the 
early stages as several of its symptoms are confounded with those of most community 
acquired pneumonias (CAP) such as tuberculosis. Approximately 60% [20] of Valley 
Fever cases are from the state of Arizona and therefore the Arizona Department of Health 
Services (ADHS) initiated an enhanced surveillance scheme for Valley Fever. ADHS 
conducted an interview based survey of 493 patients out of the 4,832 total patients 
diagnosed with Valley Fever in 2007 as part of their enhanced surveillance initiative [20]. 
They outlined several reasons for delays in the diagnosis of Valley Fever. Patients wait 
for 44 days on an average before seeking care. Another reason for delay was also lack of 
uniform awareness about the disease and treatment modalities among both physicians as 
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well as patients. From the physician’s perspective this might be due to the commonality 
of symptoms elicited by Valley Fever in comparison with other community acquired 
pneumonias. On an average Valley Fever patients visited physicians about 3 times before 
they were even tested for Valley Fever. If patients are made aware of the possibility of 
being infected due to living in an endemic region, they would perhaps not wait so long 
before seeking medical care and would even request being tested for Valley Fever. Valley 
Fever alone is known to account for $86 million in hospital charges in Arizona in the year 
2007 [20]. 
As per the CDC Summary of Notifiable Diseases in 2011 [21], 22,634 total cases 
of coccidioidomycosis were reported. Partly this number is much smaller than the 
estimated 150,000, as, in Arizona, one third [20] of the physicians were not aware that 
Valley Fever is a reportable disease and this might be the case with physicians from other 
non-endemic locations as well [22]. Also, a majority of the cases that are reported belong 
to the 40% in whom the infection does not self-resolve, thereby obscuring data from the 
remaining 60% people exposed. As per the CDC, 30-60% [23] of people living in regions 
endemic for Valley Fever will have been exposed to it. The total population of the 4 main 
states endemic for Valley Fever, namely: Arizona, California, New Mexico and Nevada 
obtained from US Census Bureau figures is approximately 49.4 million [24]. Just 30% of 
this value, 14.8 million people, as per CDC estimates would be exposed to Valley Fever 
in these endemic states.  
Current diagnostics available for this disease primarily use antibody based in-
direct methodologies such as immunodiffusion, whereby, the patients’ serum is tested for 
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the presence of IgM and IgG antibodies to major Coccidioidal antigens CF and TP. The 
problem with this technique is false negatives: approximately 5% [25] of patients [both 
immuno-compromised and immuno-competent] suffering from Valley Fever do not show 
detectable levels or even presence of antibody in their sera. A good prognosis in 
Coccidioidomycosis is when a person elicits a cell mediated immune response against the 
infection [26,27]. Sixty percent of the patients, in whom the infection is contained within 
the lungs or resolves by itself, show almost non-detectable antibody levels (by ELISA or 
Immunodiffusion) to Coccidioidal antigens. But Coccidiodes may only be contained in 
these patients’ lungs instead of being completely destroyed by their immune system and 
so the infection might recur when the patient is later in an immunocompromised state 
[26]. An antibody mediated (humoral) response is usually seen in individuals in whom 
the infection does not resolve on its own and instead disseminates. 
An alternative to this is direct detection via culturing the organism in the 
laboratory from the patients’ body fluids. However, this involves the potential risk of 
exposing the technicians to the infectious form of this fungal pathogen. Since Valley 
Fever is primarily a lung infection, a chest x-ray showing either a cavity or a patch of 
infection in the lung is followed by a nasopharyngeal wash or surgical computed 
tomogram [CT] guided lung biopsy to retrieve a sample for culturing and Hematoxylin-
Eosin staining. Both culturing and CT guided biopsies are technically cumbersome 
procedures. In an effort to avoid these invasive and potentially risky procedures, we 
propose utilizing the peptide microarray platform to ascertain a specific signature pattern 
for the early detection of Valley fever separating it from other CAPs such as tuberculosis. 
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This would help detect the infection in the 60% of people in whom the primary infection 
resolves without showing detectable antibody levels in their serum, but might latently 
recur. If patients knew they were exposed, they could make informed decisions with their 
physicians about clinical procedures requiring suppression of the immune system. 
The current alternative commercial diagnostic efforts include using nucleic acid 
amplification of Coccidioidal DNA from sputum samples through Polymerase Chain 
Reaction [28], microarray based whole genome level Comparative Genomic 
Hybridization (aCGH) technology [29] and utilizing the BacT/ALERT® [30] automated 
microbial detection media system. All these technologies do not detect early infection 
and have also not been proven to detect latent infection. The immunosignature, non-
natural peptide microarray technology [9] might surpass both these limitations, paving 
the way towards accurate and early diagnosis of Valley Fever. 
The scope of my dissertation is to ascertain the humoral immune response pattern 
that is specific for Coccidioidomycosis from IgG and IgM antibody interaction in VF 
patient sera with randomly generated (non-natural, Chapter 2) and epitope (from 
Coccidioides, Chapter 3) antigen peptides spotted on a peptide microarray platform. 
Experiments designed to examine presence and absence of classes of Coccidioides 
specific immunoglobulins were conducted in order to completely characterize the 
spectrum of patient sera we would be likely to encounter in a clinical setting. Chapter 3 
compares the diagnostic performance of non-natural sequence (random-space) VF-
predictor peptides with VF-antigen epitope peptides (life-space) to evaluate the feasibility 
of using either life versus random space diagnostic peptide reagents. Several efforts to 
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chemically characterize and classify random (never-born proteins) apart from natural 
protein sequences have been conducted in-silico [31,32]. A side by side comparison of 
non-natural versus life-space epitopes within a diagnostic context has not been previously 
reported. Through data from this work, a bioinformatic modulation to the Smith-
Waterman [33] local sequence-alignment algorithm termed ‘di-peptide inversion’ was 
suggested and implemented within GuiTope [34], an alignment program from our lab. 
This significantly improved GuiTope’s accuracy at finding alignments between natural 
VF pathogen proteins and the non-natural sequence antibody capturing VF-predictor 
peptides from the immunosignaturing platform. Platform optimization expertise obtained 
through this project was applied to the second project involving creation of a multiplexed 
peptide microarray platform for simultaneous detection of multiple priority pathogen 
infections. 
Cross-reactivity observed in peptide microarrays 
Antigen-antibody cross-reactivity is a salient feature of all immunodiagnostics 
and peptide microarrays are no exception to this rule [35]. Unlike single pathogen 
diagnostic peptide microarrays distinguishing infectious sera from uninfected sera, Felger 
et al. [5] tested their Echinococcus specific peptide microarray platform against other 
symptomatically confounding nematode infections. The peptide array was developed to 
discriminate between Echinococcus species: multilocularis and granulosus. 45 peptides 
from 6 proteins of the pathogens showed 94% specificity and 57% sensitivity, but overall 
these peptides were not effective at differentiating between the two species. Andresen et 
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al. [36] tested a 900 peptide microarray for simultaneous distinction of viral infections 
from phylogenetically related Herpes & Hepatitis C virus genotypes. CMV and EBV 
patient sera showed appropriate reactivity on their assay but Hepatitis C virus infected 
sera showed broad cross-reactivity.  
Another cross-reactive result obtained when using peptide microarrays was by 
Maeurer et al. [3] on their 7446 peptide microarray representing 12-mer overlapping 15-
mer (total length) peptides from 61 Mycobacterium tuberculosis proteins. The authors 
observed 3 patterns of patient serum IgG reactivity to peptides on the array including a 
set of 89, TB-specific peptides, capable of distinguishing TB-positive from TB-negative 
individuals. Additionally, they observed 24 TB-sensitive peptides exclusively reacting 
with TB positive patient sera but not with normal TB sero-negative sera. And, a set of 13 
peptides from M. tuberculosis exclusively recognized by only normal TB-negative 
(Quantiferon assay negative) individuals’ sera but are not recognized by TB positive 
patients sera. When performing a BLAST search of these 13 peptides for possible 
matches with the human proteome, several potential matches were identified due to 
sequence level similarities. A working hypothesis is that the innate overlap between the 
host (human) and pathogen proteomes create natural self (host)-reactive targets that react 
to identical sequences found in pathogens. Whether this could be interpreted as low level 
auto-immunity or these antibody reactivities are due to mimotopes from other 
environmental non-pathogenic Mycobacteria as originally proposed by the authors, is 
speculative in the absence of previous immune exposure history from these patients. 
Obtaining orthogonally characterized sera with detailed annotation regarding previous 
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vaccinations/infection histories would have benefitted such a study by helping resolve 
cross-reactivity observed to M. tuberculosis peptides from uninfected individuals. 
Lo et al. [6] attempted to circumvent potential cross-reactivity observed on 
peptide microarrays between phylogenetically related pathogens by selecting 27 peptides 
that were specific only to the SARS-CoV (Severe Acute Respiratory Syndrome-
Coronavirus) and not to other Coronaviruses or the human and mouse proteomes on a 
sequence level (BLAST analysis). This array was only tested against SARS infected 
versus not infected patients and not against serum from other closely related 
Coronaviruses to prove the specificity of their SARS specific peptides and justify using 
informatics intervention during peptide selection. Such an approach, of making single 
pathogen specific diagnostics using peptide microarrays is typically adopted to 
circumvent possible cross-reactivity on these assays. Due to high cross-reactivity 
observed in peptide microarray data, none of these groups have attempted multiplexing 
the diagnosis of more than one infection on the same chip/ microarray platform. 
Multiplexed diagnostics for human pathogens and bio-threat agents 
Serum based multiplexed diagnostics are implemented using technologies such as 
multiplexed ELISA’s, protein and peptide microarrays and microsphere immunoassay 
(MIA). A commercial example of a multiplexed ELISA is the ToRCH screen for 
measuring antibody reactivity in pregnant mothers against 7 vertically transmitted 
infections [37]. The infections tested are Toxoplasma gondii, Rubella virus, 
Cytomegalovirus (CMV), Herpes simplex virus (HSV) type 1 and 2, Varicella zoster 
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virus (VZV), Chlamydia trachomatis with variable IgG sensitivity per pathogen ranging 
from 46% (HSV2) to 97% (VZV) and specificity ranging from 88% (T. gondii) to 100% 
(VZV, Rubella, CMV). 
Apart from clinical diagnostic applications, multiplexed diagnostics are also 
needed for biothreat agents. Biothreat surveillance is important not only from a national 
perspective but also more pertinent to armed forces personnel being deployed in unsafe 
territories. Microbial biothreat pathogen lists from various regulatory organizations help 
prioritize exposure to pathogens based on their weapon potential and the severity of 
symptoms they are capable of causing in their hosts. The National Institute of Allergy 
and Infectious Diseases (NIAID) category A, B, C priority pathogen list [38] includes 
primarily deadly encephalitis viruses and pathogens with a high weaponization potential 
such as Bacillus anthracis in category A. Category B includes pathogens acquired of 
transmitted via food or water and Category C includes pathogens causing newly emergent 
infectious diseases. Over time these might get re-classified depending on their 
weaponization potential or change in virulence to increase severity of symptoms. Other 
priority pathogen lists are from U.S. Department of Health and Human Services (HHS) 
and U.S. Department of Agriculture (USDA) [39]. Some priority pathogens from the 
NIAID list overlap with the HHS and USDA lists, but the USDA list primarily has 
zoonotic pathogens potentially capable of infecting humans such as the African Swine 
Fever Virus (ASFV) virus [40]. The preliminary evidence for this indication came from a 
pyro-sequencing study where Loh et al. [40] found ASFV-like sequences in human 
serum from individuals having an acute febrile illness (AFI) in the Middle East and in 
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multiple sewage samples from Barcelona, Spain. Although the source of the sewage 
samples could not be identified specifically as being from human or animal origin, the 
geographic distance between these two observations was alarming enough to add ASFV 
to the HHS & USDA priority pathogen lists. 
The CDC recently developed a Luminex based microsphere immunoassay (MIA) 
simultaneously distinguishing 13 viruses listed as biothreat agents from viral families of, 
Bunyaviridae (LaCrosse encephalitis-LAC), Togaviridae (Eastern equine encephalitis-
EEE, Western equine encephalitis-WEE, Venezuelan equine encephalitis-VEE, 
Chikungunya-CHIK, Mayaro-MAY, Ross river virus-RR) and Flaviviridae (West Nile 
virus-WNV, Japanese encephalitis virus-JEV, Dengue-DEN, Yellow fever virus-YFV, 
St. Louis encephalitis-SLE, Powassan-POW) [41]. Using the LogitBoost algorithm their 
cross-validated average error rate was 8.3%. In their assay, Luminex Microplex 
(Luminex Corporation, Austin, TX) carboxylated microspheres are coated with 
commercially available anti-virus monoclonal antibodies. Viruses are generated by either 
inoculating suckling mouse brains or expressed in-vitro using recombinant vectors in 
monkey kidney fibroblast-like COS-1 cells. The viruses are then incubated with the 
monoclonal anti-viral antibody coated microspheres to allow capturing and surface 
presentation and generate a sandwich ELISA once incubated with the patient sera. The 
drawback on this assay is its requirement of unstable reagents with a shelf-life of 6 
months the handling of which needs to be monitored due to them being biothreat agents. 
These drawbacks hinder the deployability of this assay to local reference laboratories, 
requiring that samples be shipped to CDC for evaluation, delaying diagnosis. Peptide 
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microarrays on the other hand are more stable, they can be stored at room temperature 
[42] and have a shelf-life after printing can be >1 year [43,44] making them easily 
deployable to even local reference laboratories, utilize a fraction of the sample used in 
MIA’s (1:500 vs. 1:20) and represent only short sequences of biothreat agent proteomes, 
assay processing not needing supervision. The detection limit of technologies such as 
Luminex assays is 1-10 pg/ml [45].  
Alternative biothreat detection technologies such as multiplexed PCR’s and 
assays using B-cells as sensors (CANARY) [46] fall under the category of direct 
detection of pathogen instead of detecting the immune response raised by them in hosts. 
The LLMDA – Lawrence Livermore Microbial Detection Array [47,48], PathChip [49], 
GreeneChip [50] and ViroChip [51] are examples of multiplexed PCR’s. The LLMDA 
contains 388,000 probes containing 38,000 viral sequences from ~2200 viral species and 
3500 bacteria sequences representing approximately 900 different bacterial species. The 
PathChip contains approximately 170K probes and is capable of recognizing all known 
viral pathogens. The diagnostic accuracy of this assay from testing 290 pediatric nasal 
wash samples was 85.9% for Rhinoviruses or Enteroviruses and for 98.6% Parainfluenza 
virus 2. 
An antigen detection B-cell based sensor named CANARY- cellular analysis and 
notification of antigen risks and yields [46] for rapid identification of pathogens can 
detect as little as 50 CFU/50 µL of Yersinia pestis, 1000 CFU of Bacillus anthracis in 1 
ml of extraction medium, 500 CFU/50 µL of Escherichia coli (O157:H7) in contaminated 
lettuce (25 g), 500 PFU/50 µL of Vaccinia virus and 5X105 PFU/50 µL of Venezualan 
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encephalitis virus (VEE) virus. While the shelf-life of reagents required for CANARY is 
low at room temperature (RT), 2 days; prepared cells can be refrigerated for up to 2 
weeks and frozen for longer time periods. An alternative to antigen-antibody detection 
based assays would be sequencing the complementarity determining region (CDR) of 
antibodies within an infected individual’s serum to decode the antigen/pathogen they 
were raised against [52]. This technology however is cumbersome and not yet easily 
deployable in local laboratories. 
Cross-reactive components of the humoral antibody response to an infection 
The humoral antibody response in humans when responding to an 
infection/exposure could be classified into the primary and secondary adaptive immune 
response. The primary response comprises of natural antibodies, circulating antibodies 
generated through memory responses against prior exposures/ vaccinations. The 
secondary adaptive immune response is the component of humoral immunity generated 
specifically as an adaption to the new exposure. Understanding the antibody 
subcomponents is critical to creating antibody based diagnostics so as to a priori 
circumvent cross-reactivity by intelligent design of the assay. Slifka et al. [53] monitored 
the antibody response from 45 individuals for 26 years, collecting 630 serum samples 
total. They measured antibody responses to 8 pathogens, 6 being part of vaccinations e.g. 
Measles, Mumps, Rubella-MMR vaccine, Vaccinia virus (smallpox vaccine), Diphtheria 
(Corynebacterium diphtheriae) and the tetanus toxoid (Clostridium tetani). The annual 
percent change using longitudinal mixed-effects model was determined to derive the 
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antibody-half life (in years). Tetanus toxin and Diphtheria toxin had short half-lives (11 
& 19 years respectively). The half-lives of the remaining exposures ranged from 50 years 
for Varicella zoster virus to 11,552 years for Epstein Barr virus (EBV). They concluded 
that most childhood prophylactic vaccine exposures left behind circulating antibodies that 
could be detected throughout the life of these individuals tested with negligible change in 
the concentration over time. In addition to these vaccinations, Palese et al. [54] 
demonstrated through longitudinal characterization of the influenza antibodies within 40 
individual’s sera monitored for 20 years obtained through the Framingham Heart Study 
that the neutralizing antibody titers against several influenza virus strains increased over 
time. Apart from influenza they measured CMV antibodies and noted negligible change 
in anti-CMV titers within exposed individuals.  
The population prevalence estimates between 1999-2004 (age: 6-49 years) of 
CMV in United States is 50.9%, with sero-positivity in certain counties such as Los 
Angeles being higher at 69.7%.; and that among certain ethnic minorities such as 
Mexican American individuals residing in LA being 79.7% [55]. Palese et al. chose to 
measure the antibody reactivity to CMV due to the antigenic stability of this virus as 
compared to influenza and its higher prevalence within the general population. Other 
pathogens showing notable sero-prevalence within the population are Varicella (96%), 
Rubella (91.2%), Mumps (90%), Measles (95.9%), HSV-2 (17.3%), HSV-1 (58.1%), 
Hepatitis A virus (35.9%), Toxoplasma gondii (11%) [55]. Given the high prevalence of 
these exposures and their ability to leave behind a memory response with circulating 
antibodies observed throughout an individual’s lifetime, developing a sensitive diagnostic 
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capable of distinguishing all known human pathogens simultaneously becomes 
challenging. Sensitive technologies such as peptide microarrays are capable of measuring 
these interfering memory antibody responses, leading to interference observed with the 
signature of a given infection. Such as effort would require the use of data analysis 
techniques allowing for discerning more than one exposure simultaneously so as to 
distinguish the inseparable matrix of prior exposure related antibody reactivity versus the 
most current exposure and compensate for cross-reactivity observed on these platforms. 
Project II: Multiplexed priority pathogen proteome peptide array 
This work is aligned with a DTRA (Defense Threat Reduction Agency) funded 
project (Grant# HDTRA1-11-1-0010) which involves development of a scalable 
technology so as to monitor the exposure of military personnel to NIAID Category A, B, 
C Priority biothreat pathogens. The first task of this proposed work involves generation 
of a 100K random peptide silicon chip, the proprietary technology for which could later 
be used if needed to create a 1 million peptide feature chip so as to represent all known 
human pathogen proteomes. The second milestone required the production and 
evaluation of a 10K peptide prototype pathogen proteome array capable of distinguishing 
between five or more infectious bio-threat agents simultaneously in a multiplexed assay. 
This work required testing the feasibility of such a system, designing peptide candidates 
to be tested on the microarray, thermodynamically and physically optimizing array 
configuration and testing the platform, bioinformatically assessing the expected versus 
actually observed peptide antigen-antibody cross-reactivity from sera for evolutionarily 
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related and unrelated bio-threat agents. The pathogens selected to be represented on the 
array were based on infectious serum availability. Their epitope selection strategy and 
thermodynamic considerations while optimizing the assay to reduce cross-reactivity are 
explained in greater detail in Chapter 4. An analysis pipeline specific to the multiplexed 
pathogen proteome peptide array was created by combining eight statistical metrics. A 
novel aspect of this work was observing a reduction in assay accuracy after adding 
influenza peptides along-side priority pathogen peptides.  The addition of Influenza 
peptides required a change in the data-analysis strategy adopted previously and is detailed 
in Chapter 5. The antibody cross-reactivity observed after including influenza peptides 
required mapping the ‘umbrellas of antibody reactivity’ down to an n-mer (peptide sub-
sequence) level in an attempt to circumvent cross-reactivity and detect the cognate 
infection. 
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CHAPTER 2 
APPLICATION OF IMMUNOSIGNATURES TO DIAGNOSIS OF VALLEY FEVER. 
Abstract 
Background   
Valley Fever (VF, Coccidioidomycosis) infection is difficult to diagnose based on 
symptoms in part because of the similarity to community-acquired pneumonias (CAP).  
Confirmatory diagnostics detect IgM and IgG antibodies against Coccidioidal antigens 
via Immunodiffusion (ID).  However, the false negative rate using ID can be 50-70% and 
5% of symptomatic patients never show detectable antibody levels at all.  Here we test 
the capability of the immunosignature diagnostic to resolve the false negative diagnostic 
problem for VF.  Immunosignatures are developed from arrays of non-natural-sequence 
peptides. Blood antibodies bind to the arrays to create disease specific signatures. 
Methods  
A 10,000 peptide array was used to determine if VF infection produced signatures 
distinct from 3 other infections.  A similar array was used to distinguish VF infection 
from non-infection in a training/test set format. The signature peptides from the 10,000 
peptide array were used to design a smaller VF-specific array of 96 select peptides. The 
performance of the 10,000 peptide array and the 96 peptide array were compared to the 
ID diagnostic standard. 
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Results  
The 10,000 peptide array classified the VF samples from the other 3 infections with 98% 
accuracy.  The array was also able to classify all the VF, ID negative patients versus non-
infected controls with 100% sensitivity in a blinded test set. The sensitivity of ID on the 
test set was 28%. In comparison the 96 peptide array performed with 82% sensitivity on 
the same sample sets. 
Conclusion 
The immunosignature diagnostic can be used to simultaneously distinguish VF infections 
from a fungal and two other bacterial infections. The same array can diagnose with 100% 
sensitivity the clinically important ID negative patients.  A smaller 96 peptide array was 
less specific in diagnosing the ID negative patients. We conclude that by training using a 
clinically confounding sample set a robust immunosignature diagnostic could be 
developed to be used in combination, or possibly in lieu of, the existing diagnostics.  
Abbreviations 
BSL, Biosafety level; CAP, community acquired pneumonia; CF, Complement Fixation; 
CNS, Central Nervous System; CT, Computed Tomography; EIA, Enzyme 
Immunoassay; ID, Immunodiffusion; IDCF, Complement fixation antibodies detected by 
Immunodiffusion; IDTP, Tube precipitin antibodies detected by Immunodiffusion; KNN, 
K-nearest neighbors; LVS, Live Vaccine Strain; subsp, Sub-species; LDA, Linear 
Discriminate Analysis; LOOCV, Leave One Out Cross Validation; NPV, Negative 
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predictive value; PPV, Positive predictive value; TP, Tube Precipitation; TB, 
Tuberculosis; VF, Valley Fever. 
Introduction 
Coccidioidomycosis, commonly known as Valley Fever (VF), is caused by a 
fungus Coccidioides immitis (California strain) or C. posadasii found in the arid soil of 
the southwestern desert regions of United States and South America. Human disease is 
caused by inhalation of the arthroconidia (spores) of the fungus, and presents primarily 
with flu-like symptoms or, progressively, pneumonia.  VF affects an estimated 150,000 
[19] people in US every year, primarily in the states of Arizona [56], California [57], 
Nevada, New Mexico and Utah.  A major problem in the management of the disease is 
the failure of detection (sensitivity) in 30% of the infected individuals. We have tested 
whether a new diagnostic technology, immunosignatures, could address this problem. 
Sixty percent [26] of the VF exposed individuals are either asymptomatic or have 
mild symptoms with the infection usually being self-limiting. The remaining 40% [58] of 
exposed individuals demonstrate symptoms such as skin rash and respiratory ailment 
lasting from months to years.  In 5-10% [26,59] of these, infection disseminates, affecting 
other organs, skin, bones and nervous system. Individuals from non-Caucasian ethnicities 
[19] such as African Americans, Filipino and Asians and 65 years or older, pregnant 
women and patients with immunocompromised immune systems are more susceptible to 
VF and particularly the disseminated form of the disease.  As per Arizona Department of 
Health Services (ADHS), VF patients visit physicians on average three times before they 
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are tested for VF, more so if patients visiting AZ from non-endemic regions are 
diagnosed by physicians unacquainted with diseases of the American Southwest [60].  
VF alone is known to account for $86 million in hospital charges in Arizona in the year 
2007 [60], and an unestimated amount in states outside AZ. 
The confirmatory diagnostic test for VF is an immunodiffusion (ID) assay 
detecting antibodies against antigens within fungal coccidioidin causing complement 
fixation (CF) and tube precipitation (TP).  Coccidioidin is a culture filtrate of the 
mycelial form of C. immitis, the heat treated portion of which is used to detect IgM 
antibodies, and the untreated portion is used to detect IgG antibodies [61].  The 
sensitivity of IDCF is 77% and IDTP is between 75-91% [62].  An  alternative is to 
culture the organism from body fluids or tissue, but a concern is infection of technicians 
[63].  Although, culture is a preliminary diagnostic for pneumonias, the sensitivity of this 
approach for VF ranges from 23-100% depending on clinical status [64]. The recovery 
rate of this pathogen through culture ranges from 0.4% from blood to 8.3% from 
respiratory tract specimens [65].  As noted the most clinically pressing issue is the low 
sensitivity of these diagnostics as primary tests. 
We propose utilizing the immunosignature diagnostic technology [11] to address 
some or all the limitations of current diagnosis of VF, particularly as a diagnosis for 
patients misclassified at the first test.The immunosignature technology utilizes a high-
density array of non-life-space peptides to provide mimics of epitopes, for even 
discontinuous epitopes or non-protein antigens. In this report the arrays consist of 10,000 
peptides whose sequences were chosen from random sequence space.  The peptides are 
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20 amino acids long with 17 variable positions and 3 constant at the attachment end.  As 
opposed to single antigen ELISA-based assays, the disease-specific signature signal in an 
immunosignature comes from multiple peptides that form a distinct, disease-specific 
pattern of antibody binding. Most antibody based immunological tests examine the 
presence of new antibodies in infected individuals.   
An immunosignature can actually display both, the presence of new antibodies 
relative to infection or chronic disease, but also any suppression of antibodies (measured 
as loss of signal) that were commonly present in healthy controls reflecting memory 
responses to vaccinations and common pathogen exposures.  An immunosignature, unlike 
many genetic or immunological tests, is both sample sparing and robust to sample 
handling [66]. Because the sensitivity of an immunosignature is higher than that of 
ELISA-based serological tests [10,11], and disease discrimination is possible on the same 
array across multiple infectious diseases, we asked whether the platform was suited to be 
used as a VF, disease-specific diagnostic.  VF diagnosis frequently results in false 
negatives, resulting in late recognition of the disease [67-69], adversely affecting patient 
outcomes.  We therefore proposed a series of tests to characterize whether an 
immunosignature assay performs better than existing diagnostics for detecting VF.  We 
postulate this assay would detect VF earlier and with a greater sensitivity and at lower 
cost than conventional methods. Here we report testing this possibility. The ability of 
immunosignatures to distinguish VF from 3 other infections was tested. The same array 
was used to test the ability to discern ID negative patients from non-infected controls.  
The effect of reducing the number of peptides to a smaller array was also evaluated.  
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Methods 
Serum samples used in this study 
All patient sera used in this study are listed in Table 2- 1.  
Table 2- 1 Patient sample cohorts per infection utilized in this study 
No. Infection No. of patients No. of samples 
Confounding infection pilot study 
1 Aspergillus 20 20 
2 Chlamydia 20 20 
3 Mycoplasma 19 19 
4 Normal 31 31 
5 VF-Training set 18 18 
Valley fever patient sera with non-VF controls 
1 VF-Training set (U of A) 35 55 
2 VF-Test set (U of A) 25 67 
3 Normal individuals (ASU) 41 41 
4 
Influenza vaccinees (2006-
2007-seasonal vaccine) (ASU) 7 7 
 
Confounding infection samples   
For the experiment testing different infections, patient sera representing 19 
Aspergillus fumigatus, 19 Mycoplasma pneumoniae and 19 Chlamydia pneumoniae were 
processed alongside 18 VF and 31 normal sera on the 10,000 peptide microarray.  The A. 
fumigatus, M. pneumoniae and C. pneumoniae samples were acquired from SeraCare 
Life Sciences (Gaithersburg, MD) and were tested by commercial ELISA tests for 
presence of antibodies to respective infections by SeraCare (Supplementary Table 2- 1). 
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Valley Fever and normal donor serum samples used in this study  
A training cohort of 55 samples and a blinded test set of 67 samples were 
obtained as de-identified human patient sera from John Galgiani at the University of 
Arizona (IRB# FWA00004218).  Non-disease sera included 7 influenza vaccine (2006-
2007) recipient sera ‘pre-vaccine’ and ‘post-vaccine’ plus 41 locally obtained healthy 
donor samples (ASU IRB 0905004024) which were used to ensure specificity.  
Following submission of our classification results to J. Galgiani, the test set was un-
blinded and revealed to contain 25 patients with two or more serum samples collected 
longitudinally per patient during subsequent clinic visits.  For each patient in the test 
cohort the initial sample was measured as having a zero-titer (negative) on IDCF but 
sero-converted at a later date as the infection progressed.  All samples were serologically 
characterized by J. Galgiani’s laboratory for IDCF and IDTP titers.  Table 2- 2 and Table 
2- 3 describe the patients CF titer distribution in training and test cohorts respectively.  
Table 2- 2 Diagnosis (IDCF) of 55 unique patient samples from the VF training cohort 
CF 
Titer 
# 
Samples 
0 6 
1 4 
2 8 
4 5 
8 3 
16 8 
32 11 
64 5 
128 3 
256 2 
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Table 2- 3 Diagnosis (IDCF) of 67 blinded samples from the VF test cohort. 
CF 
Titer 
# Samples 
(# patients) 
0 48 (25) 
1 5 (4) 
2 7 (7) 
4 3 (3) 
8 1 (1) 
16 2 (2) 
32 1 (1) 
 
Blinded test patient sample set 
The test sample set includes 25 patients with two or more serum samples per 
individual, for a total of 67 samples.  24 of these symptomatic patients had an IDCF titer 
of zero and were given a negative diagnosis for VF after their first clinic visit.  All 24 
patients returned to the clinic for a follow-up appointment between 7 and 27 days and 
blood samples were drawn for the second time at which point 12 of them were still sero-
negative on the IDCF test.  Of the 12 IDCF negative patients only 6 returned for the third 
follow up visit due to continued symptoms and 6 others returned either for monitoring of 
increasing CF titers or re-testing due to a positive IDTP result.  The time interval for the 
third visit ranged between 4 and 159 days after the second visit.  Four of these patients’ 
samples were drawn again between 96 and 147 days at which time a verified IDCF titer 
was observed in 2 patients who were given a positive VF diagnosis.  One symptomatic 
patient returned for a fifth visit and remained negative on both the IDCF and IDTP tests 
113 days later despite being symptomatic for Valley Fever. 
 26 
 
Microarray production and processing 
The 10,000 (10K) non-natural sequence peptide immunosignature array and the 
96 peptide ‘VF diagnostic’ arrays were produced and processed as described in Legutki 
and Stafford et al. [2,11]. Briefly, the peptides are spotted onto standard slides using a 
piezo-electric printer.  The average spot diameter is ~140µm.  The slides are washed with 
buffer and the serum (diluted 500-fold in buffer) is applied to the array for 1hr. It is then 
washed with buffer and the antibody binding pattern determined by incubation with a 
secondary to human IgG antibody.  The 16-bit 10µm TIFF images from the Agilent ‘C’ 
scanner were aligned using GenePix 6.0 software (Axon Instruments, Union City, CA) 
and the data files imported into GeneSpring 7.3.1 (Agilent, Santa Clara, CA) and R [70] 
for further analysis.  Each training patient sample was processed in triplicate on the 10K 
array. The 10K array data was median-normalized per chip and per feature.  Any array 
with a Pearson Correlation Coefficient less than 0.80 across technical replicates was re-
processed. Patient samples were excluded from further analyses if they consistently 
produced extremely high background and/or consistently failed to provide reproducible 
results across technical replicates, suggesting serum degradation. 
Statistical classification of disease groups   
The statistical classification of disease groups was done using Naïve Bayes from 
the R ‘klaR’ package [71] combined with the Leave one out cross validation (LOOCV) 
and Holdout algorithm as implemented in the R package ‘DMwR’ [72].  Testing the 
classifier was done using a data-holdout experiment where training and test datasets are 
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combined and 70% of randomly chosen data is used to train and predict on the remaining 
30% dataset.  This procedure is repeated 20-times to ensure every sample was predicted 
more than once by training on multiple combinations of other samples..  The evaluation 
of diagnostic metrics such as sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy of the CF-Titer test based on its 
performance on our specific patient sample set are reported alongside for comparison 
purposes. 
Statistical classification of confounding infections 
To assess if the random peptide microarray could specifically distinguish multiple 
confounding infections, samples were processed on the 10K random peptide array under 
similar assay conditions as before. Six different slide batches were used to process these 
sera and ComBat normalization was applied to median normalized data to eliminate 
differences between samples due to batch effects. [73,74]  243 random peptides capable 
of distinguishing between the five classes namely, VF, Aspergillus, Mycoplasma, 
Chlamydia and Normal were selected using Fisher’s exact association test as 
implemented in GeneSpring GX 7.3.1. Since a physically separate training and test 
dataset were missing for this analysis, the stringent holdout cross-validation as 
implemented in R package ‘DMwR’ was applied to the training dataset as described 
previously [72].  
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Results 
Valley Fever immunosignature is distinct from that of other infections  
Our first question was whether VF infection would produce an immunosignature 
that was distinguishable from other infections. The concern was that a general 
inflammatory response to infection may dominate the signature. To test this issue we 
used sera from individuals infected with A. fumigatus, M. pneumoniae and C. 
pneumoniae. Figure 2- 1 and Table 2- 4 show the results from an experiment where 
disease cohorts were tested for observable signature differences, and cross-validated 
using the 70/30 train/test hold out approach described in Methods. 
Table 2- 4 Classification results from samples shown in Figure 2- 1 
 Naïve Bayes was used to simultaneously classify the 108 patients into their respective 
groups using hold out (70% train, 30% test, 20 iterations) cross-validation to estimate 
error. 
Infection Sensitivity Specificity PPV NPV Accuracy 
Aspergillus 92% 98% 93% 98% 97% 
Chlamydia 95% 99% 97% 99% 98% 
Mycoplasma 98% 98% 87% 100% 97% 
VF 88% 99% 97% 98% 98% 
 
Figure 2- 1 shows the relative intensities of 243 peptides found by Fisher’s exact 
test with the grouping of the individual cohorts shown on the X-axis.  Each disease cohort 
groups together in the heatmap. A quantitative assessment of the classification using the 
Naïve Bayes algorithm is presented in Table 2- 4. The accuracy of simultaneous 
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classification was 97% for Aspergillus and Mycoplasma and 98% for Chlamydia and VF. 
These results support the conclusion that a VF specific signature can be distinguished 
from other potentially confounding infections. 
 
Figure 2- 1 Hierarchical clustering of informative peptides across five diseases.   
Peptides (Y-axis) are colored by intensity with blue corresponding to low intensity, red to 
high intensity.  Patients (X-axis) are grouped by their corresponding peptide values with 
Aspergillus (black), Mycoplasma (red), Chlamydia (green), Normal (blue) and Valley 
Fever (brown) grouping by cohort as computed by GeneSpring 7.3.1 (Agilent, Santa 
Clara, CA).  Peptides were selected by Fisher’s exact test. 
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Valley Fever immunosignature is distinct from that of uninfected individuals  
We examined antibody signature responses of 45 out of the 55 total VF clinical 
samples shown in Table 2- 2 on the 10K peptide microarray and identified 1586 peptides 
from a 1-way ANOVA (5% FWER-family wise error correction) with a threshold of 
p<1x10-14 indicating significance between the 45 VF training samples and 34 non-disease 
controls and 7 flu-vaccine recipients both pre-vaccine and 21 days post-vaccine. The 
influenza signature was included to exclude a potential common confounding signal.  
This signature is presented as a heatmap in Figure 2- 2.   
 
Figure 2- 2 Hierarchical clustering of Valley Fever Immunosignature apart from 
uninfected individuals.  
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1586 peptides from a 1-way ANOVA between VF and uninfected individuals are plotted 
on the Y-axis. Coloring is based on signal intensities obtained from relative binding on 
the 10K array with blue representing low relative intensity and red representing high 
signal intensity. Each column represents one individuals’ Immunosignature with VF 
patients (red) and uninfected individuals (blue) including influenza pre-vaccine (green) 
and post-vaccine sera (magenta).  
There are three distinct clusters within groups of non-VF normals as highlighted 
in Figure 2-2 above the status color legend. The first and third clusters within non-VF 
individuals include influenza vaccine recipient sera showing mild overlapping VF 
signature. This may be due to these samples being obtained from endemic donors. Note 
that the differences between non-VF and VF samples include reactivity that is higher in 
non-VF than the VF samples.  Using 70% of the sample to define a classification 
immunosignature and then testing the classifier on the 30% withheld and averaging the 
performance of repeating this 20 times, the infected from non-infected samples are 
classified with 100% accuracy.   
Creating a 96 peptide VF diagnostic microarray   
Under some circumstances it may be useful to use the 10K array as a discovery 
platform for informative peptides and then create a smaller, diagnostic-specific array.  To 
test this idea we selected 96 peptides from the 1586 peptide signature described above 
and using pattern matching algorithms within GeneSpring GX.  We used 96 peptides as 
this is the number easily handled on standard microtiter plates. 48 peptides were chosen 
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based on the criteria of capturing consistently high antibody signal across ID titers in the 
VF samples and low antibody signal in the flu vaccine samples. The other 48 were 
chosen based on the criteria of consistently low antibody signal in the VF samples but 
high in the flu vaccine samples. The patterns of performance are depicted in Figure 2- 3 
in a line-plot showing the values for each of the 96 peptides across patients (X-axis) 
whose signals were averaged by their CF titer.  The Y-axis shows the median normalized 
signal intensities represented on a logarithmic scale.  
 
Figure 2- 3 Signal intensity (y-axis) for 96 peptides from the 10,000 peptide microarray 
that distinguish both VF and influenza vaccine recipients.   
X-axis indicates signal response averaged across patients for each CF-titer.  Far right 
are signals averaged for the flu vaccine recipients and normal donors.  These data 
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originate from the full 10,000 peptide array. 48 peptides that capture high antibody 
binding in VF patients and low signals in normal/influenza vaccine recipients are colored 
in red. 48 peptides showing higher signals in normal/ influenza vaccine recipients and 
low signals for VF patients are colored in blue. Consistency is seen across the Valley 
Fever patients, and a reversal in signal is seen for non-VF patients. 
To test the robustness of these signature peptides, we performed a permuted T-test 
by randomly reassigning the patient identifiers on the samples. The best p-value then 
obtainable was p<2.8X10-3, 9 orders of magnitude larger than when patients were 
correctly labeled.  It is therefore, unlikely, that the selected peptides were obtained by 
random chance.  Figure 2- 4 shows a heatmap representation of these same 96 peptides, 
averaged per CF-titer or flu vaccine status.  Hierarchical clustering was used to cluster 
patient groups (X-axis, individual columns) and peptides (Y-axis, individual rows), with 
colors within cells representing high (red) to low (blue) intensities from the microarray.  
The horizontal red bar represents VF patients signal intensities (averaged by CF-Titer), 
blue bar represents the averaged signals from seven influenza vaccine recipients, cyan 
represents the averaged vaccine recipient’s signature response 3 days prior to receiving 
the vaccine and yellow indicates the 34 averaged normal donor signatures. Table 2- 5 
lists the performance of pairwise comparisons using 70% training/30% test, averaged 
over 20 reiterations. The best performance was in distinguishing VF infection from non-
infection (100% sensitivity, 97% specificity) and the worst was VF infection versus flu 
vaccines (100% sensitivity, 82% specificity).  Based on this performance in the context 
of the 10K array, these 96 predictor peptides were re-synthesized (Sigma GenoSys, St. 
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Louis, MO) and printed on a smaller array to test the performance of the VF focused 
array. 
 
Figure 2- 4 Heat map showing normalized average signals from the 96 predictor 
peptides as in Figure 2- 2, but displaying the cohort separation.  
Data averaged per CF titer and patient group for 45 VF patients (Red bars), 34 healthy 
controls (yellow bar), 7 pre-2006 influenza vaccine recipients (cyan bar) and 21-day post 
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vaccine (dark blue bar) (x axis).  T-test identified 96 peptides (y-axis) highly significant 
for distinguishing VF and healthy controls. 
Table 2- 5 Naïve Bayes classification results from the VF training cohort on the 10K 
peptide microarray using the 96 predictor peptides.  Holdout splits all data randomly 
into 70% train/30% predict.  Results are from 20 iterations of random holdouts. 
Dataset used: Training 
(Holdout expt.)  
Sensitivity Specificity PPV NPV Accuracy 
VF, Normal 100% 97% 97% 100% 98% 
VF, Influenza Vaccine 100% 91% 99% 100% 99% 
VF, Normal, Influenza 
Vaccine 
100% 96% 96% 100% 98% 
0 (CF-Titer), Influenza 
Vaccine 
100% 82% 76% 100% 88% 
LOOCV, noHoldOut (all 
data)  
100% 92% 92% 100% 96% 
For comparison: 
CF-Titer (IDCF results) 87% 100% 100% 50% 88% 
 
Performance of a 96 peptide VF-diagnostic microarray  
The diagnostic capability of the VF-diagnostic sub-array was tested using a 
smaller set of training and non-VF control samples.  Upon verification, the complete 
training and blinded test samples (67 blinded samples, 13 non-VF controls) were 
processed on the VF-diagnostic 96 peptide sub-array under similar conditions as the 10K 
array.  Table 2- 6 shows the resulting classification performance. Of particular note is the 
performance against the CF Titer=0 samples.  While the VF diagnostic peptide set clearly 
had higher sensitivity compared to the ID assay, there was a substantial drop in the 
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specificity compared to the ID assay and the performance of those peptides in the 10K 
array. 
Table 2- 6 Naïve Bayes classification results from 96 peptide VF diagnostic array.  Top 
Panel: 96 peptide diagnostic-array data was tested for performance on a blinded cohort 
of false-negative VF patients.  Middle Panel: Performance using all possible patient 
samples including test and training samples. Bottom Panel: Performance using only the 
training dataset. 
Dataset used: Test Sensitivity Specificity PPV NPV Accuracy 
CF-Titer (IDCF results) 28% 100% 100% 13% 35% 
CF-Titer = 0 100% 43% 92% 100% 93% 
All data (0 & other titers) 99% 43% 94% 75% 93% 
Dataset used: Training & Test 
Holdout 20 iterations 
Sensitivity Specificity PPV NPV Accuracy 
CF Titer (IDCF results) 52% 100% 100% 19% 57% 
CF-Titer = 0 91% 85% 96% 70% 90% 
All data (0 & other titers) 82% 92% 99% 37% 83% 
Dataset used: Training 
LOOCV 
Sensitivity Specificity PPV NPV Accuracy 
CF-Titer (IDCF results) 87% 100% 100% 50% 88% 
CF-Titer = 0 100% 67% 75% 100% 83% 
All data (0 & other titers) 100% 67% 96% 100% 96% 
 
To examine the difference in performance of the different arrays, we examined 
the detection limits for each peptide in the context of the actual fold change values as 
measured from patient samples. Figure 2- 5 is a graph combining real fold-change values 
for every peptide (vertical bars) plotted against the detection limit (delta, represented by 
the black curve) and the p-value obtained from a t-test between the VF vs. normal cohorts 
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(red circles). The smaller the delta (black curve), the more sensitive the peptide is to a 
signal and, consequently, the smaller the fold change needed to exceed this limit.  Of note 
are Panels B and C which compare the performance differences between 96 VF-
diagnostic peptides within the context of the 10,000 peptide arrays and the same peptides 
that were resynthesized and independently printed on the VF-diagnostic arrays.  This 
comparison demonstrates the higher performance of the 96 peptides in the context of the 
10K array. 
 
Figure 2- 5 Limits of detection graphed from a post-hoc power calculation.   
The black curve in each figure represents the ± delta (minimum detectable fold-change) 
calculated from the statistical precision of each peptide independently.  The probes along 
the X-axis are sorted by the calculated power, thus forming a smooth curve.  Delta was 
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calculated using α=1/Number of peptides/microarray, β=0.20 and N = number of 
patients per group.  The vertical bars (Y axis) represent the log2 ratio between healthy 
and VF-infected patients with red bars indicating a peptide selected to predict VF, and 
blue bars representing peptides selected for detection of non-VF condition.  The red 
circles on top of certain bars specify statistically significant fold changes at p-
value<0.01.  Panel A: 10,440 random peptides (Training dataset) using VF and healthy 
controls.  Panel B: 96 VF predictor peptides (Training dataset) within the 10K 
microarray.  Panel C:  96 resynthesized VF predictor peptides (Training dataset) ‘VF-
diagnostic’ assay.  Panel D: 96 VF predictor peptides (Test dataset) ‘VF-diagnostic’ 
assay. 
Discussion 
Our objectives in this study were to determine if the immunosignature diagnostic 
had the potential to address the clinical problem of detecting infection in IDCF-titer=0 
patients, and if so what was the best array format.  We first demonstrated that VF 
infection as assayed on the 10K array has a distinct immunosignature relative to 2 
bacterial and one other fungal infection.  We then showed using a 70% training/30% test 
format that the 10K array could accurately discriminate VF infection samples from non-
VF infection and flu vaccinees. 1586 peptides were statistically significantly different 
between the classes.  A portion of the signature was from peptides that had less reactivity 
in the VF infection samples than the non-infection controls. 96 peptides from the 1586 
that had good signature performance in the context of the 10K array were resynthesized 
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and used to create a smaller VF diagnostic subarray.  When tested against the VF 
infection and control samples this array demonstrated increased sensitivity (100%) than 
the conventional IDCF assay, but poorer specificity.  Individual statistical analysis of the 
96 peptides demonstrated that all performed better in the context of the 10K array than 
the subarray format.  
We had previously published studies demonstrating that influenza virus infection 
in mice [75] and the flu vaccine in humans [11] could be distinguished from normal 
controls by immunosignatures. Here we extend this list showing that the 
immunosignatures of two different species of bacteria and two fungi are distinct.  Only 
283 peptides of the 10K array were required to simultaneously distinguish the 4 
infections with >97% accuracy.   Development of the immunosignature diagnostic for 
clinical application will require further validation testing against other common agents of 
community acquired pneumonias and infections causing flu-like symptoms.  
As noted, for VF a clinically important issue is the people that report with 
symptoms caused by VF infection but are not detected as sero-positive by the standard 
immunological tests, the CF titer=0 patients.  Using the 10K immunosignature array we 
demonstrated that there were 1586 peptides that were reproducibly different between VF 
infection samples and non-VF samples. The non-VF samples included ones that had 
received the flu vaccine as an effort to exclude flu infection signatures.  Noteworthy is 
that a large portion of this signature was composed of peptides that had lower signal in 
the VF-infection sample than the non-infection.  We have noted this phenomenum before 
[2,11,13].  This type of reactivity would not be easily detected in standard ELISA-like 
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assays.  We pose that this may be due to the infection causing suppression or elimination 
of B-cells producing antibodies that are normally present in most people.  
A reasonable strategy for developing immunosignatures would be to use the large 
10K array as a discovery format and then produce subarrays with smaller number of 
peptides for the clinical diagnostic.  The advantages of the smaller arrays would be that 
they may be less expensive to manufacture since fewer peptides would be required, the 
peptides could be of higher quality and they may be simpler to read.  To test this 
approach we chose 96 peptides from the 1586 10K signature and pattern matching 
analysis between disease and non-disease groups.  48 were chosen which were 
consistently high in VF infection samples but low in flu vaccine samples and 48 with the 
converse signature.  From a practical perspective, 96 is convenient as it is the basic unit 
used in peptide synthesis and spotting the arrays.  The peptides were selected based on 
their consistent signal over all titers, including the CF=0, of the standard ID assay.  We 
did not determine if signatures that distinguish the titers could be selected to monitor VF 
progression.  The implication is that the antibody reactivity that these peptides measure is 
independent of that measured in the ID assay.   
This VF diagnostic sub array was tested in a blinded test against the VF infection 
and non-infection samples.  The infection samples include the CF titer=0 samples.  While 
this subarray was significantly more sensitive than the IDCF assay, it was also less 
specific.  This increase in sensitivity but loss of specificity was evident in the CF titer=0 
samples.  The implication is that this subarray at least would need to be used in 
combination with the standard ID to obtain maximum specificity and sensitivity.   
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Interestingly, the sub-array performed less well than the 10K array.  This may in 
part be due to the selection criteria for the 96 peptides which were against the flu vaccine 
samples.  Peptides selected against a wider assortment of non-VF infection samples could 
perform better.  It may also be that the additional peptides on the 10K array distribute the 
antibody response to infection in a finer resolution allowing high sensitivity and 
specificity.   The 10K format, as demonstrated here for 3 other infections, may have the 
advantage of being used to discriminate multiple infections on the same platform.   
We have demonstrated that the immunosignature platform has clinical diagnostic 
potential relative to VF infection.  It can address the clinical problem of the CF titer=0 
infections, either on the 10K format or the sub-array format in combination with the 
standard ID assay.  There are ~50M people in the VF endemic region, with an estimated 
30% being exposed over time to the infectious agent.  However, since most people have 
little if any symptoms, it is unlikely a diagnostic would be used generally to screen for 
VF infection.  There is an existing standard antifungal treatment (Fluconazole) and a new 
one in development (Nikkomycin).  An improved diagnostic could at least identify 
symptomatic patients more accurately for having VF infections and may allow more 
effective use of treatments.  
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Supplementary Data: 
 
Supplementary Table 2- 1 Non-VF infection samples, ELISA data from SeraCare 
Name of assay: Platelia for Aspergillus spp. IgG from Bio-Rad (Hercules, CA) 
No. Patient No. Infection  ELISA (AU/ml) 
 1 2016079638 Aspergillus 61.9 
 2 2016088190 Aspergillus 35.8 
 3 2016173268 Aspergillus >80 
 4 2016187069 Aspergillus 18.1 
 5 2016191891 Aspergillus >80 
 6 2016200731 Aspergillus >80 
 7 2016231777 Aspergillus 21 
 8 2016244297 Aspergillus 24.8 
 9 2016245083 Aspergillus 23.9 
 10 2016293410 Aspergillus >80 
 11 2016330923 Aspergillus 18.1 
 12 2016332606 Aspergillus 24.1 
 13 2016362872 Aspergillus 57.3 
 14 2016393395 Aspergillus 21.3 
 15 2016397247 Aspergillus 44.7 
 16 2016397812 Aspergillus >80 
 17 2016451743 Aspergillus 38 
 18 2016454148 Aspergillus 60.3 
 19 2016479167 Aspergillus 80 
 20 2016203861 Aspergillus 22.9 
 
     
Name of assay: ANI labsystems for Mycoplasma pneumoniae IgG (Vantaa, Finland) 
No. Patient No. Infection ELISA (AU/L) 
 1 86 Mycoplasma 57 
 2 131 Mycoplasma 47 
 3 1596 Mycoplasma 50 
 4 3356 Mycoplasma 96 
 5 5659 Mycoplasma 95 
 6 2011444020 Mycoplasma 91 
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7 2016061010 Mycoplasma 115 
 8 2016062204 Mycoplasma 68 
 9 2016065663 Mycoplasma 209 
 10 2016065745 Mycoplasma 71 
 11 2016065862 Mycoplasma 131 
 12 2016080956 Mycoplasma 108 
 13 2016084956 Mycoplasma 153 
 14 2016085828 Mycoplasma 84 
 15 2016086204 Mycoplasma 99 
 16 2016088339 Mycoplasma 179 
 17 2016088435 Mycoplasma 111 
 18 2016090988 Mycoplasma 141 
 19 2016091115 Mycoplasma 309 
 20 2016092572 Mycoplasma 79 
 
     
No. Patient No. Infection  ELISA (S/CO) Name of assay 
1 9245819 Chlamydia 5.456 
Trinity Biotech EIA 
(Ireland) 
2 9245824 Chlamydia 4.186 Trinity Biotech EIA 
3 9245825 Chlamydia 4.211 Trinity Biotech EIA 
4 9245826 Chlamydia 5.873 Trinity Biotech EIA 
5 9245827 Chlamydia 6.434 Trinity Biotech EIA 
6 9245829 Chlamydia 4.868 Trinity Biotech EIA 
7 9245830 Chlamydia 5.579 Trinity Biotech EIA 
8 9245833 Chlamydia 1.3 Trinity Biotech EIA 
9 2013298347 Chlamydia 43 (UA/L) 
NovaLisa from 
NovaTec for 
Chlamydia 
pneumoniae IgG 
(Germany) 
10 2013352672 Chlamydia 42 (UA/L) 
NovaLisa from 
NovaTec for 
Chlamydia 
pneumoniae IgG 
11 2016328813 Chlamydia 46 (UA/L) 
NovaLisa from 
NovaTec for 
Chlamydia 
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pneumoniae IgG 
12 2016343255 Chlamydia 41 (UA/L) 
NovaLisa from 
NovaTec for 
Chlamydia 
pneumoniae IgG 
13 BM200809 Chlamydia 2.077 Trinity Biotech EIA 
14 BM201051 Chlamydia 2.048 Trinity Biotech EIA 
15 BM201105 Chlamydia 1.815 Trinity Biotech EIA 
16 BM201340 Chlamydia 3.168 Trinity Biotech EIA 
17 BM202017 Chlamydia 1.815 Trinity Biotech EIA 
18 BM202083 Chlamydia 2.851 Trinity Biotech EIA 
19 BM205162 Chlamydia 1.124 Trinity Biotech EIA 
20 BM205163 Chlamydia 1.192 Trinity Biotech EIA 
     
Name of assay: Complement fixation antibodies detected using Immunodiffusion 
(IDCF) measured by Dr. John Galgiani's lab 
No. Patient No. Infection CF-Titer/ IDCF 
 1 VF0-1077 Valley fever 0 
 2 VF0-1176 Valley fever 0 
 3 VF1-1153 Valley fever 1 
 4 VF1-142 Valley fever 1 
 5 VF1-178 Valley fever 1 
 6 VF1-432 Valley fever 1 
 7 VF2-1304 Valley fever 2 
 8 VF2-1344 Valley fever 2 
 9 VF2-1346 Valley fever 2 
 10 VF2-2 Valley fever 2 
 11 VF16-1 Valley fever 16 
 12 VF16-1142 Valley fever 16 
 13 VF16-399 Valley fever 16 
 14 VF32-1280 Valley fever 32 
 15 VF64-262 Valley fever 64 
 16 VF64-556 Valley fever 64 
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17 VF128-1012 Valley fever 128 
 18 VF256-793 Valley fever 256 
  
 47 
 
CHAPTER 3 
COMPARISON OF NON-NATURAL MIMOTOPE VERSUS EPITOPE PEPTIDES IN 
DIAGNOSING VALLEY FEVER 
Abstract 
Peptide-based diagnostics are not in widespread use not because of poor 
sensitivity but because of diminished specificity.  Numerous reports suggest that protein-
based rather than peptide-based detection is more specific.  We examined two different 
approaches to peptide-based diagnostics using Valley Fever (VF) as the model.  Although 
the pathogen was discovered more than a century ago, a sensitive diagnostic is not 
available.  We present a case study where two different approaches were used:  the first, a 
standard overlapping VF-epitope peptide array representing immunodominant 
Coccidioides antigens.  Second, a set of random sequence peptides that function as 
mimotopes and partial epitopes was used. Such a comparison within a diagnostic context 
has not been previously reported. My results indicate that non-natural (random) sequence 
peptides show higher accuracy at classifying all stages of VF infection over VF-epitope 
peptides in a microarray format.  The epitope peptide array did provide better 
performance than the standard immunodiffusion array, but when directly compared to the 
random sequence peptides, reported lower overall accuracy.  This study hints at novel 
aspects associated with antibody recognition on an amino acid level and suggests 
methods for improving the accuracy of peptide microarray based diagnostic 
immunoassays not previously considered. 
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Abbreviations 
CAP, Community Acquired Pneumonias; CF, Complement Fixation; CT, Computed 
Tomography; CNS, Central Nervous System; EIA, Enzyme Immunoassay; FPR, False 
Positive Rate; ID, Immunodiffusion; IDCF, Complement fixation antibodies detected by 
Immunodiffusion; IDTP, Tube precipitin antibodies detected by Immunodiffusion; LDA, 
Linear Discriminate Analysis; KNN, K-nearest neighbors; LOOCV, Leave One Out 
Cross Validation; LVS, Live Vaccine Strain; NPV, Negative Predictive Value; PPV, 
Positive Predictive Value; TP, Tube Precipitation; TB, Tuberculosis; VF, Valley Fever. 
Introduction 
Superficial fungal infections affecting nails and skin afflict approximately 1.7 
billion people worldwide and this number is much higher as compared to the 1.5 million 
people per year mortality due to invasive fungal infections [76]. Valley Fever (VF) is 
caused by a dimorphic fungus, Coccidioides, prevalent in the southwestern Sonoran 
desert region of the United States and in certain areas of South America. The pathogen is 
known to cause both superficial as well as invasive disease in infected individuals. 
Diagnosis and treatment of VF is surrounded by several delays, due to diagnostic 
challenges as well as clinical inadequacies. Figure 3- 1 is a flowchart describing the 
clinical insufficiencies hindering early diagnosis of VF infection as highlighted by an 
Arizona Department of Health Services (ADHS) survey [20]. Additionally, the diagnostic 
delays involve very low recovery rates of this pathogen, 0.4% [n=5,026] from blood and 
8.3% [n=10,372] from respiratory tract specimens [3.2% overall i.e. from blood, 
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respiratory tract, urinary tract, bone marrow, cerebrospinal fluid, other sterile and non-
sterile body sites; n=55,788] as ascertained from a retrospective analysis of fungal culture 
specimens submitted to a lab in Phoenix (endemic for VF) by Sussland et al. [77]. The 
sensitivity of serum based assays such as Enzyme Immunoassay (EIA) is 83-87%, that of 
complement fixation and tube-precipitation antibodies detected by Immunodiffusion 
(IDCF,IDTP) is 71-73% and that of complement fixation by itself is low between 56-75% 
[78,79]. We demonstrated in our previous study [80] that Immunosignatures [2,10-12] 
using non-natural sequence peptide microarray technology could be successfully applied 
to resolve the diagnostic challenges surrounding VF serum based diagnosis. The random 
peptide ‘VF-diagnostic’ microarray platform accurately classified 63 longitudinal 
samples from 25 symptomatic yet clinically false-negative (IDCF=0 titer) patients as 
having valley fever. The confirmatory assay, IDCF’s sensitivity on this specific training 
and initially blinded test dataset used in the previous assay was 52% and specificity 
100%. Despite being a difficult sample set, the non-natural sequence peptide microarray 
out-performed IDCF with an overall cross-validated (holdout) sensitivity of 82% and 
specificity of 92%.  In this work we sought to test an alternative diagnostic approach 
using epitope peptides representing immunodominant VF antigens. This article compares 
the diagnostic performance of non-natural (random) sequence predictor peptides for VF 
and that from VF-epitope (life-space) peptides representing four immunodominant VF 
antigens. In doing so, it evaluates a central hypothesis of whether randomly generated; 
non-natural sequence predictor peptides from Immunosignatures are more or less 
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effective at accurately capturing all stages of VF infection with more sensitivity and 
specificity than pathogen antigen peptides in a similar microarray. 
 
Figure 3- 1 The clinical problem in Valley fever diagnosis. 
A diagnostic peptide microarray composed of 96 random peptides was created as 
part of a prior study [80] to enable sensitive diagnosis of VF in patients that were initially 
characterized as false-negatives by the IDCF titer gold-standard diagnostic assay.  
Briefly, a well characterized VF patient serum sample training set was tested on a 10,000 
random peptide microarray to select the 96 VF predictor peptides for the smaller sub-
array.  These 96 random peptides were selected for specificity in discriminating VF 
patient samples from both non-VF disease and healthy controls in the training set. 
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Influenza vaccinee sera were included as a confounding infection. Encouraged by higher 
sensitivity obtained on this smaller sub-array for predominantly false negative samples 
(IDCF=0), we sought to test whether using antigen epitope peptides from C. immitis 
might deliver an equally sensitive and perhaps more specific diagnostic than that obtained 
by using non-natural (random-sequence) predictor peptides. To this effect, we chose to 
represent four immunodominant VF antigens that are potential vaccine candidates in the 
form of six amino acid overlapping peptides. These antigens are chitinase-F (CF) [81], 
Antigen-2 [82], Expression Library Immunization-Antigen1 (ELI-Ag1) [83] and 
Coccidioides immitis specific antigen (CSA) [84] from Coccidioides immitis (strain-RS).  
The CF antigen is considered the main immune stimulating antigen as measured by the 
IDCF assay [61].  IDCF detects antibodies to several protein antigens present within an 
untreated (by heat), autolyzed, mycelial culture filtrate.  In this study, a side by side 
comparison of the diagnostic capability of these 96 VF specific non-natural peptides was 
made with 83 antigen epitope peptides representing four VF immunodominant antigens. 
Additional bioinformatic analyses were conducted to ascertain the reasons underlying 
high sensitivity and specificity of the 96 non-natural VF predictor peptides. 
When classifying non-natural proteins versus natural antigen proteins, one of the 
several metrics used for classification is the amino acid frequency of sequences being 
compared [31]. Within these groups of characteristic metrics, a di-peptide frequency 
pattern is typically used to automatically annotate proteomes by classifying protein 
sequences and informatically attributing function based on di-peptide complexity [85]. In 
order to ascertain why the 96 non-natural peptides function as VF predictors, a di-peptide 
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and short-sequence (2-mer to 6-mer) composition analysis is performed. For the purpose 
of this study, instead of the di-peptide frequency, the total possible di-peptides in 
common between 96-random and 83-life space epitope peptides versus VF proteome is 
calculated. Additionally we use an amino acid sequence similarity based alignment 
program named GuiTope [34] to compare the 96 non-natural VF predictor peptides to the 
four VF protein antigens in an effort to de-convolute the mechanism enabling randomly 
generated non-natural sequence peptide predictors to sensitively detect VF. GuiTope is a 
program that aligns non-natural sequence peptides to natural sequence proteins based on 
sequence level amino acid physico-chemical and structural similarity in an effort to map 
back to the original antigen from observed antibody binding on a microarray. It includes 
the novel feature of aligning sequences by taking into consideration di-peptide inversions 
within random peptides which was a phenomenon first observed while analyzing the data 
presented in this article and led to statistically significant improvement in GuiTope’s 
epitope discovery accuracy. 
Methods 
Serum samples used in this study 
A training and blinded test serum sample set were collected under the University 
of Arizona’s IRB# FWA00004218 and received by The Center for Innovations in 
Medicine at Arizona State University under their IRB# 0905004024 allowing unfettered 
data analysis of this material. Most patients sample within the training and blinded test 
set were initially characterized as being false negative on the CF-titer (IDCF) assay. 
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Supplementary Table 3- 1 describes the CF titer distribution in the samples from the 
training cohort. A training sample set consisting of 55 longitudinal samples from 35 VF 
symptomatic individuals including some 0 CF-titer early time point sera from 6 
individuals that later sero-converted was acquired from the University of Arizona. The 
accuracy of diagnosis using IDCF for the training set sera was 88%, with sensitivity = 
87%, specificity = 100%, PPV (Positive predictive value) = 100% and NPV (Negative 
predictive value) = 50%. Supplementary Table 3- 2 describes the CF titer distribution in 
the samples from the initially blinded test cohort. A blinded test sample set was acquired 
containing 67 serum samples of which 48 which were later revealed to be sero-negative 
on IDCF. These test group sera were from 25 patients with two or more serum samples 
per individual collected longitudinally during their disease progression. Supplementary 
Table 3- 3 summarizes the individual sample characteristics of patients sera included 
within the test set. The accuracy of diagnosis using IDCF for the test set sera was 35%, 
with sensitivity = 28%, specificity = 100%, PPV = 13% and NPV = 35%. The overall 
accuracy of both training and test dataset samples using IDCF for diagnosis was 57% 
(sensitivity= 52%, specificity= 100%, PPV= 19% and NPV= 57%). 
For the exploratory non-natural feature selection training portion of the 
experiment, 45 out of the total 55 training sera were processed to ensure adequate 
representation of all CF-titers (progressive stages of infection) on a 10,000 random 
peptide Immunosignature microarray.  Additionally, blood samples were processed from 
48 otherwise healthy male and female individuals of various ages along with 7 influenza 
vaccinee’s who supplied blood 3 days prior (‘pre’) to receiving the 2006/2007 influenza 
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vaccine and 21 days later (‘post’), and the data from their antibody reactivity’s to the 
10,000 peptides were classified as ‘non-disease’ for training purposes. 96-random VF 
predictor peptides were selected out of 10K peptides from this exploratory assay as 
explained in the prior publication [80]. 
All VF training and blinded test samples were processed on the smaller diagnostic 
array containing the selected 96-random and 83-life space epitope peptides in triplicate. 
Thirteen non-disease samples, including sera from healthy volunteers as well as influenza 
vaccinee samples were processed on the smaller diagnostic array.  To measure the 
specificity of the smaller diagnostic array, we processed 10 Fransicella tularensis (LVS-
Live Vaccine Strain) vaccinated individuals sera obtained from Dr. Anders Sjöstedt’s lab 
from Umeå University. This serum was part of a time course study and the samples 
selected for processing were the ones that were collected 28-30 days post receiving the 
LVS vaccine.  
Microarray production and processing 
The 96 random peptides as well as 83 life space peptides were synthesized by 
Sigma (St.Louis, MO) and printed as described in Legutki et al. [11]  Every 17 amino 
acid peptide was designed to have an N-terminal CSG linker and printed on aminosilane-
coated glass slides which were activated with sulfo-SMCC (Pierce, Rockland, MD).  All 
peptides were printed in triplicate next to each other in a two array printings per slide 
format.  Arrays were printed using a Nanoprint 60 (ArrayIt, Santa Clara, CA) at 60% 
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relative humidity at 23°C.  Patient serum from training and test sets were processed on 
this smaller microarray in duplicate.  
Microarray slides were pre-washed with a solution containing 7.33% acetonitrile, 
33% isopropanol and 0.55% TFA to remove any unbound peptides.  Slides were blocked 
in 1X PBS, 3% BSA, 0.05% Tween 20, 0.014% β-mercaptohexanol for 1hr at 25oC.  Sera 
samples were diluted 1:500 in the Incubation buffer containing 3% BSA, 1X PBS, 0.05% 
Tween 20, and allowed to bind to the microarray for 1 hour at 37°C in 100 µl total 
volume per array on a Tecan 4800 Pro Hybridization Station (Tecan, Salzburg, Austria). 
Slides were washed in-between primary and secondary antibody incubation steps for 30 
seconds with 1X tris-buffered saline (TBS), 0.05% Tween 20 pH 7.2.  Patient IgG 
antibodies were detected using 5nM, DyLight-549 conjugated Goat anti-Human, IgG Fc 
(γ) fragment specific secondary antibody and 5nM, Dylight-649 conjugated Goat anti-
Human, IgM (5µ) fragment specific antibody from Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA diluted in the incubation buffer.  These slides were 
scanned using the Agilent ‘C’ Scanner (Agilent Technologies, Santa Clara, CA) at 532 
nm and 647 nm excitation wavelengths under 100% PMT and 100% laser power with a 
10 µm image resolution. Both red and green channel TIFF images were simultaneously 
aligned per individual array, using the GenePix software (Axon Instruments, Union City, 
CA) and the data files imported into GeneSpring 7.3.1 (Agilent, Santa Clara, CA) for 
further analysis. 
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Pre-processing of data for analysis 
Data are collected in the form of .gpr files.  Each .gpr file contains the peptide 
name and the foreground intensity for each measured peptide for both IgG (green, 545nm 
channel) and IgM (red, 647nm channel).  Data were loaded into GeneSpring GX 7.3.1 for 
analysis.  Since the diagnostic array included two color data, a Lowess normalization was 
completed in GeneSpring whereby the ratio between the signal and control channels was 
used for classification.  Any array with a Pearson Correlation Coefficient less than 0.80 
across technical replicates was re-processed. Upon reprocessing if the Pearson correlation 
between replicates did not improve, that patient’s sample was excluded from further 
analysis. 
Statistical analysis 
Classification was performed using the Naïve Bayes algorithm as implemented in 
the klaR [71] package in R. Due to the unbalanced nature of this dataset, the holdout 
algorithm was used to balance the groups, from the R package DMwR as published in the 
book, Data Mining with R [72]. This helped overcome in-accurate estimation of 
specificity due to lesser non-disease samples. The holdout experiment was done by 
combining the training and test dataset and is a more rigorous cross-validation technique 
whereby 70% of randomly selected total data was used for training and prediction was 
made on the remaining 30% data. This was done for 20 iterations so as to predict the 
class of every sample more than once and get a better assessment of diagnostic metrics 
such as sensitivity, specificity, negative predictive value (NPV), positive predictive value 
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(PPV) and accuracy. The results for both standard train and test (without cross-
validation) and holdout are included side-by-side for every comparison. 
GuiTope analysis 
Previous work done by Halperin et al. [34] showed an unusual property of 
antibody recognition of near-epitope sequences.  Two amino acids in a row could be 
swapped in position with no decrease in the apparent binding affinity.  This occurred 
often enough in a broad analysis of monoclonals and polyclonals on Immunosignature 
random peptide microarrays, and phage display datasets from MimoDB [86] that 
Halperin and colleagues embedded an allowance for this in a program for analysis of 
peptide alignments called GuiTope [34]. The current article is the first report displaying 
the use of this program for finding mimotopes within non-natural peptides through 
antibody binding observed from VF patient sera. 
The protein sequences of the four immunodominant VF antigens were uploaded 
as a .fasta format file into the Protein section of GuiTope. The 96 non-natural space 
peptide sequences were uploaded into the peptide input section. In the library section, the 
original 10K random peptide library was uploaded from which the 96-random peptides 
were selected as VF predictors. These 96 selected random peptides were excluded from 
the library section. This was done so as to calculate the false-positive rate (FPR) by 
calculating the score for an equal number of library peptides as the selected VF-
predictors (96) for multiple iterations (1000) and assessing the probability of finding 
another peptide in the library that had a higher similarity to the four VF proteins, above 
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that calculated for the 96-selected. The default amino acid distance matrix, Grantham 
1974 [87] was used but the amino acid frequencies of the query proteins and query 96-
random peptides were pasted into the appropriate sections under the Generate Matrix tab. 
Under the parameters tab, the inversion weight was set to 1 or 0 to either include or 
exclude the di-peptide inversion modulation to the Smith-Waterman maximal gapless 
local alignment algorithm [33]. A new distance matrix was generated after taking into 
consideration the amino acid frequencies for the query protein and peptide. The sampling 
iterations under the ‘Graphical output’ tab was set to 1000, which is the number of times 
96 other peptides would be selected at random from the 10K library to compare scores 
for the selected 96-peptides and generate the FPR.  
Results 
Comparing classification accuracy and sensitivity of life space versus random 
peptides 
A comparison between pathogen epitope peptides and non-natural sequence 
peptides within a peptide microarray diagnostic had not been previously reported in the 
literature.  We examined the signature response captured by 83 valley fever antigen 
epitope peptides and compared that to the antibody response captured by 96 non-natural 
VF-diagnostic peptides as depicted in Figure 3- 2. 
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Figure 3- 2 VF patient signal average intensity data per CF-titer.  
The Y-axis displays the average raw (non-normalized) signal in fluorescence intensity 
units (FIU) captured by 83 VF antigen life-space peptides in Panel A and 96 non-natural 
(random) peptides in panel B. Error bar depict standard error. The X-axis displays 
signal intensities as averaged by CF-titer (IDCF) with ‘n’ reflecting the number of 
patients in the training and test groups combined per CF-titer. 
IgG antibody averaged signals in panel A captured by tiled VF-antigen peptides 
do not show incremental correlation with increasing CF-titer until the CF-titer reaches 
1:256.  At every CF-titer, except 1:256, the 96-random peptides capture higher amount of 
antibodies on average as compared to the life-space peptides.  The 96-random VF 
predictor peptides might thus have more potential for accurately measuring symptomatic 
yet false-negative patient sera mis-classified by the IDCF test. Table 3- 1 summarizes the 
Naïve Bayes classification result from false negative (CF-titer=0) patients within the VF 
dataset and compares the performance of the 83 life-space peptides versus 96-random 
peptides.  
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Table 3- 1 Naïve Bayes classification result on VF test dataset using random vs life space 
peptides. 
IgG Peptides Sensitivity Specificity PPV NPV Accuracy 
0 (CF-
Titer) 
Random 
(96) 100% 43% 92% 100% 93% 
  
Life space 
(83) 96% 71% 96% 71% 93% 
       IgM Peptides Sensitivity Specificity PPV NPV Accuracy 
0 (CF-
Titer) 
Random 
(96) 94% 43% 92% 50% 87% 
  
Life space 
(83) 88% 57% 93% 40% 84% 
       Holdout exp (70- 30), 20 iterations         
IgG Peptides Sensitivity Specificity PPV NPV Accuracy 
0 (CF-
Titer) 
Random 
(96) 91% 85% 96% 70% 90% 
  
Life space 
(83) 86% 71% 93% 52% 83% 
       IgM Peptides Sensitivity Specificity PPV NPV Accuracy 
0 (CF-
Titer) 
Random 
(96) 99% 58% 86% 96% 88% 
  
Life space 
(83) 80% 68% 91% 46% 78% 
 
The random peptides are more sensitive at diagnosing valley fever than the life 
space peptides. The top half of this table represents the IgG (green-channel) and IgM 
(red-channel) sensitivity from generating a Naïve Bayes model by training on the training 
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dataset and testing on a physically separate test dataset. The bottom half of the table 
represents a more rigorous assessment of these metrics by performing the holdout cross-
validation for 20 iterations and using 70% randomly selected training samples to train 
and predict the remaining 30% of data. The results presented are averaged for multiple 
predictions per sample for all 20 iterations. The resulting values are more accurate 
estimates to be expected from this assay when testing with additional clinical samples in 
the future. Random peptides detect false-negative symptomatic patient sera more 
accurately as compared to life space epitope peptides. As might be expected early in an 
infectious response the IgM responses offer higher sensitivity (98.96%, random 
peptides). 
Bioinformatic rationale underlying the sensitivity of random (96) vs. life-space (83) 
epitope peptides 
A linear B-cell antibody epitope ranges from 4-12 amino acids in length as 
previously delineated through peptide microarray analysis [88].  Sun et al. [89] 
determined from 161 Protein Data Bank (PDB) antigen-antibody pair structures that in 
conformational epitopes, antibody paratopes associate with antigens in short non-
contiguous segments, 2-5 amino acids in length.  The reasons underlying higher 
sensitivity and specificity of random predictor peptides in comparison to pathogen 
epitope peptides could be bioinformatically ascertained by comparing the level of short 
sequence overlap between the two groups of predictor peptides and the VF proteome. 
Figure 3- 3 depicts the number of unique n-mers between the 96-random and 83-lifespace 
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peptides in common with the VF pathogen proteome (panel A) and the randomly 
generated VF proteome (panel B).  
 
Figure 3- 3 Sensitivity of assay - Number of unique n-mers (2-6 amino acid short 
sequences) between the 96-random and 83-lifespace peptides in common with the VF 
pathogen proteome (panel A) and the randomly generated VF proteome (panel B). 
The Y-axis shows the number of 2-6 mers in common between groups of peptides and 
pathogen proteomes as a continuous line graph with n-mer groups displayed on the X-
axis. 
The bioinformatically in-silico generated artificial VF proteome uses amino acid 
alphabets in an unbiased random manner to match the number and length per protein 
within the natural Coccidioides immitis strain-RS proteome. The total possible 
combinations of di-peptides using 20 amino acids is 400 and the 96-random peptides 
represent 360 out of those 400 possibilities. The 83 life-space peptides only represent 303 
out of the 400 possible di-peptide combinations.  The number of overlapping 6-mers in 
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common between the life-space peptides and the natural VF-proteome increase but this 
extent of overlap is not by random chance as depicted by the artificially generated VF 
proteome. The number of 6-mers identical between the 96-random peptides and both the 
natural and artificially generated VF-proteome is low and show the true randomness of 
these 96 VF-predictor non-natural peptides. 
Specificity and robustness of random (96) vs. life-space (83) VF epitope peptides 
In an effort to assess the specificity of this assay, we statistically classified all CF-
titer (non-zero) VF patient sera to test whether the peptide microarray could distinguish 
all progressing stages of VF infection apart from uninfected sera (normal donors, 
influenza vaccinees). Additionally, we processed sera from Francisella tularensis (LVS) 
vaccinated individuals 28-30 days post-vaccine. When Francisella tularensis infects the 
lungs, symptoms resemble those of respiratory distress similar to those observed in VF 
[90].  To measure specificity against a confounding exposure, the 10 LVS samples were 
randomly split between the training and the test samples (5 per group). Separate 
classifications were done for 2 groups (VF vs. non-VF – Part A, without LVS sera) or 3 
groups (VF vs. non-VF vs. LVS – Part B) (Table 3- 2). The assay performance metrics 
for IDCF are included for side-by-side comparison in Part A. 
Table 3- 2 Naïve Bayes classification results using IgG and IgM signals from VF 96 
random predictor peptides and 83 VF epitope peptides 
A.) Groups: VF, Normals (No LVS) 
IgG Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 99% 43% 94% 75% 93% 
  Life space 96% 50% 94% 57% 91% 
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(83) 
  
     
  
IgM Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 99% 25% 92% 67% 91% 
  
Life space 
(83) 90% 50% 94% 36% 85% 
CF-Titer  IDCF results 28% 100% 100% 13% 35% 
Holdout experiment (70-30), 20 iterations 
IgG Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 82% 92% 99% 37% 83% 
  
Life space 
(83) 79% 73% 96% 30% 78% 
  
     
  
IgM Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 93% 74% 97% 55% 91% 
  
Life space 
(83) 
84% 68% 96% 34% 
82% 
CF-Titer  IDCF results 52% 100% 100% 19% 57% 
       B.) Groups: VF, LVS, Normals 
IgG Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 99% 50% 92% 86% 91% 
  
Life space 
(83) 96% 62% 93% 73% 90% 
  
     
  
IgM Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 99% 46% 90% 86% 90% 
  
Life space 
(83) 87% 54% 91% 44% 
81% 
Holdout experiment (70-30), 20 iterations 
IgG Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 79% 87% 97% 44% 80% 
  
Life space 
(83) 
91% 73% 94% 62% 
87% 
  
     
  
IgM Peptides Sensitivity Specificity PPV NPV Accuracy 
All (CF-Titer) Random (96) 93% 70% 93% 67% 89% 
  Life space 83% 75% 94% 48% 81% 
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(83) 
 
A - Model classifying between 2 groups VF and Non-VF (Normal) 
B - Model classifying between 3 groups VF, Non-VF and LVS 
Holdout experiment - combine training and test set data, Train on randomly selected 
70% data and test on remaining 30% (20 iterations) 
Naïve Bayes (no holdout) yielded 99% sensitivity using both IgG and IgM signals 
from 96-random predictor peptides when including the LVS samples (Table 3- 2, Part B). 
In comparison, the 83 life-space epitope VF peptides showed 96% sensitivity when using 
IgG signals and 87% when using IgM signals. The holdout experiment was performed so 
as to reduce biased estimates of specificity due to comparatively lower number of non-
disease patient sera tested on this assay in comparison to VF patient sera. The specificity 
at distinguishing VF apart from normal by non-natural 96-random VF predictor peptides 
through the holdout analysis for IgG is 92% (Table 3- 2, Part A) in comparison to 73% 
(Table 3- 2, Part A) from 83 VF life-space epitope peptides. This was unexpected given 
our original hypothesis of expecting higher specificity from VF life-space epitope 
peptides as compared to non-natural sequence peptides (96-Random). When testing the 
classification (holdout) of these same VF and normal samples in the context of LVS, the 
specificity of non-natural peptides capturing IgG reactivity within this assay dropped 
from 92% (Table 3- 2, Part A) to 87% (Table 3- 2, Part B) merely because the platform 
was not originally trained or designed to distinguish between these specific disease 
groups. This 87% specificity though is still higher than that demonstrated by life-space 
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VF epitope peptides (73%). The sensitivity (91%) and accuracy (87%) of life-space 
peptides was higher than non-natural peptides when including the LVS group (Table 3- 2, 
Part B). 
As often seen in assays involving antigen-antibody interactions [3,5], some 
peptide-level cross-reactivity was observed from the LVS vaccinees towards some 
random and life-space peptides selected to distinguish Valley Fever from influenza and 
healthy controls.  The cross-reactivity of these VF predictor peptides to antibodies from 
individuals exposed to LVS might be partially explained due to the number of 
overlapping 5-mers between them and the pathogen proteomes tested in this analysis 
(Figure 3- 4).  
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Figure 3- 4 Cross-reactivity observed on VF-diagnostic array hypothetically explained 
using the number of unique 5-mers in common (Y-axis) between random (blue bars) and 
life space (red bars) peptides and pathogen proteomes (X-axis). 
Influenza/A/Wisconsin and New Caledonia and Influenza/B/Malaysia strains 
were included in the 2006-2007 seasonal Influenza vaccine.  The extent of identical 
overlapping 5-mers between the Valley Fever proteome and both the random and life-
space peptides is much higher compared to Influenza or Fransicella proteomes.  The 
extent of overlap may also be partially affected by the significantly different size of these 
pathogen proteomes, with C. immitis having 10,440 proteins and F. tularensis str. SchuS4 
having 1,556 proteins and F. tularensis str. LVS having 1,754 proteins while only 12 
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proteins represent the  Influenza proteomes. The 96-random peptides performed with 
higher specificity in being able to distinguish VF from non-VF patients and LVS 
vaccinees as compared to VF epitope peptides (life-space). Figure 3- 5 shows the number 
of unique n-mers (2-6 amino acids) between the 96-random and 83-lifespace peptides in 
common with the LVS proteome (panel A) and the randomly generated LVS proteome 
(panel B).  
 
Figure 3- 5 Specificity of assay - Number of unique n-mers (2-6 amino acid short 
sequences) between the 96-random and 83-lifespace peptides in common with the LVS 
proteome (panel A) and the randomly generated LVS proteome (panel B). 
The Y-axis shows the number of 2-6 mers in common between groups of peptides and 
pathogen proteomes as a continuous line graph with n-mer groups displayed on the X-
axis. 
The extent of 5-mer and 6-mer overlap between random peptides and the LVS 
proteome whose signature they were not designed to capture is low as compared to that 
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observed between the two peptide groups and VF proteome in Figure 3, Panel A. This 
explains why the specificity of non-natural (96-Random) peptides at distinguishing a 
previously un-trained on exposure (LVS) was higher than that of VF epitope peptides 
(life-space). 
Bioinformatic rationale underlying the specificity of random (96) vs. life-space (83) 
epitope peptides 
A comparison between the 96-random peptides and the 4 immunodominant VF 
antigens was done using GuiTope. Using the protein BLAST program [91] very few 
alignments were found between the VF proteins and 96-random peptides.  Table 3- 3 and 
Figure 3- 6 summarize the positive matches between 96-random peptides and 4 VF 
antigen proteins.  
Table 3- 3 Summary of GuiTope matches between 96-Random VF predictor peptides and 
4 VF antigens 
Score cutoff: 6.56 Moving Average: 15 
Sampling Iterations: 1000 Subtracting Mean Lib Scores? Checked 
Part A.) Inversions = 1 
Name 
Ran
k 
Max 
Score 
Max Score 
Position 
(amino 
acid) FPR 
Length 
(aa) 
No. of 
Guitope 
Matches 
CF-CIMG_02795 1 7.32 249 0 427 82 
CSA-CIMG_01181 2 6.64 40 0 146 46 
Eli-Ag1-CIMG_10032 3 6.34 159 0 224 62 
AG2-CIMG_09696 4 5.44 145 0.001 194 43 
       Part B.) Inversions = 0 
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Name 
Ran
k 
Max 
Score 
Max Score 
Position 
(amino 
acid) FPR 
Length 
(aa) 
No. of 
Guitope 
Matches 
CF-CIMG_02795 1 6.37 362 0 427 51 
CSA-CIMG_01181 2 6.33 60 0 146 23 
Eli-Ag1-CIMG_10032 3 4.68 210 0.0013 224 39 
AG2-CIMG_09696 4 4.55 74 0.0015 194 16 
 
The number of positive hits obtained when using the di-peptide inversion 
modulation in addition to the Smith-Waterman [33] positional search algorithm is higher 
than those obtained without including di-peptide inversions. The individual peptide 
positive hits per protein are summarized in Supplementary Table 3- 4 with inversions and 
Supplementary Table 3- 5 without inversions.  
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Figure 3- 6 GuiTope analysis comparing 96-random peptide VF predictors with each of 
the 4 VF proteins tiled for the 83 life-space epitope peptides.  
The X-axis shows amino acid position on the protein and Y-axis shows the GuiTope score 
calculated after library subtraction. Panel A shows the score distribution per amino acid 
residue when Inversion weight is set to a maximum value of 1 and Panel B shows the 
detection rate when the di-peptide inversion algorithm is not used to find peptide vs. 
protein matches for the same dataset (inversion weight=0).  
When inspecting the raw signal data averaged per peptide (83 life-space) per CF-
titer (Figure 3- 7), as expected, earlier in the infection (CF-titer=0), the IgM antibody 
response is much higher than the IgG antibody level.   
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Figure 3- 7 VF predictor random peptides (96) overlapping 83 life-space peptides from 
Valley fever.  
The un-normalized IgG and IgM antibody signals (X-axis) from VF patients as captured 
by the 83 life-space peptides (Y-axis) are displayed. Patient signals are averaged based 
on the individual patient’s CF-titer (cyan= 0-titer, brown = IDCF-titer 1 etc.) per life-
space peptide. The red line is a moving average representing the trend observed in these 
data. The pink line displays the overall coverage of GuiTope matches between 96-
random peptides and 4 VF protein antigens.  
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Figure 3- 8 BLAST alignment map depicting VF-protein coverage of 96-random peptides 
through positive hits from GuiTope. 
Figure 3- 8 shows the BLAST alignment map per antigen depicting positive 
GuiTope hits between 96-random peptides and matching short protein sequences on the 4 
VF antigens. Some regions have multiple positive hits with several different peptides 
within the 96-random VF predictor peptides. These bioinformatics analysis might begin 
to explain why non-natural sequence peptides are capable of capturing disease specific 
antibody reactivity. 
Discussion 
We generated a sub-array for testing the diagnostic performance of 96-random 
non-natural sequence VF predictor peptides versus 83 life-space epitope peptides from 
VF. The 96-random peptides selected for this comparison were previously empirically 
tested to be good predictors for capturing VF specific antibody reactivity [80].  The 
current comparison is presented to ascertain whether non-natural peptides or life-space 
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peptides would be most useful in distinguishing infections such as Valley Fever in a 
microarray diagnostic format.  We tested VF patient sera for IgG and IgM antibody 
against VF.  As expected for a chronic infection, we observed higher IgM antibody early 
in patients that were sero-negative on the gold-standard IDCF assay.  We then tested this 
array’s ability to distinguish VF patient sera (including false-negatives; IDCF=0) from 
normal using 55 sera with various CF-titers from an orthogonally characterized training 
set and 63 sera from an initially blinded test set.  VF patients were distinguished from 
non-VF individuals using either the 96-random or 83 life-space epitope peptides by Naïve 
Bayes.  The sensitivity of these two groups of peptides was assessed using 0-titer samples 
and comparing against non-VF sera. The specificity of diagnosing every stage of the 
infection was assessed by using incremental CF-titer samples suggestive of progression 
versus non-VF sera.  In both comparisons, random peptides performed more accurately 
compared to life-space epitope peptides.  The higher accuracy obtained might be partially 
attributable to the 96-random peptides having a higher diversity of di-peptides as 
compared to 83 life-space peptides.  More diversity of di-peptides within random 
peptides could translate to more combinations of di-peptide antibody contact points 
presented by random peptides.  A comparison of the 96-random VF predictor peptides 
versus the four life-space VF antigens using GuiTope explains why these 96 non-natural 
sequence peptides perform with higher accuracy when distinguishing VF. Using di-
peptide inversions there are 233 unique short-sequence matches (129 matches without 
inversions) between the 96 random VF predictor peptides and VF antigens allowing 
 75 
 
random peptides to compete for antibodies originally generated against VF epitope 
peptides. 
Cross-reactivity is an inherent problem observed in antigen-antibody assays with 
VF specific assays not being an exception to this rule [92]. Kuberski et al. [93] 
recommended using the cross-reactivity observed on a Histoplasma antigen assay from 
VF infected individuals samples for VF diagnosis. By comparing a previously un-trained 
on exposure capable of presenting confounding symptoms, we assessed the specificity 
and robustness of both non-natural and epitope peptides. Since the random peptides were 
not originally trained to distinguish between VF and LVS, as expected the specificity 
dropped from 92% (without LVS group) to 87% (with LVS, Naïve Bayes, holdout, Table 
3- 2 - Part A and B).  This highlights an important problem in the biomarker field 
whereby during the initial training phase of assay development, if the diagnostic system 
is not trained a priori to rule out similar confounding infections, the sensitivity of the 
assay might not be easily affected but the specificity will change significantly. Ideally, 
for testing the specificity of such an assay one would compare clinically confounding 
infections that cause similar symptoms or are presented by pathogens that operate under 
similar mechanisms of pathogenicity (e.g. invasive mycoses). Additional appropriate 
confounding infections for training and feature selection would be Community Acquired 
Pneumonias (CAP) such as tuberculosis (TB), and invasive mycoses such as 
Blastomyces, Histoplasma and Crytococcus. 
A CF-Titer of 1:2 or 1:4 suggests a better prognosis, whereas a titer of 1:16 or 
greater (up to 1:256) is indicative of disseminated disease. Several patient case histories 
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of zero CF-Titer or a titer not suggestive of dissemination i.e. under 1:16 have been 
documented to show meningeal dissemination [67]. Approximately 1% of patient 
samples post-dissemination are false negative on the IDCF assay [94]. While this is not 
an alarming statistic, it is nevertheless important when the dissemination is meningeal. 
Early detection is crucial to better prognosis for patients with meningeal VF [95].  The 
blinded test set also included a CSF sample that was false negative on the CF-titer assay 
but was accurately diagnosed as being sero-positive for VF on the random peptide sub-
array. Thus, the immunosignature technology, due to its higher positive predictive value 
(PPV), may be able to assess disease progression, especially in cases of meningeal 
dissemination despite a negative IDCF (confirmatory test) result. 
From a survey of 39,500 infected valley fever patient sera Smith et al. [96] 
determined that within the first week, complement fixation antibodies measured by the 
IDCF assay were detected in approximately 10% of patients and were significantly 
reduced a month later.  This is correlated by the measurably lower amount of antibody 
captured by the life-space epitope peptides (as measured by average intensity) as 
compared to random peptides (Figure 3-2, panel A). Pappagianis et al. (2011) recently 
demonstrated in-vitro that early treatment with anti-fungal agents like Fluconazole, 
results in reduced or absent production of the chitinase antigen in Coccidioidal cultures 
[97].  They thereby correlated early intervention with anti-fungals such as Fluconazole in 
some patients causing a reduction in IDCF detectable levels of IgG antibodies 
predominantly to the chitinase antigen.  This, in their opinion, results in delaying patient 
diagnosis and therefore they recommend that primary pulmonary infections not be treated 
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with the antifungal before being tested and monitored for Valley Fever.  A similar trend 
in the reduction of galactomannan antigenemia in invasive Aspergillosis post anti-fungal 
intervention with Fluconazole was not mis-construed as being detrimental due to reduced 
diagnosis on assay [98].  In fact, a decrease in antigenemia correlated with survival and 
an increase despite anti-fungal intervention correlated with morbidity in infected 
individuals.  These problems in diagnosis are typically observed in single correlates of 
infection.  Technologies such as immunosignatures may surpass limitations posed by 
such single correlates for diagnosis due to being strengthened by multiple predictors 
while assessing infection. 
The 96 non-natural peptides have a higher number of 5-mer sequence overlap 
with the VF proteome (686 identical 5-mers in common) as compared to the F. tularensis 
(LVS) proteome (162 identical 5-mers in common). As per Lund et al., 85% of antibody 
structures characterized in the Protein Data Bank (PDB) database are associated with 5-
mers epitope sequences [99]. Figure 3-7 and Figure 3-8 partially explain the 96 non-
natural peptides ability to capture VF-specific antibodies through their coverage of 83 
VF-epitopes and the 4 immunodominant VF-antigens they represent, respectively. 
Current methods of diagnosis are quite course and rely on single markers such as CF titer. 
Graybill  and colleagues [100] noted that CF titer did not change significantly during 
treatment, where patient symptoms had greatly improved.  With a larger panel of sensors 
(peptides), a more complete picture of the status of the humoral immune response can be 
observed, without the risk of relying on the abundance or antibody response to a single 
antigen. High information-content technologies like Immunosignatures can enable more 
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subtle modulation of antifungal interventions, relieving the patient of the burden of side 
effects. This work presents encouraging evidence suggesting that non-natural sequence 
peptides might serve as more accurate molecular beacons for VF diagnosis than life-
space pathogen epitopes. 
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Supplementary Tables: 
Supplementary Table 3- 1 Sample characteristics of the training set for Valley fever 
study. 
IDCF 
Titer 
# Samples 
0 6 
1 4 
2 8 
4 5 
8 3 
16 8 
32 11 
64 5 
128 3 
256 2 
 
Note: 55 sera from 35 patients within the training dataset.  The IDCF titer and number of 
patients with that titer are shown in columns 1 and 2.   
Supplementary Table 3- 2 Sample characteristics of the 67 blinded test sera from 25 
patients. 
IDCF # Samples 
0 48 
1 5 
2 7 
4 3 
8 1 
16 2 
32 1 
 
Note: These samples were initially blinded by the clinic. 
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Supplementary Table 3- 3 Individual patient characteristics from the un-blinded test set. 
Tube # Patient # CF titer TP titer Date diff. 
False Negative 
CF results 
# Blood draws 
1 109 0 0 0 1 1 
2 109 2 0 25   2 
3 109 0 0 26 CSF 1 CSF 
4 116 0 0 0 1 1 
5 116 4 0 7   2 
7 123 4 0 0   1 
8 123 0 0 27 1 2 
9 138 0 0 0 1 1 
11 138 1 0 44   2 
12 162 0 0 0 1 1 
14 162 16 1 71   2 
15 184 0 0 0 1 1 
16 184 2 0 18   2 
18 188 0 0 0 1 1 
19 188 0 1 24 1 2 
20 188 0 0 84 1 3 
21 216 0 0 0 1 1 
23 216 2 0 12   2 
25 232 0 0 84 1 1 
26 232 0 0 42 1 2 
27 232 0 1 10 1 3 
28 236 0 0 0 1 1 
30 236 2 0 41   2 
31 251 0 0 0 1 1 
32 251 0 0 41 1 2 
33 251 0 0 90 1 3 
35 251 16 0 96   4 
36 288 0 0 0 1 1 
37 288 1 0 44   2 
38 288 0 0 159 1 3 
40 290 0 0 0 1 1 
41 290 0 1 23 1 2 
42 290 0 0 88 1 3 
43 363 0 0 0 1 1 
44 363 2 0 8   2 
45 383 0 0 0 1 1 
46 383 0 0 85 1 2 
47 383 1 0 14   3 
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49 391 0 0 0 1 1 
50 391 0 1 18 1 2 
51 401 0 0 0 1 1 
52 401 0 0 30 1 2 
54 401 0 1 4   3 
55 407 0 0 0 1 1 
56 407 32 0 71   2 
57 412 0 0 0 1 1 
58 412 1 0 49   2 
60 412 1 0 94   3 
61 413 0 0 0 1 1 
62 413 0 1 10 1 2 
63 437 0 0 0 1 1 
65 437 4 0 45   2 
66 437 2 0 80   3 
67 437 0 0 98 1 4 
68 472 0 0 0 1 1 
70 472 2 0 18   2 
71 473 0 0 0 1 1 
73 473 0 1 7 1 2 
74 487 0 0 0 1 1 
75 487 0 0 40 1 2 
76 487 0 1 49 1 3 
77 487 0 1 147 1 4 
79 487 0 0 113 1 5 
80 503 0 0 0 1 1 
81 503 0 0 20 1 2 
82 503 0 0 36 1 3 
84 503 8 0 113   4 
 
Note: False negative CF-titer results are coded as 1 for each sample tested. The 
accession numbers of these patients were left out of this table to de-identify them further 
for this work. 
Supplementary Table 3- 4 Summary of GuiTope results with inversion weight =1 from 
alignment of 96-random peptides to 4 immunodominant antigens of C.immitis 
Library subtracted, moving average=15 
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Match data for score cut 6.56 for protein : 
CF-CIMG_02795 
        ************** FORWARD PEPTIDES ************************** 
No. SEQUENCE 
SCOR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
1 
RVMFEGFQ
GKGPNYLQ
VGSC 6.757 5 14 15 LvqaS LqvgS 
2 
MQWHSNY
MMKRPYNP
ELGSC 6.671 9 23 8 MpnsypvPE MmkrpynPE 
3 
QVDWTRWR
KPKNEMAW
KGSC 6.903 11 45 2 
VnWaiygrgh
N 
VdWtrwrkpk
N 
4 
GFMLFGGN
PLEYAWYA
HGSC 6.872 9 45 10 vnwAiYgrG leyAwYahG 
5 
RTMNTALW
IIPLTWALW
GSC 7.893 5 47 14 WAiyG WAlwG 
6 
LYTSEQMTF
YGGRDDEIG
SC 8.235 7 49 9 iYGrghn fYGgrdd 
7 
NRKNKGHA
YRDGHNIQL
GSC 7.386 8 50 9 YgrGHNpQ YrdGHNiQ 
8 
RIIRWSPGQ
DAKFQDQN
GSC 7.943 12 52 4 
RghnpQDlK
adq 
RwspgQDaK
fqd 
9 
MAIQGMNI
YTWFTDRI
MGSC 10.485 18 61 2 
AdQfthIlyaF
anirpsg 
AiQgmnIytw
Ftdrimgs 
10 
MTRRWKTF
PHEIEDRIKG
SC 7.065 6 73 14 nirpsg drikgs 
11 
YDVMLSQP
NPVSWMRF
PGSC 7.599 17 79 2 
eVyLSdtwad
tdkhyPG 
dVmLSqpnp
vswmrfPG 
12 
YFWLDVNY
DEWTAVVD 7.804 12 79 5 
eVylsdtwAdt
D 
dVnydewtAv
vD 
 83 
 
QGSC 
13 
TKRIHKWPQ
DAYRIRRGG
SC 7.76 6 91 5 khyPgD hkwPqD 
14 
TMIHMQRV
KPRKLTNY
VGSC 7.4 4 104 15 NvyG NyvG 
15 
MRPRHAMP
NIKEYMLSP
GSC 9.201 6 109 10 IKqmyL IKeymL 
16 
PNPWLEWM
HMLLWNNQ
DGSC 
8.2050
01 13 109 5 
ikqMylLkkN
Nrn 
lewMhmLlw
NNqd 
17 
EFTWMLNK
NNEMHRHP
PGSC 8.319 7 113 4 ylLkKNN wmLnKNN 
18 
WFNERKRA
QLYEVGEFT
GSC 7.787 17 118 3 
NnRnlktLlsi
GgwTyS 
NeRkraqLye
vGefTgS 
19 
HMRAMNPF
KPHTNIGRW
GSC 
7.5320
01 5 135 6 pnFKt npFKp 
20 
ARWKKKSH
FHRGKKKM
FGSC 
8.7289
99 8 142 7 SteegrKK ShfhrgKK 
21 
HRGKKAPD
FQVGYLKA
DGSC 10.442 15 145 1 
egrKKfaDtsl
klmK 
hrgKKapDfq
vgylK 
22 
RKFKKRRH
WHFPKFPK
WGSC 8.31 13 147 1 
RKkfadtslkl
mK 
RKfkkrrhwhf
pK 
23 
FDMLFKDS
YIWGMTIMF
GSC 7.937 12 157 4 
LmKDlgfdG
idI 
LfKDsyiwG
mtI 
24 
HEGLEGDQ
TIYQFMIEY
GSC 
6.9889
99 10 159 1 kdlgfdgidI heglegdqtI 
25 
KGDFGAEW
GRWRKWVT
KGSC 7.392 4 162 2 GfdG GdfG 
26 
VTGTEGQW
DGYPLWHL
FGSC 7.423 5 169 8 dweYP wdgYP 
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27 
DQWMTMR
VKFRDWVQ
LIGSC 7.391 9 181 12 DfVlLlkaC DwVqLigsC 
28 
YSWDAINW
RGKAYPVE
TGSC 7.844 11 191 4 eAldaysakhP dAinwrgkayP 
29 
KARWNGRN
MTAPVYWR
NGSC 7.75 7 198 1 akhpNGk karwNGr 
30 
YANRGNGK
KVHWLLFY
QGSC 
8.9990
01 13 198 2 
AkhpNGKK
fllti 
AnrgNGKKv
hwll 
31 
MYYFPDTG
GQPDGSMW
NGSC 7.591 12 207 1 lltiaspaGpqn 
myyfpdtgGq
pd 
32 
FNLGWKVQ
GKLDMSAP
KGSC 8.642 8 208 11 LtiasPaG LdmsaPkG 
33 
KQKLPHWY
RRLDRPVTV
GSC 8.394 12 221 1 
KlKLaemdk
yLD 
KqKLphwyrr
LD 
34 
TRQLAPYFD
WHNYSIAIG
SC 
8.6259
99 13 231 7 
ldfWnlmayd
fsg 
yfdWhnysiai
gs 
35 
DKFHYWMY
MLYGINDKI
GSC 10.083 19 232 1 
DfwnlmaYdf
sGswDKvsg 
DkfhywmYm
lyGinDKigs 
36 
EVERGDMN
WLTISVNNA
GSC 
8.4070
01 5 232 6 DfwnL DmnwL 
37 
WAEKPKIK
NWLGRQKL
GGSC 7 11 234 9 
wnLmaydfs
GS 
nwLgrqklgG
S 
38 
GFNQWFSID
NWLHTAQW
GSC 8.596 10 234 10 wnLmaydfsg nwLhtaqwgs 
39 
YKMDWSIA
FQIMHFDVS
GSC 11.234 11 234 9 
wnlMayDfS
GS 
fqiMhfDvSG
S 
40 
RPPIRLRDV
LNDHYEVR
GSC 7.092 10 235 10 nlmaYdfsGS lndhYevrGS 
41 RLCKNKTFC 8.001 8 237 12 maydfsGS fyaqweGS 
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WGFYAQWE
GSC 
42 
HGPDWTIHP
FPGLWVFD
GSC 7.614 7 237 13 maydfsg lwvfdgs 
43 
IALFDPTKW
PEHHQYFA
GSC 7.919 9 237 1 mAydfsgsW iAlfdptkW 
44 
VYEMWYNT
SANIDQDHR
GSC 
6.8819
99 10 237 4 
MaYdfSgsw
D 
MwYntSani
D 
45 
MFDYSPWW
EMYSYGVL
PGSC 8.917 11 239 2 
yDfSgsWdk
vS 
fDySpwWem
yS 
46 
NTAEADWG
TESTWSMH
RGSC 8.568 9 242 11 Sgswdkvsg Stwsmhrgs 
47 
HHRTHRPK
DGHVQWM
HVGSC 7.391 6 245 14 WdkVsg WmhVgs 
48 
IHKTEHWIS
TNADDWRA
GSC 8.196 6 245 14 wdkvsg dwrags 
49 
QDLLDYHLS
DFVLFAHM
GSC 9.332 11 246 2 
DkvsgHmSn
vf DlldyHlSdfv 
50 
VKGKLSNV
PSWFNHFHS
GSC 9.226 8 248 1 VsGhmSNV VkGklSNV 
51 
LSVISGMHS
EWPVLWLF
GSC 9.548 8 248 4 vSGhmSnv iSGmhSew 
52 
YSGHRHNV
PEIDMRQQF
GSC 8.232 8 248 1 vSGHmsNV ySGHrhNV 
53 
KYIGEHPVF
ESTEYRQGG
SC 6.672 5 255 8 VFpST VFeST 
54 
MYDAATNF
FMDSKGVR
KGSC 8.877 8 267 9 FssdKaVk FmdsKgVr 
55 
TPTDHIRSA
AARHKYLIG 7.499 15 275 4 
DyIkagvpan
KivlG 
DhIrsaaarhK
yliG 
 86 
 
SC 
56 
QKAPNKFE
HNVINAHN
WGSC 
7.8569
99 5 282 3 paNKi apNKf 
57 
KLVLQWAV
HMRKWNA
MDGSC 9.563 18 285 1 
KiVLgmply
gRafastDG 
KlVLqwavh
mRkwnamD
G 
58 
MTFHGYMV
RGSRGDIID
GSC 9.089 11 293 5 ygrafaStdgI gymvrgSrgdI 
59 
SLDGVARS
WPGGYGEG
HGSC 8.418 14 299 1 
StDGigtSfn
GvgG 
SlDGvarSwp
GgyG 
60 
GEDDTMQR
SYNWYQTN
VGSC 6.584 8 301 4 DgigtSfN DtmqrSyN 
61 
YMEAHKTY
NKQISRGVS
GSC 7.036 5 310 15 vggGS gvsGS 
62 
ISVETQWVP
LHDTGWDQ
GSC 8.628 11 314 2 
SwEngvwdy
kD 
SvEtqwvplh
D 
63 
YAENGAWD
VRVYSSAN
QGSC 9.904 8 316 3 ENGvWDyk ENGaWDvr 
64 
TNATWHYY
SINLMYQAQ
GSC 
6.6629
99 15 317 2 
NgvWdYkd
mpqqgaq 
NatWhYysinl
myqa 
65 
PKMRDRIQ
WTPVFTELQ
GSC 8.318 15 322 3 
ykDmpQqga
qvTELe 
mrDriQwtpvf
TELq 
66 
DRQQLEGTL
VERFERLW
GSC 
6.8520
01 14 328 6 
qGaqVtelEdi
aaS 
eGtlVerfErlw
gS 
67 
KKQSAWGL
WVAELNYM
HGSC 7.268 13 329 7 
GaqVtELedi
aaS 
GlwVaELny
mhgS 
68 
KYSNQKIW
ASYDSAPSR
GSC 7.739 9 347 4 NkryliSYD NqkiwaSYD 
69 
NGKDNVSID
YLHTRLGIG
SC 7.956 8 348 3 Krylisyd Kdnvsidy 
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70 
DTFWQFEK
YPEYNMHM
DGSC 7.546 12 355 1 
DTvkiagKka
EY 
DTfwqfeKyp
EY 
71 
TEYSLTPEK
VEYYAWEG
GSC 8.248 13 359 5 
iagkKaEYitk
nG 
ltpeKvEYya
weG 
72 
KSITDRGQK
TWWEWRR
NGSC 6.934 4 376 11 mWwe wWew 
73 
YLSTSMEQE
QEQVHGNW
GSC 7.346 15 385 4 
TgnEslvgtV
vnglG 
TsmEqeqeqV
hgnwG 
74 
RWFVGSMN
GQNPVGTFS
GSC 8.828 9 386 8 gneslVGTv ngqnpVGTf 
75 
GRWLGEPN
VQAGPTFFP
GSC 7.641 12 390 3 
lvGtvvnglGg
T 
wlGepnvqaG
pT 
76 
VKPVDFMG
RYGQLHNF
EGSC 8.166 14 395 4 
VnglGgtGkL
eqrE 
VdfmGryGq
LhnfE 
77 
TLAPWQGL
KIWERQVPN
GSC 7.757 9 401 6 tGkleqren qGlkiwerq 
78 
SYKQYHIGR
HIDLESLEG
SC 
7.2020
01 14 403 6 
kleqrenelSyp
eS 
higrhidleSleg
S 
79 
DSNKNEEN
QTDRSQYDS
GSC 8.612 15 406 3 
qrenElsypeS
vYDn 
nkneEnqtdrS
qYDs 
80 
IHQFEVTRQ
QHEYSPFDG
SC 7.888 7 406 8 qrenElS rqqhEyS 
81 
RKGNVPRT
ARLFSVEW
WGSC 7.753 5 422 2 KngmP KgnvP 
82 
PVENKGRTS
THGFILWHG
SC 6.841 6 422 4 knGmpS nkGrtS 
        
Match data for score cut 6.56 for protein : 
CSA-CIMG_01181 
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        ************** FORWARD PEPTIDES ************************** 
No. SEQUENCE 
SC
OR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
1 
KYIGEHPVFES
TEYRQGGSC 
7.01
6 5 15 7 vpFtS pvFeS 
2 
RWFVGSMNG
QNPVGTFSGS
C 
7.23
6 5 15 13 VpftS VgtfS 
3 
PKMRDRIQWT
PVFTELQGSC 
7.18
2 4 15 11 vpFT pvFT 
4 
VYEMWYNTS
ANIDQDHRGS
C 
6.84
9 10 25 8 sttdlsyDth tsanidqDhr 
5 
QDLLDYHLSD
FVLFAHMGSC 
7.37
5 18 27 1 
tDLsydthyD
dpslAlsG 
qDLldyhlsDf
vlfAhmG 
6 
NSWNQEYTD
HVVYHGMFG
SC 
8.20
9 19 30 2 
SydthYdDps
lalsgvtcs 
SwnqeYtDhv
vyhgmfgsc 
7 
SYKQYHIGRHI
DLESLEGSC 
7.20
4 6 30 1 SYdthy SYkqyh 
8 
ISVETQWVPL
HDTGWDQGS
C 
7.23
7 8 32 12 DThyDdpS DTgwDqgS 
9 
ETNRWHRNR
QGYLAHSTGS
C 
8.09
100
1 15 34 6 
Hyddpslalsg
vtcs 
Hrnrqgylahst
gsc 
10 
TNATWHYYSI
NLMYQAQGS
C 
6.96
3 15 34 6 
HYddpsLals
gvtcs 
HYysinLmyq
aqgsc 
11 
YDVMLSQPNP
VSWMRFPGSC 
6.83
8 11 35 1 
YDdpslalsg
V 
YDvmlsqpnp
V 
12 
TRQLAPYFDW
HNYSIAIGSC 
10.2
67 10 35 10 yddpSlAlsg whnySiAigs 
13 
NRKNKGHAY
RDGHNIQLGS
C 
7.15
8 9 36 11 DdpslaLsg DghniqLgs 
14 
MYYFPDTGGQ
PDGSMWNGS
C 
6.70
9 8 37 12 DpSlalsg DgSmwngs 
15 
YKMDWSIAFQ
IMHFDVSGSC 
6.94
2 6 37 4 DpSlAl DwSiAf 
 89 
 
16 
LSVISGMHSE
WPVLWLFGSC 
8.89
1 8 39 1 slalSGvt lsviSGmh 
17 
RTMNTALWIIP
LTWALWGSC 
7.19
4 5 40 15 lalsg alwgs 
18 
VQERMHNRT
WKRFGGSMG
SC 
8.32
7 6 43 15 sgvtcs gsmgsc 
19 
FDMLFKDSYI
WGMTIMFGSC 
8.20
500
1 9 48 7 sdgdnGMit dsyiwGMti 
20 
EVERGDMNW
LTISVNNAGSC 
9.78
8 14 50 5 
GDngmiTkg
yNtAG 
GDmnwlTisv
NnAG 
21 
GEDDTMQRSY
NWYQTNVGS
C 
6.96
9 11 50 1 
GdngmitkgY
N 
GeddtmqrsY
N 
22 
SKTRSLSHAH
QMPASWFGSC 7 11 56 3 
TkgyntAgei
P TrslshAhqmP 
23 
HMRAMNPFKP
HTNIGRWGSC 
6.57
3 9 57 9 KgyntaGei KphtniGrw 
24 
GFNQWFSIDN
WLHTAQWGS
C 
7.61
5 13 58 1 
GyNtageIpN
ypH 
GfNqwfsIdN
wlH 
25 
MFDYSPWWE
MYSYGVLPGS
C 
7.03
1 15 59 4 
YntagEipnY
phvgG 
YspwwEmys
YgvlpG 
26 
RVMFEGFQGK
GPNYLQVGSC 
9.44
5 10 63 9 
GeiPNYphV
G 
GkgPNYlqV
G 
27 
RKFKKRRHW
HFPKFPKWGS
C 
6.69
6 9 64 10 eiPnyPhvG hfPkfPkwG 
28 
MQWHSNYM
MKRPYNPELG
SC 
9.48
9 7 66 12 PnyPhvG PynPelG 
29 
RKGNVPRTAR
LFSVEWWGSC 
10.6
53 16 67 4 
NyPhvggaFt
VEtWnS 
NvPrtarlFsV
EwWgS 
30 
DTFWQFEKYP
EYNMHMDGS
C 7.33 7 67 12 nypHvgG ynmHmdG 
31 
GRWLGEPNVQ
AGPTFFPGSC 
7.32
2 9 69 7 PhVggafTv PnVqagpTf 
32 
YSWDAINWR
GKAYPVETGS
C 
8.88
6 8 72 10 GgAftVET GkAypVET 
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33 
YAENGAWDV
RVYSSANQGS
C 
12.3
19 16 73 5 
GAftVetwnS
pNcGkC 
GAwdVrvys
SaNqGsC 
34 
QKAPNKFEHN
VINAHNWGSC 
6.58
3 14 75 7 
FtvetwNspN
cGkC 
FehnviNahN
wGsC 
35 
IHKTEHWISTN
ADDWRAGSC 
7.16
8 7 78 5 EtWnSpN EhWiStN 
36 
YFWLDVNYD
EWTAVVDQG
SC 
7.32
2 11 78 10 
EtwnspncGk
C 
EwtavvdqGs
C 
37 
TMIHMQRVKP
RKLTNYVGSC 
8.17
9 8 87 9 KcyKvTyn KprKlTny 
38 
HRGKKAPDFQ
VGYLKADGSC 
6.64
1 8 89 9 ykVtYnak fqVgYlka 
39 
NRAKHRHWL
FPDKDHNLGS
C 
9.50
7 14 96 6 
ktifltaiDHsn
sg 
rhwlfpdkDH
nlgs 
40 
INRHGDWNQH
FQIPKHPGSC 
7.67
9 9 107 8 NsgFnIaKk NqhFqIpKh 
41 
ARWKKKSHF
HRGKKKMFGS
C 
6.95
4 10 108 7 
SgFniaKKs
M 
ShFhrgKKk
M 
42 
MYDAATNFF
MDSKGVRKGS
C 
7.23
7 7 110 7 fniakks nffmdsk 
43 
MAIQGMNIYT
WFTDRIMGSC 
6.73
6 10 112 1 iAkksMdvlT mAiqgMniyT 
44 
KSITDRGQKT
WWEWRRNGS
C 
7.21
099
9 5 120 3 lTngr iTdrg 
45 
LYTSEQMTFY
GGRDDEIGSC 7.82 7 123 12 GRaeElG GRddEiG 
46 
DRQQLEGTLV
ERFERLWGSC 
10.1
22 18 124 2 
RaeelGrikvt
yEevasS 
RqqleGtlverf
ErlwgS 
        
Match data for score cut 6.56 for protein : 
Eli-Ag1-CIMG_10032 
        ************** FORWARD PEPTIDES ************************** 
No. SEQUENCE SCORE 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
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1 
QDLLDYHLS
DFVLFAHM
GSC 11.818 10 1 6 mHLSgiVfaf yHLSdfVlfa 
2 
FDMLFKDS
YIWGMTIMF
GSC 6.879 10 3 10 lsGivfaFsS iwGmtimFgS 
3 
YKKMYFRR
WQPTARLS
RGSC 7.137 9 21 6 FRlvdPppR FRrwqPtaR 
4 
YFWLDVNY
DEWTAVVD
QGSC 7.189 5 21 2 FrLvd FwLdv 
5 
YSGHRHNV
PEIDMRQQF
GSC 6.567 9 24 11 vDppprgfS iDmrqqfgS 
6 
VQERMHNR
TWKRFGGS
MGSC 6.562 10 37 8 trfpcgGqSM rtwkrfGgSM 
7 
PVENKGRTS
THGFILWHG
SC 7.219 6 47 4 sKsRTS nKgRTS 
8 
SKTRSLSHA
HQMPASWF
GSC 11.149 7 48 1 ksrtSvS sktrSlS 
9 
TEYSLTPEK
VEYYAWEG
GSC 6.562 6 51 1 TsvSLT TeySLT 
10 
YKMDWSIA
FQIMHFDVS
GSC 7.267 11 58 3 
lempIAlemg
H 
mdwsIAfqim
H 
11 
ISQQMVLH
MRYAPELL
GGSC 6.902 9 58 7 LeMpiAlEm LhMryApEl 
12 
MAIQGMNI
YTWFTDRI
MGSC 
7.9699
99 6 62 1 iAlemg mAiqgm 
13 
LSVISGMHS
EWPVLWLF
GSC 
9.5919
99 14 64 4 
lemgHdqtaV
qvLl 
isgmHsewpV
lwLf 
14 
HEGLEGDQ
TIYQFMIEY
GSC 12.15 13 69 7 
DQTavQvlla
lGS 
DQTiyQfmie
yGS 
15 DKFHYWMY 6.665 13 73 7 vqvLlalgshp mymLygindk
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MLYGINDKI
GSC 
GS iGS 
16 
HHRTHRPK
DGHVQWM
HVGSC 
8.1079
99 8 74 12 qvllalGS vqwmhvGS 
17 
TRQLAPYFD
WHNYSIAIG
SC 7.772 5 77 15 lAlGS iAiGS 
18 
ETNRWHRN
RQGYLAHS
TGSC 8.791 7 79 13 LgshpGS LahstGS 
19 
VKGKLSNV
PSWFNHFHS
GSC 6.671 12 79 5 
LgshPgsnfni
t 
LsnvPswfnhf
h 
20 
ASNSHHRPP
KLHNFYPH
GSC 7.209 4 82 16 hpGS phGS 
21 
KARWNGRN
MTAPVYWR
NGSC 9.49 10 88 8 NiTlvptfRq 
NmTapvywR
n 
22 
PKMRDRIQ
WTPVFTELQ
GSC 
7.3809
99 8 92 11 vptfrqvG pvftelqG 
23 
QRSWFSGK
EPKFQRIWK
GSC 7.645 9 93 10 PtFrqvglG PkFqriwkG 
24 
RVMFEGFQ
GKGPNYLQ
VGSC 6.898 7 93 12 PtfrQVG PnylQVG 
25 
FNLGWKVQ
GKLDMSAP
KGSC 
7.7529
99 15 95 5 
frqvGlgDfcl
PsvS 
wkvqGklDm
saPkgS 
26 
WAEKPKIK
NWLGRQKL
GGSC 
8.1849
99 6 96 13 RQvglG RQklgG 
27 
VYEMWYNT
SANIDQDHR
GSC 6.736 11 106 8 pSvslDeqrlG tSaniDqdhrG 
28 
YLSTSMEQE
QEQVHGNW
GSC 9.074 16 107 3 
SvSldeqrlgV
kpvdG 
StSmeqeqeq
VhgnwG 
29 
NGKDNVSID
YLHTRLGIG 7.101 11 107 7 
SvsldeqRLG
v SidylhtRLGi 
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SC 
30 
NSWNQEYT
DHVVYHGM
FGSC 7.049 15 109 2 
Sldeqrlgvkp
vdGM 
Swnqeytdhvv
yhGM 
31 
VKPVDFMG
RYGQLHNF
EGSC 10.087 7 117 1 VKPVDgM VKPVDfM 
32 
EVERGDMN
WLTISVNNA
GSC 11.996 12 121 5 
dgMNatlqv
VtN 
gdMNwltisV
nN 
33 
INRHGDWN
QHFQIPKHP
GSC 8.169 9 121 5 dgmNatlQv gdwNqhfQi 
34 
RTMNTALW
IIPLTWALW
GSC 9.139 9 123 3 MNatLqvvt MNtaLwiip 
35 
MYYFPDTG
GQPDGSMW
NGSC 10.358 11 131 7 
TnGdPnGgl
yN 
TgGqPdGsm
wN 
36 
NRKNKGHA
YRDGHNIQL
GSC 7.036 10 133 11 
gdpNggLyn
C dghNiqLgsC 
37 
LYTSEQMTF
YGGRDDEIG
SC 
6.6410
01 9 139 1 LYncadiTF LYtseqmTF 
38 
YSWDAINW
RGKAYPVE
TGSC 
7.2769
99 20 140 1 
YncadItfsstte
ytvpsSC 
YswdaInwrg
kaypvetgSC 
39 
ISVETQWVP
LHDTGWDQ
GSC 7.56 8 149 2 StteytVP SvetqwVP 
40 
KYIGEHPVF
ESTEYRQGG
SC 
8.7830
01 9 151 12 TEYtvpsSC TEYrqggSC 
41 
MRPRHAMP
NIKEYMLSP
GSC 7.238 6 152 12 EYtvps EYmlsp 
42 
RPPIRLRDV
LNDHYEVR
GSC 7.327 8 152 13 eYtVpsSC hYeVrgSC 
43 
KGDFGAEW
GRWRKWVT
KGSC 7.754 7 153 14 ytvpsSC wvtkgSC 
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44 
KQKLPHWY
RRLDRPVTV
GSC 7.34 6 154 15 tvpsSC vtvgSC 
45 
RLCKNKTFC
WGFYAQWE
GSC 
7.1720
01 5 159 3 CKNgT CKNkT 
46 
RKGNVPRT
ARLFSVEW
WGSC 12.072 14 160 2 
KngtgvTAtp
FSgE 
KgnvprTArl
FSvE 
47 
LANVLYRE
QTRPNATER
GSC 6.604 13 160 7 
kngTgvtATp
fsg 
reqTrpnATer
gs 
48 
EFTWMLNK
NNEMHRHP
PGSC 7.471 13 160 7 
kngtgvtatPfs
g 
nknnemhrhP
pgs 
49 
HGPDWTIHP
FPGLWVFD
GSC 7.806 11 162 2 
GtgvTatPFs
G 
GpdwTihPFp
G 
50 
YDVMLSQP
NPVSWMRF
PGSC 7.291 4 169 16 pfsg fpgs 
51 
GRWLGEPN
VQAGPTFFP
GSC 7.291 4 169 16 pfsg fpgs 
52 
DSNKNEEN
QTDRSQYDS
GSC 7.795 16 177 4 
rNanesTpng
QpqrGn 
kNeenqTdrs
QydsGs 
53 
YAENGAWD
VRVYSSAN
QGSC 
7.3279
99 6 182 13 StpNgq SsaNqg 
54 
YMEAHKTY
NKQISRGVS
GSC 11.146 13 183 7 
TpNgQpqR
GnSGS 
TyNkQisRG
vSGS 
55 
RWFVGSMN
GQNPVGTFS
GSC 
9.7984
99 12 185 8 
NGQpqrGns
gsg 
NGQnpvGtfs
gs 
56 
KSITDRGQK
TWWEWRR
NGSC 7.435 5 189 15 qRgnS rRngS 
57 
TLAPWQGL
KIWERQVPN
GSC 6.768 6 189 14 QrgNsg QvpNgs 
58 HMRAMNPF 6.626 5 190 15 rgnsg grwgs 
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KPHTNIGRW
GSC 
59 
MFDYSPWW
EMYSYGVL
PGSC 7.046 15 200 3 
niaghlEtatw
GVLg 
dyspwwEmy
syGVLp 
60 
GFNQWFSID
NWLHTAQW
GSC 
9.9959
99 12 200 7 
nIaghLeTAt
WG 
sIdnwLhTAq
WG 
61 
NTAEADWG
TESTWSMH
RGSC 7.695 7 206 9 etaTWgv tesTWsm 
62 
GFMLFGGN
PLEYAWYA
HGSC 7.391 10 214 1 
GaivvGGva
L GfmlfGGnpL 
        
Match data for score cut 6.56 for protein : 
AG2-CIMG_09696 
        ************** FORWARD PEPTIDES ************************** 
No. SEQUENCE 
SCOR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
1 
MQWHSNY
MMKRPYNP
ELGSC 8.671 8 1 1 MQfshali MQwhsnym 
2 
RTMNTALW
IIPLTWALW
GSC 6.791 11 7 9 lIaLvaAglaS iIpLtwAlwgS 
3 
KGDFGAEW
GRWRKWVT
KGSC 6.622 6 31 4 FvealG FgaewG 
4 
HEGLEGDQ
TIYQFMIEY
GSC 8.102 7 35 3 lgndgcT glegdqT 
5 
MAIQGMNI
YTWFTDRI
MGSC 7.222 11 41 10 TrlTDfkchcs 
TwfTDrimgs
c 
6 
INRHGDWN
QHFQIPKHP
GSC 
6.8359
99 16 42 3 
RltDfkcHcsk
PelPG 
RhgDwnqHf
qiPkhPG 
7 
YKMDWSIA
FQIMHFDVS 7.175 9 43 12 ltdfkchcs mhfdvsgsc 
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GSC 
8 
EVERGDMN
WLTISVNNA
GSC 7.333 15 63 1 
veEacpldaris
vsN 
evErgdmnwlt
isvN 
9 
RKGNVPRT
ARLFSVEW
WGSC 
8.4790
01 12 68 6 
PldARisvsni
v 
PrtARlfsvew
w 
10 
TPTDHIRSA
AARHKYLIG
SC 7.951 7 68 2 PlDariS PtDhirS 
11 
QDLLDYHLS
DFVLFAHM
GSC 
7.8309
99 12 69 2 ldarisvSniVv dlldyhlSdfVl 
12 
YFWLDVNY
DEWTAVVD
QGSC 8.695 16 69 4 
LDarisvsniV
VDQcS 
LDvnydewta
VVDQgS 
13 
YKKMYFRR
WQPTARLS
RGSC 6.596 4 71 13 ARiS ARlS 
14 
HRGKKAPD
FQVGYLKA
DGSC 7.04 12 73 9 
isVsnivvDqc
s 
fqVgylkaDgs
c 
15 
TNATWHYY
SINLMYQAQ
GSC 7.318 8 75 8 vSnivvdQ ySinlmyQ 
16 
DTFWQFEK
YPEYNMHM
DGSC 
8.8300
01 8 77 13 NivvDqcs NmhmDgsc 
17 
HGPDWTIHP
FPGLWVFD
GSC 7.701 7 78 14 iVvDqcs wVfDgsc 
18 
YDVMLSQP
NPVSWMRF
PGSC 7.545 11 79 1 
vvdqcSkagv
p 
ydvmlSqpnp
v 
19 
YSGHRHNV
PEIDMRQQF
GSC 6.96 4 88 8 VPie VPei 
20 
PKMRDRIQ
WTPVFTELQ
GSC 
6.6939
99 8 90 7 IeipPVdT IqwtPVfT 
21 
IALFDPTKW
PEHHQYFA
GSC 
7.6719
99 11 92 1 
IppvDtTaaP
E 
IalfDpTkwP
E 
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22 
GRWLGEPN
VQAGPTFFP
GSC 7.902 12 102 6 
EPsetAePTa
eP 
EPnvqAgPTf
fP 
23 
LANVLYRE
QTRPNATER
GSC 7.252 9 112 8 EpTeeptaE EqTrpnatE 
24 
TEYSLTPEK
VEYYAWEG
GSC 7.158 14 114 1 
TEeptaeptaE
ptA 
TEysltpekvE
yyA 
25 
KYIGEHPVF
ESTEYRQGG
SC 
8.0820
01 13 131 5 
hePteEpTav
ptG 
ehPvfEsTeyr
qG 
26 
ISVETQWVP
LHDTGWDQ
GSC 6.588 11 134 4 teeptavptgt etqwvplhdtg 
27 
KARWNGRN
MTAPVYWR
NGSC 7.157 9 138 10 TAvptgtgG TApvywrnG 
28 
MYYFPDTG
GQPDGSMW
NGSC 6.643 6 140 4 vPtgtG fPdtgG 
29 
SLDGVARS
WPGGYGEG
HGSC 10.264 15 140 5 
VptgtgGGvp
tGtGS 
VarswpGGyg
eGhGS 
30 
RWFVGSMN
GQNPVGTFS
GSC 11.723 15 140 4 
VptgtGggvp
tgtgs 
VgsmnGqnp
vgtfsg 
31 
VTGTEGQW
DGYPLWHL
FGSC 7.705 17 143 2 
gtggGvptGtg
sftvtG 
tgteGqwdGy
plwhlfG 
32 
YSWDAINW
RGKAYPVE
TGSC 6.97 10 145 10 
GggvPtgTG
S GkayPveTGS 
33 
ETNRWHRN
RQGYLAHS
TGSC 6.922 9 146 11 GgvptgTGS GylahsTGS 
34 
MYYFPDTG
GQPDGSMW
NGSC 6.643 6 148 4 vPtgtG fPdtgG 
35 
LYTSEQMTF
YGGRDDEIG
SC 7.173 11 150 3 TgtgsftvtGR 
TseqmtfygG
R 
36 NTAEADWG 7.82 11 150 8 tgtgsftvtgr gtestwsmhrg 
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TESTWSMH
RGSC 
37 
KQKLPHWY
RRLDRPVTV
GSC 6.976 4 156 15 tvtG vtvG 
38 
IHKTEHWIS
TNADDWRA
GSC 7.934 11 164 9 
STpAefpgA
GS 
STnAddwrA
GS 
39 
YAENGAWD
VRVYSSAN
QGSC 7.23 6 172 5 agsnVR gawdVR 
40 
MTFHGYMV
RGSRGDIID
GSC 7.785 11 173 5 
GsnVRaSvG
gI 
GymVRgSrG
dI 
41 
YMEAHKTY
NKQISRGVS
GSC 
6.9819
99 5 177 14 RasvG RgvsG 
42 
ISQQMVLH
MRYAPELL
GGSC 6.93 7 183 11 iAaaLLG yApeLLG 
43 
KKQSAWGL
WVAELNYM
HGSC 7.933 9 186 5 AllglaAyL AwglwvAeL 
 
Supplementary Table 3- 5 Summary of GuiTope results with inversion weight =0 from 
alignment of 96-random peptides to 4 immunodominant antigens of C.immitis 
Library subtracted, moving average=15 
Match data for score cut 6.56 for protein : 
CF-CIMG_02795 
        
 
************** FORWARD PEPTIDES ************************** 
No. SEQUENCE 
SCOR
E 
ALIGN 
LENGTH 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
1 
ARWKKKSH
FHRGKKKM
FGSC 6.67 7 144 10 eeGrKKf hrGkKKm 
2 
KARWNGRN
MTAPVYWR 7.437 19 363 1 
KAeyitkNg
mgggmWwe
KArwngrN
mtapvyWrn
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NGSC sS gS 
3 
HMRAMNPF
KPHTNIGRW
GSC 6.584 10 122 8 lKtllsIGgW fKphtnIGrW 
4 
KQKLPHWY
RRLDRPVTV
GSC 8.394 12 221 1 
KlKLaemdk
yLD 
KqKLphwyr
rLD 
5 
KSITDRGQK
TWWEWRRN
GSC 6.762 3 377 11 WWE WWE 
6 
QVDWTRWR
KPKNEMAW
KGSC 6.903 11 45 2 
VnWaiygrg
hN 
VdWtrwrkp
kN 
7 
NRKNKGHA
YRDGHNIQL
GSC 7.386 8 50 9 YgrGHNpQ YrdGHNiQ 
8 
HHRTHRPKD
GHVQWMHV
GSC 6.709 7 52 3 RgHnPqD RtHrPkD 
9 
VKGKLSNVP
SWFNHFHSG
SC 9.226 8 248 1 VsGhmSNV VkGklSNV 
10 
MTRRWKTFP
HEIEDRIKGS
C 6.9 13 137 5 
fKTpasteEg
RkK 
wKTfpheiEd
RiK 
11 
MRPRHAMP
NIKEYMLSP
GSC 
8.294
999 12 201 8 
PNgKkflLti
aS 
PNiKeymLs
pgS 
12 
TPTDHIRSAA
ARHKYLIGS
C 7.499 15 275 4 
DyIkagvpan
KivlG 
DhIrsaaarhK
yliG 
13 
KYSNQKIWA
SYDSAPSRG
SC 7.739 9 347 4 NkryliSYD NqkiwaSYD 
14 
YMEAHKTY
NKQISRGVS
GSC 6.956 10 276 1 
YikAgvpaN
K 
YmeAhktyN
K 
15 
HRGKKAPDF
QVGYLKAD
GSC 7.162 4 361 3 GKKA GKKA 
16 
RTMNTALWI
IPLTWALWG
SC 7.893 5 47 14 WAiyG WAlwG 
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17 
DQWMTMRV
KFRDWVQLI
GSC 7.391 9 181 12 DfVlLlkaC DwVqLigsC 
18 
KKQSAWGL
WVAELNYM
HGSC 7.268 13 329 7 
GaqVtELedi
aaS 
GlwVaELny
mhgS 
19 
DKFHYWMY
MLYGINDKI
GSC 7.278 13 62 1 
DqFthilYafa
nI 
DkFhywmY
mlygI 
20 
QDLLDYHLS
DFVLFAHMG
SC 7.948 6 180 9 nDFVLl sDFVLf 
21 
KLVLQWAV
HMRKWNA
MDGSC 9.563 18 285 1 
KiVLgmply
gRafastDG 
KlVLqwavh
mRkwnamD
G 
22 
YANRGNGK
KVHWLLFY
QGSC 
8.999
001 13 198 2 
AkhpNGKK
fllti 
AnrgNGKK
vhwll 
23 
MYYFPDTGG
QPDGSMWN
GSC 7.566 10 309 9 
GvggGSwe
NG 
GqpdGSmw
NG 
24 
MFDYSPWW
EMYSYGVLP
GSC 8.917 11 239 2 
yDfSgsWdk
vS 
fDySpwWe
myS 
25 
HEGLEGDQT
IYQFMIEYGS
C 6.562 5 12 8 QTlvQ QTiyQ 
26 
GEDDTMQRS
YNWYQTNV
GSC 6.584 8 301 4 DgigtSfN DtmqrSyN 
27 
FDMLFKDSY
IWGMTIMFG
SC 7.937 12 157 4 
LmKDlgfdG
idI 
LfKDsyiwG
mtI 
28 
DTFWQFEKY
PEYNMHMD
GSC 7.546 12 355 1 
DTvkiagKk
aEY 
DTfwqfeKy
pEY 
29 
PNPWLEWM
HMLLWNNQ
DGSC 
8.205
001 13 109 5 
ikqMylLkk
NNrn 
lewMhmLlw
NNqd 
30 
YAENGAWD
VRVYSSANQ
GSC 9.904 8 316 3 
ENGvWDy
k ENGaWDvr 
31 DRQQLEGTL 6.852 14 328 6 qGaqVtelEd eGtlVerfErl
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VERFERLWG
SC 
001 iaaS wgS 
32 
YKMDWSIAF
QIMHFDVSG
SC 
11.23
4 11 234 9 
wnlMayDfS
GS 
fqiMhfDvS
GS 
33 
LSVISGMHS
EWPVLWLF
GSC 9.047 12 18 2 
SsmSsMpns
yPV 
SviSgMhse
wPV 
34 
GFMLFGGNP
LEYAWYAH
GSC 6.872 9 45 10 vnwAiYgrG leyAwYahG 
35 
SLDGVARSW
PGGYGEGHG
SC 8.418 14 299 1 
StDGigtSfn
GvgG 
SlDGvarSw
pGgyG 
36 
KYIGEHPVF
ESTEYRQGG
SC 6.672 5 255 8 VFpST VFeST 
37 
YDVMLSQPN
PVSWMRFPG
SC 7.599 17 79 2 
eVyLSdtwa
dtdkhyPG 
dVmLSqpnp
vswmrfPG 
38 
SYKQYHIGR
HIDLESLEGS
C 6.564 13 2 4 
rflIGalltLqt
L 
qyhIGrhidLe
sL 
39 
YSWDAINW
RGKAYPVET
GSC 
7.599
999 11 352 1 
iSyDtvkiaG
K 
ySwDainwr
GK 
40 
WFNERKRA
QLYEVGEFT
GSC 7.787 17 118 3 
NnRnlktLlsi
GgwTyS 
NeRkraqLye
vGefTgS 
41 
VKPVDFMG
RYGQLHNFE
GSC 8.166 14 395 4 
VnglGgtGk
LeqrE 
VdfmGryGq
LhnfE 
42 
NGKDNVSID
YLHTRLGIG
SC 7.931 8 122 11 LkTlLsIG LhTrLgIG 
43 
YSGHRHNVP
EIDMRQQFG
SC 8.232 8 248 1 vSGHmsNV ySGHrhNV 
44 
EFTWMLNK
NNEMHRHPP
GSC 8.319 7 113 4 ylLkKNN wmLnKNN 
45 
RVMFEGFQG
KGPNYLQVG 6.755 10 359 7 iaGKkaeYit 
fqGKgpnYl
q 
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SC 
46 
RWFVGSMN
GQNPVGTFS
GSC 7.354 4 241 16 FSGS FSGS 
47 
PKMRDRIQW
TPVFTELQG
SC 8.318 15 322 3 
ykDmpQqga
qvTELe 
mrDriQwtpv
fTELq 
48 
ISVETQWVP
LHDTGWDQ
GSC 7.241 13 152 4 
dTslklmkDl
GfD 
eTqwvplhDt
GwD 
49 
TEYSLTPEK
VEYYAWEG
GSC 8.248 13 359 5 
iagkKaEYit
knG 
ltpeKvEYya
weG 
50 
TRQLAPYFD
WHNYSIAIG
SC 6.944 7 230 7 YlDfwNl YfDwhNy 
51 
VYEMWYNT
SANIDQDHR
GSC 
6.881
999 10 237 4 
MaYdfSgsw
D 
MwYntSani
D 
        
Match data for score cut 6.56 for protein : 
CSA-CIMG_01181 
        ************** FORWARD PEPTIDES ************************** 
No
. SEQUENCE 
SCOR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
1 
RKFKKRRHW
HFPKFPKWG
SC 6.696 9 64 10 eiPnyPhvG hfPkfPkwG 
2 
ARWKKKSHF
HRGKKKMFG
SC 6.954 10 108 7 
SgFniaKKs
M 
ShFhrgKKk
M 
3 
RKGNVPRTA
RLFSVEWWG
SC 
10.65
3 16 67 4 
NyPhvggaFt
VEtWnS 
NvPrtarlFsV
EwWgS 
4 
SKTRSLSHAH
QMPASWFGS
C 7 11 56 3 
TkgyntAgei
P 
TrslshAhqm
P 
5 
RTMNTALWII
PLTWALWGS
C 7.192 10 11 6 AavfvPfTsA AlwiiPlTwA 
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6 
QKAPNKFEH
NVINAHNWG
SC 6.583 14 75 7 
FtvetwNspN
cGkC 
FehnviNahN
wGsC 
7 
MYDAATNFF
MDSKGVRKG
SC 6.77 8 93 2 YnAkTiFl YdAaTnFf 
8 
IHKTEHWIST
NADDWRAGS
C 7.168 7 78 5 EtWnSpN EhWiStN 
9 
EVERGDMN
WLTISVNNA
GSC 9.788 14 50 5 
GDngmiTkg
yNtAG 
GDmnwlTis
vNnAG 
10 
MFDYSPWWE
MYSYGVLPG
SC 7.031 15 59 4 
YntagEipnY
phvgG 
YspwwEmy
sYgvlpG 
11 
LYTSEQMTF
YGGRDDEIGS
C 7.82 7 123 12 GRaeElG GRddEiG 
12 
GEDDTMQRS
YNWYQTNV
GSC 6.969 11 50 1 
Gdngmitkg
YN 
GeddtmqrsY
N 
13 
YAENGAWD
VRVYSSANQ
GSC 
12.31
9 16 73 5 
GAftVetwn
SpNcGkC 
GAwdVrvys
SaNqGsC 
14 
GFNQWFSIDN
WLHTAQWGS
C 7.615 13 58 1 
GyNtageIpN
ypH 
GfNqwfsId
NwlH 
15 
NSWNQEYTD
HVVYHGMFG
SC 6.918 8 30 2 SydthYdD SwnqeYtD 
16 
YKMDWSIAF
QIMHFDVSGS
C 6.942 6 37 4 DpSlAl DwSiAf 
17 
MAIQGMNIY
TWFTDRIMG
SC 6.736 10 112 1 iAkksMdvlT 
mAiqgMniy
T 
18 
YSWDAINWR
GKAYPVETG
SC 8.886 8 72 10 GgAftVET GkAypVET 
19 
MQWHSNYM
MKRPYNPEL
GSC 8.238 10 52 6 
NgMitkgYN
t 
NyMmkrpY
Np 
20 RVMFEGFQG 9.445 10 63 9 GeiPNYphV GkgPNYlqV
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KGPNYLQVG
SC 
G G 
21 
INRHGDWNQ
HFQIPKHPGS
C 7.679 9 107 8 NsgFnIaKk NqhFqIpKh 
22 
ISVETQWVPL
HDTGWDQGS
C 7.237 8 32 12 DThyDdpS DTgwDqgS 
23 
TRQLAPYFD
WHNYSIAIGS
C 6.68 8 35 10 yddpSlAl whnySiAi 
        
Match data for score cut 6.56 for protein : 
Eli-Ag1-CIMG_10032 
        ************** FORWARD PEPTIDES ************************** 
No
. SEQUENCE 
SCOR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
1 
KARWNGRN
MTAPVYWRN
GSC 7.759 10 161 5 NGtgvTAtpf 
NGrnmTAp
vy 
2 
RKGNVPRTA
RLFSVEWWG
SC 7.586 14 160 2 
KngtgvTAtp
FSgE 
KgnvprTArl
FSvE 
3 
KSITDRGQKT
WWEWRRNG
SC 6.694 4 54 2 SlTD SiTD 
4 
KGDFGAEWG
RWRKWVTK
GSC 
6.640
999 13 208 6 
AtWGvlgai
VvgG 
AeWGrwrk
wVtkG 
5 
SKTRSLSHAH
QMPASWFGS
C 8.974 6 15 5 SLStAH SLShAH 
6 
YMEAHKTYN
KQISRGVSGS
C 
11.14
6 13 183 7 
TpNgQpqR
GnSGS 
TyNkQisRG
vSGS 
7 
RLCKNKTFC
WGFYAQWE
GSC 
7.172
001 5 159 3 CKNgT CKNkT 
8 
PVENKGRTST
HGFILWHGSC 7.219 6 47 4 sKsRTS nKgRTS 
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9 
RTMNTALWII
PLTWALWGS
C 8.551 17 198 2 
TsNiAghleta
TWgvlG 
TmNtAlwiip
lTWalwG 
10 
DKFHYWMY
MLYGINDKIG
SC 6.665 13 73 7 
vqvLlalgshp
GS 
mymLygind
kiGS 
11 
QDLLDYHLS
DFVLFAHMG
SC 8.154 8 1 6 mHLSgiVf yHLSdfVl 
12 
YLSTSMEQE
QEQVHGNW
GSC 7.191 6 190 14 rGNsGS hGNwGS 
13 
EVERGDMN
WLTISVNNA
GSC 7.045 16 97 1 
qVglGDfclp
svSlde 
eVerGDmn
wltiSvnn 
14 
WAEKPKIKN
WLGRQKLGG
SC 6.622 7 110 11 LdeQrLG LgrQkLG 
15 
YKKMYFRR
WQPTARLSR
GSC 7.137 9 21 6 FRlvdPppR FRrwqPtaR 
16 
MYYFPDTGG
QPDGSMWNG
SC 
10.35
8 11 131 7 
TnGdPnGgl
yN 
TgGqPdGs
mwN 
17 
MFDYSPWWE
MYSYGVLPG
SC 7.046 15 200 3 
niaghlEtatw
GVLg 
dyspwwEmy
syGVLp 
18 
LYTSEQMTF
YGGRDDEIGS
C 
6.641
001 9 139 1 LYncadiTF LYtseqmTF 
19 
HEGLEGDQTI
YQFMIEYGSC 12.15 13 69 7 
DQTavQvll
alGS 
DQTiyQfmi
eyGS 
20 
FDMLFKDSYI
WGMTIMFGS
C 6.879 10 3 10 lsGivfaFsS 
iwGmtimFg
S 
21 
NTAEADWGT
ESTWSMHRG
SC 
6.794
999 15 143 5 
ADitfsSTtey
tvpS 
ADwgteST
wsmhrgS 
22 
HGPDWTIHPF
PGLWVFDGS
C 7.806 11 162 2 
GtgvTatPFs
G 
GpdwTihPF
pG 
23 
GFNQWFSIDN
WLHTAQWGS
9.995
999 12 200 7 
nIaghLeTAt
WG 
sIdnwLhTA
qWG 
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C 
24 
NSWNQEYTD
HVVYHGMFG
SC 6.658 7 148 2 SsttEYT SwnqEYT 
25 
YKMDWSIAF
QIMHFDVSGS
C 7.267 11 58 3 
lempIAlemg
H 
mdwsIAfqi
mH 
26 
LSVISGMHSE
WPVLWLFGS
C 7.292 7 75 13 VLlalGS VLwlfGS 
27 
GFMLFGGNP
LEYAWYAHG
SC 7.391 10 214 1 
GaivvGGva
L 
GfmlfGGnp
L 
28 
KYIGEHPVFE
STEYRQGGSC 
8.783
001 9 151 12 TEYtvpsSC TEYrqggSC 
29 
VKPVDFMGR
YGQLHNFEG
SC 
10.08
7 7 117 1 VKPVDgM VKPVDfM 
30 
NGKDNVSID
YLHTRLGIGS
C 7.101 11 107 7 
SvsldeqRLG
v SidylhtRLGi 
31 
ISQQMVLHM
RYAPELLGGS
C 6.902 9 58 7 LeMpiAlEm LhMryApEl 
32 
TLAPWQGLKI
WERQVPNGS
C 6.643 15 119 4 
PvdGmnatlq
vVtNG 
PwqGlkiwer
qVpNG 
33 
RVMFEGFQG
KGPNYLQVG
SC 6.898 7 93 12 PtfrQVG PnylQVG 
34 
RPPIRLRDVL
NDHYEVRGS
C 7.327 8 152 13 eYtVpsSC hYeVrgSC 
35 
INRHGDWNQ
HFQIPKHPGS
C 8.047 9 77 11 lalgsHPGS fqipkHPGS 
36 
ISVETQWVPL
HDTGWDQGS
C 6.771 13 14 1 
ISlsTahfrLv
Dp 
ISveTqwvp
LhDt 
37 
TEYSLTPEKV
EYYAWEGGS
C 6.562 6 51 1 TsvSLT TeySLT 
38 TRQLAPYFD 7.772 5 77 15 lAlGS iAiGS 
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WHNYSIAIGS
C 
39 
VYEMWYNTS
ANIDQDHRG
SC 6.736 11 106 8 
pSvslDeqrl
G 
tSaniDqdhr
G 
        
Match data for score cut 6.56 for protein : 
AG2-CIMG_09696 
        ************** FORWARD PEPTIDES ************************** 
No
. SEQ 
SCOR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WINDOW 
PEP 
WINDOW 
1 
ETNRWHRNR
QGYLAHSTG
SC 6.922 9 146 11 GgvptgTGS GylahsTGS 
2 
RTMNTALWII
PLTWALWGS
C 6.791 11 7 9 lIaLvaAglaS 
iIpLtwAlwg
S 
3 
KKQSAWGL
WVAELNYM
HGSC 
7.236
001 9 12 5 AaGLasAqL 
AwGLwvAe
L 
4 
IHKTEHWIST
NADDWRAGS
C 7.934 11 164 9 
STpAefpgA
GS 
STnAddwrA
GS 
5 
QDLLDYHLS
DFVLFAHMG
SC 6.597 6 69 4 LDariS LDyhlS 
6 
EVERGDMN
WLTISVNNA
GSC 7.257 5 73 12 ISVsN ISVnN 
7 
YKKMYFRR
WQPTARLSR
GSC 6.596 4 71 13 ARiS ARlS 
8 
SLDGVARSW
PGGYGEGHG
SC 
10.26
4 15 140 5 
VptgtgGGv
ptGtGS 
VarswpGGy
geGhGS 
9 
IALFDPTKWP
EHHQYFAGS
C 
7.671
999 11 92 1 
IppvDtTaaP
E 
IalfDpTkwP
E 
10 
GRWLGEPNV
QAGPTFFPGS 7.902 12 102 6 
EPsetAePTa
eP 
EPnvqAgPT
ffP 
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C 
11 
YSWDAINWR
GKAYPVETG
SC 6.97 10 145 10 
GggvPtgTG
S 
GkayPveTG
S 
12 
MTFHGYMVR
GSRGDIIDGS
C 7.785 11 173 5 
GsnVRaSv
GgI 
GymVRgSr
GdI 
13 
ISQQMVLHM
RYAPELLGGS
C 6.93 7 183 11 iAaaLLG yApeLLG 
14 
INRHGDWNQ
HFQIPKHPGS
C 
6.835
999 16 42 3 
RltDfkcHcs
kPelPG 
RhgDwnqHf
qiPkhPG 
15 
PKMRDRIQW
TPVFTELQGS
C 
6.693
999 8 90 7 IeipPVdT IqwtPVfT 
16 
YFWLDVNYD
EWTAVVDQG
SC 8.695 16 69 4 
LDarisvsniV
VDQcS 
LDvnydewta
VVDQgS 
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CHAPTER 4  
MULTI PATHOGEN PEPTIDE BASED SEROLOGICAL DIAGNOSTIC 
Abstract 
Pathogen detection is vital for successful detection of sudden outbreaks with 
diffuse symptoms.  It is important to detect pathogens with high specificity.  While DNA 
detection conforms to the requirement of high specificity, sufficient pathogen must 
remain in the patient to ensure positive signals.  Host-based immunological detection 
should overcome this limitation, as well as provide information on the hosts’ health 
status, unlike pathogen based PCR.  To enable the broadest possible panel of 
immunological tests that are highly accurate, such that a new outbreak (SARS) or an 
intentional bio-threat release could be rapidly located, one requires a larger, more 
complex detection panel, such as one representing all NIAID priority pathogens.  While a 
peptide microarray tiling all possible pathogen proteins may seem like a promising 
platform for such a detection panel, we tested the concept and found non-obvious 
problems that appeared, and possible solutions.  We developed a pathogen peptide 
microarray using tiled peptides.  Results suggest a profound lack of specificity, but 
illuminated several possible sources for cross-reactivity.  We modified a number of assay 
conditions to minimize cross-reactivity and provide a comparison study of six different 
pathogen exposures.  We eventually improved our assay from <50% specificity to 
simultaneous detection accuracy with >90% AUC-ROC on a 4K peptide microarray.  The 
array is composed of peptides from fourteen priority pathogens.  The basic platform 
could be further developed as a surveillance tool or as an epidemiological probe for 
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monitoring outbreaks, but more importantly, several fundamental biochemical conditions 
were optimized specifically for multiplexed host-based immune detection. 
Keywords 
Multiplexed, peptide microarray, multi-pathogen, specificity, peptide cross-reactivity, 
epitope, diagnostic assay, immunosignature, antibody. 
Abbreviations 
BLAST, Basic local alignment search tool; Cytomegalovirus, CMV; Epstein Barr virus, 
EBV; Hepatitis C virus, HCV; HSV1, Herpes simplex virus 1; HSV2, Herpes simplex 
virus 2; Human Immunodeficiency virus, HIV; ROC-AUC, Receiver operator 
characteristics – area under the curve; Severe acute respiratory syndrome, SARS; 
ToRCH, Toxoplasma gondii+Rubella+CMV+HSV1 & HSV2. 
Introduction 
Peptide microarray-based diagnostics have been used for diseases such as 
tuberculosis [3,4], Echinococcus spps. [5] and SARS [6,7].  The antibody response 
mapping strategy as outlined through these research efforts involve testing patient sera 
relative to normal donor sera.  List et al [5] diverged from this accepted methodology and 
tested their Echinococcus specific peptide microarray platform against other 
symptomatically confounding nematode infections.  Due to the relatively high cross-
reactivity observed in peptide epitope arrays, none of these groups have attempted 
multiplexing the diagnosis of more than one infection from unrelated pathogens on the 
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same microarray.  The goal of the present project was to test the feasibility of creating a 
functional multiplexed pathogen proteome peptide epitope array. 
Cross-reactivity is a generic feature of any antigen-antibody detection system 
[101,102]. Polyreactivity is a feature of certain viral infections such as Hepatitis viruses, 
HIV and Epstein Barr virus (EBV) [103].  Ulrich et al. [92] attempted to use Yersinia 
pestis protein microarrays to distinguish infections of Y. pestis as well as seven other 
species of gram-negative bacteria vs. Bacillus anthracis.  The authors acknowledged 
detection of cross-reacting antibodies to Y. pestis proteins from these unrelated pathogen 
exposures but rather than see this as a lack of specificity, instead used it as a fingerprint 
for detecting those unrelated infections.  They attributed this cross-reactivity to sequence-
level similarities between different unrelated bacterial proteins. 
Following the success of creating multiplexed ToRCH [104] protein assays that 
use crude whole pathogen protein extracts from five vertically transmitted pathogens, 
namely, Toxoplasma gondii, Rubella, Cytomegalovirus and Herpes simplex virus 1 and 
2, Andresen et al. [36] created a peptide microarray containing 900 peptides for 
distinguishing Hepatitis C virus, EBV, Cytomegalovirus (CMV), Herpes simplex virus 1 
(HSV1) and HSV2.  Individual patients infected with CMV and EBV showed reactivity 
to their cognate peptides but the authors noted broad cross-reactivity from HSV1 and 
HSV2 infected patients making it impossible to serologically discriminate between these 
viruses using antibody-binding data from multiplexed peptide arrays.  From this work we 
expected to observe inconsistent patterns of antibody binding per patient and infection on 
our multiplexed array.  
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Similarly confounding results were obtained by List et al. [5], when they 
attempted to discriminate between Echinococcus species: multilocularis and granulosus 
using 45 peptides from 6 proteins of the pathogens.  One of the best performing peptides 
out of 45 selected had 94% specificity and 57% sensitivity at detecting Echinococcosis 
apart from other nematode infections, but was ineffective at differentiating between the 
two species.  Maeurer et al. [3] on their 7446 peptide microarray representing 61 
Mycobacterium tuberculosis proteins found positive antibody reactivities from TB 
negative (Quantiferon assay negative) individuals’ sera.  Whether this could be 
interpreted as cross-reactivity attributable to non-pathogenic Mycobacterium species or to 
autoimmunity is speculative in the absence of immune histories from these patients.  
Auto-immunity has been documented to be a side effect from several common infections 
such as measles, mumps and chicken pox [103].  Chow et al. [6] attempted to circumvent 
this issue by selecting 27 peptides that were restricted to the SARS-CoV (Severe Acute 
Respiratory Syndrome-Coronavirus) but without any portion of other Coronaviruses or 
human or mouse proteomes.  This array was only tested against SARS infected versus 
uninfected patients, not against serum from other closely related Coronaviruses but it 
implied that informatics should be used to filter peptide selection. 
In our study we developed a multiplexed pathogen peptide array representing 14 
priority pathogens such that either the complete proteomes of small viruses or a few 
immunodominant antigens for large bacteria and viruses were tiled contiguously.  
Surprisingly there was a pronounced lack of specificity in initial assays.  In order to 
reduce cross-reactivity, we subsequently optimized physical assay conditions to capture 
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specific reactivity from infected sera and reduce signals from non-targets.  First, we 
examined the effect of the surface density of the peptides by changing the spacing of the 
linker that attaches peptide to the glass slide.  Next, we examined detecting antibody 
concentrations, then the temperature of incubation and finally we tested a number of 
competitors for the primary sera incubation step.  The literature for antigen-antibody 
thermodynamics [105] and protein and peptide microarray optimization [3,5,6,8,36], 
suggests that incubating serum samples longer (as in an ELISA) might allow the system 
to approach equilibrium and better discriminate antibody affinities.  The patient serum 
samples we used to train this system are characterized using alternative immunoassays 
(ELISA or immunodiffusion) representing exposures to Coccidioides spps. (Valley 
Fever-VF), Fransicella tularensis - attenuated live vaccine strain (LVS), Vaccinia (small 
pox), African Swine Fever Virus (ASFV, a non-human pathogen), Plasmodium (Malaria) 
and West Nile Virus (WNV). 
Methods 
Serum samples and rationale for choosing pathogens to be represented 
Human patient serum samples from five Vaccinia vaccine recipients and five non-
disease individuals were collected under the ASU IRB 0905004024, “Blood Collection 
for Immunological Studies”.  Fransicella tularensis subsp. holarctica live vaccine strain 
(LVS) vaccinated individuals’ sera from 11 individuals were received from Dr. Anders 
Sjöstedt’s laboratory at Umeå University, Sweden under the same IRB approval.  
Samples used were 28-30 days post-vaccination.  VF infected patient sera was received 
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from Dr. John Galgiani at the University of Arizona (IRB# FWA00004218, 122 
samples).  Two Plasmodium and 6 WNV infected sera was obtained from SeraCare Life 
Sciences (Milford, MA).  Four ASFV infected porcine sera with 2 uninfected control pig 
sera were obtained from Dr. Linda Dixon at The Pirbright Institute, UK under the USDA 
import license # 111099 by Dr. Kathryn Sykes. The choice of pathogens to be 
represented on the assay was based on serum sample availability for testing NIAID 
Category A, B and C priority pathogens [38]. The majority of pathogens chosen were 
small encephalitis viruses along with other priority pathogens with larger proteomes.  
Table 4- 1 displays the distribution of peptides per pathogen on the pathogen proteome 
peptide (PPP) array.  
Table 4- 1  Peptide selection strategy for PPP array 
Type of 
Pathogen 
Pathogen Name 
(NIAID Priority 
Pathogens list 
category) 
Number of 
Proteins in 
Proteome 
Proteins 
Selected 
Number 
of 
Peptides 
% Coverage 
(Proteome) 
Viruses 
Japanese 
encephalitis virus 
(B) 
13 all 203 100% 
Equine 
encephalitis virus 
(B) 
2 all 223 100% 
Venezuelan 
encephalitis virus 
(B) 
2 all 215 100% 
Machupo Virus 
(A) 
4 all 181 100% 
Junin Virus (A) 4 all 199 100% 
Guanarito Virus 
(A) 
4 all 204 100% 
Lassa Virus (A) 4 all 205 100% 
West Nile Virus I 13 + 13 all 194 + 120 100% 
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+ II (B) 
African Swine 
Fever Virus 
(USDA 
Veterinary 
services select 
agent) 
188 
12 [106-
108] 
299 6.38% 
Vaccinia Virus – 
Western Reserve 
(A) 
223 
32 [109-
111] 
567 14.34% 
Bacteria 
Francisella 
tularensis SCHU 
S4 (A) 
1604 
45 
[112,113] 
862 2.80% 
Bacillus anthracis 
(A) 
5715 1 [114-116] 44 0.05% 
Protist 
Plasmodium vivax 
(Infections 
observed in 
deployed 
populations) 
5051 17 [117] 708 0.31% 
Fungi 
Coccidioides 
immitis (C) 
10454 
4 [81-
83,118,119] 
83 0.03% 
 
Three approaches were considered for selecting the epitopes to be represented on 
the array.  The first approach utilized the Immune Epitope Database’s (IEDB) collection 
of empirically mapped epitopes that yielded 4,124 total B-cell epitopes representing the 
14 priority pathogens.  The distribution of these epitopes was severely skewed for some 
pathogens.  The second approach relied on utilizing information from the six [120-123], 
B-cell linear epitope prediction algorithms provided through IEDB.  Each one of these 
algorithms gives weight to a certain characteristic of the peptide sequence, e.g. the Chou 
& Fasman Beta turn prediction algorithm, predicts whether a portion of the protein could 
have a trans-membrane domain due to presence of beta-turns in their structure.  The 
Bepipred algorithm includes propensity scaling of the amino acids based on their 
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probability of occurring in an antigenic site in addition to a Hidden Markov model 
(HMM) approach to systematically identifying cryptic sites.  This resulted in ~24,000 
peptide epitopes predicted from the 11 out of 14 pathogen proteomes under 
consideration. A summary of both these approaches is depicted in Table 4- 2. 
Table 4- 2 Predicted & Empirical epitopes (IEDB-Bepipred) [Accessed on: 30th 
November, 2011] 
Organism  
# Predicted Epitopes 
(Bepipred)  
# Epitopes in 
IEDB database  
Total proteins in 
Proteome  
Bacillus anthracis  18486 3174 5289 
Francisella 
tularensis (SchuS4)  4365 797 1604 
ASFV  723 128 128 
Junin virus  98 4 4 
Machupo virus  96 4 4 
Guanarito virus  98 4 4 
Lassa fever virus  86 4 4 
West Nile virus I & 
II  137 2 10 + 10 
JEV  70 1 10 
VEE  136 3 2 
EEE  137 3 2 
Total  24432 4124 7071 
 
The third approach involved tiling the whole proteome of the pathogen into 
contiguous 17-mers.  This is easily achievable for several of the encephalitis viruses 
having smaller proteomes, containing at most 2-10 proteins in their proteome.  Bacteria 
and fungi have much larger proteomes and would result in more 17-mer peptides than the 
physical limit allowed on this platform.  As summarized in Table 4-3 the 14 pathogen 
proteomes under consideration have 12,744 total proteins and would amount in 344,316 
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contiguous 17-mer peptides. Our current piezo printed array can accommodate only 
20,000 peptides per slide.   
Table 4- 3 Number of peptides per priority pathogen proteome 
Organism  
Total proteins 
in Proteome  Amino acids total  
# of contiguous non-
overlapping 17-mers  
Bacillus anthracis  5289 1460522 85913 
Francisella 
tularensis 
(SchuS4)  1604 497951 29291 
Vaccinia virus  223 57833 3402 
Plasmodium vivax 
(Sal-I) 5390 3748088 220476 
ASFV (Georgia 
2007/1) 188 55884 3287 
Junin virus  4 3353 197 
Machupo virus  4 3363 198 
Guanarito virus  4 3332 196 
Lassa fever virus  4 3377 199 
West Nile virus I 
& II  10 + 10  
WNV-I: 3433 + 
WNV-II: 3430 202 + 202  
JEV  10 3432 202 
VEE  2 3748 221 
EEE  2 5612 330 
Total 12744 5853358 344316 
 
We therefore chose to represent complete viral proteomes for small viruses and 
partial proteomes for larger pathogens representing tiled empirically classified 
immunodominant proteins (Table 4- 1).  We hypothesized that including only 
immunodominant antigens would be sufficient to help distinguish that infection from 
others on the array.  The peptides were filtered so as not to include any duplicate 16 or 
17-mers.  Any duplication in a sequence between amino acid lengths 5 through 15 was 
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noted so as to map possible binding events observed due to short peptide sequence 
identity (Table 4- 4). The n-mer level overlap observed when using natural sequence 
epitopes is much higher than that observed by chance in a randomly generated peptide 
library containing the same number of peptides and in comparison to two separate 
randomly generated, non-natural sequence 10K Immunosignature peptide libraries (Table 
4- 4). The peptides were then printed onto glass slides and all assay conditions such as 
time and temperature of serum sample incubation, slide surface, blocking buffer were 
systematically optimized to reduce cross-reactivity. 
Table 4- 4 Duplicate 5-mers – 16-mers within the 4337 peptides from the PPP array and 
10K non-natural sequence peptide Immunosignature array 
n-mer 
size 
# n-mers observed more 
than once in pathogen 
peptides 
#n-mer observed more 
than once in random 
sequence peptides 
10K(v2) 10K(v1) 
16-mer 211 2 2 0 
15-mer 345 5 16 0 
14-mer 522 8 141 0 
13-mer 763 13 378 5 
12-mer 1061 19 635 12 
11-mer 1435 27 908 32 
10-mer 1903 37 1123 45 
9-mer 2482 62 1389 61 
8-mer 3467 358 1659 114 
7-mer 4673 694 2167 584 
6-mer 6737 1819 5143 3912 
5-mer 9171 3143 9530 8309 
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Microarray production and processing 
An N-terminal CRH (cysteine-arginine-histidine) linker sequence was added to 
the 17mer pathogen peptides.  A total of 4337 peptides were purchased from Sigma 
Genosys (St. Louis, MO).  Array printing was performed at AMI (Applied Microarrays, 
Tempe, AZ) using non-contact piezo printing.  Slides were either Schott Nexterion 
(Gena, Germany) aminosilane-coated slides which provide ~1nm spacing between 
covalently-attached peptides, or Postech NSB slides (Seoul, Korea).  The NSB slides 
were either NSB-9 (3nm spacing between peptides) or NSB-27 (6nm spacing between 
peptides).  All slide surfaces were coated with sulfo-SMCC linker (Pierce, Rockland, 
MD) and peptides were conjugated to the surface using maleimide conjugation chemistry 
at 70% humidity.  Identical arrays were printed on the top and bottom half of each slide, 
and each peptide was printed twice within an array. 
Microarray slides were pre-washed with a solution containing 7.33% acetonitrile, 
33% isopropanol and 0.55% TFA to remove unbound peptide.  Slides were blocked in 1X 
PBS, 3% BSA, 0.05% Tween 20, 0.014% β-mercaptohexanol for 1hr at 25oC.  Sera 
samples were diluted 1:500 or 1:5000 in Incubation buffer containing 3% BSA, 1X PBS, 
0.05% Tween 20, and allowed to bind to the microarray for varying time points including 
1 or 16 hour at either 23°C or 37°C in 200 µl total volume per array.  A Tecan 4800 Pro 
Hybridization Station (Tecan, Salzburg, Austria) was used for array incubation and 
primary sera was detected using Alexa Fluor-647 conjugated Goat anti-Human, IgG Fc 
(γ) fragment specific secondary antibody from Jackson ImmunoResearch (West Grove, 
PA).  The slides were scanned using Agilent C scanner (Santa Clara, CA) at 635nm 
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excitation wavelength with 100% PMT and high laser power at 10 µm image resolution.  
The 16-bit TIFF images were aligned using GenePix 6.0 software (Axon Instruments, 
Union City, CA) and the data files imported into GeneSpring 7.3.1 (Agilent, Santa Clara, 
CA) and Matlab (version R2012a, MathWorks, Natick, MA) for further analysis.  Every 
patient’s serum sample was processed in duplicate and since every peptide was printed 
twice within a sub-array, it gave 4 measurements from the same peptide upon combining 
both technical replicates.  Any sample with a Pearson Correlation Coefficient less than 
0.85 across technical replicates was re-processed. Upon meeting the quality criteria, all 
technical replicates for a given individual patient were averaged for further data analysis. 
Data analysis 
Median spot signal intensities were imported into Matlab (Natick, MA) for further 
analysis.  Spots flagged as bad based on visual inspection were treated as missing data, 
and values of replicate spots were averaged.  The global median background intensity 
was subtracted from each slide.  The background subtracted median spot signals are 
referred to as the peptide signals in subsequent analysis.  Analysis of patient data used 
eight statistical metrics for scoring pathogen peptides, average signal, T-test, and 
Pearson’s Correlation were the most predictive. Each pathogen on the array is not 
represented by equal numbers of peptides.  The proportion of peptides per array and per 
pathogen was noted for each assessment.  
Analysis methods: 
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1) Average signal method: the arithmetic mean signal intensity of the peptides 
belonging to each pathogen is used to generate a rank order, without incorporating 
standard deviation or number of peptides/pathogen. 
2) T-test p-value method: the p-value from a one-sided t-test between the signal 
intensities of the peptides belonging to each pathogen compared to the rest of the 
peptides on the array, assuming variance is unequal. 
3) Pearson Correlation method:  correlation is calculated between a vector 
containing the signal intensities for a patient and a binary vector composed of 1’s 
(representing a signal within the cognate pathogen) and 0’s (everywhere else).  
4) Signal – log(P-value) method:  The mean signal for each patient’s peptides 
multiplied by the negative of the log10 p-value across the patient vs. all other 
peptides on the array. 
5) Signal to noise method:  The average peptide signal for each pathogen group is 
divided by the standard deviation of the peptide signal across those groups. 
6) Median Signal method:  A nonparametric rank based on the median of the signal 
of peptides within a pathogen.  Highest rank is the designated call. 
7) Mean ranks method:  Per sample, peptides are ranked by signal intensity and the 
mean of the rank is calculated per pathogen. 
8) Wilcoxon Mann Whitnet Rank sum method:  Non-parametric version of T-test 
across patient peptides and all other peptides on the array. 
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In the NSB-9 and NSB-27 combined analysis, the geometric mean of the average signal 
or t-test p-value were used, while the arithmetic mean of the Pearson correlations from 
each platform were used. 
Receiver Operating Characteristics (ROC) curve calculation 
Receiver Operating Characteristics (ROC) [124] curves were calculated using the 
‘perfcurve’ function in Matlab.  A ROC curve is a plot of the True Positive Rate (TPR) 
against the False Positive Rate (FPR).  The area under the ROC curve (AUC) represents 
the probability that a positive example (in this case the score for the correct pathogen) has 
a higher score than a negative example (in this case the score for another pathogen). 
Results 
Physical optimization of pathogen proteome peptide (PPP) array 
Basic peptide microarray assay conditions such as the blocking and incubation 
buffer and the concentration of the secondary antibody were previously optimized for 
other peptide microarray assays[11].  These were the starting conditions and provided 
extremely low specificity when testing multiple infectious sera.  The temperature and 
incubation time had been optimized for Immunosignature arrays, so these conditions may 
not be optimal for the analysis of antibody binding to cognate linear epitopes [105].  The 
first condition tested was the effect of temperature. 
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Comparison 1: The effect of temperature on antibody-peptide association 
The Aminosilane slide surface was used and temperature of incubating serum 
sample or monoclonal antibody was varied (23°C vs. 37°C). The primary sera incubation 
time was held constant at 1 hour with 1:500 serum dilution or 5nM monoclonal antibody 
concentration processed. Figure 4- 1 represents the average signal intensities of peptides 
per pathogen group of proteins from Aminosilane slides at the end of one hour 
incubation.  Serum samples from one LVS vaccinee, one VF patient, one Normal donor 
and monoclonal antibody p53Ab1 were tested.  Red bars represent data from slides 
processed at 37°C and blue bars from slides processed at 23°C.  The monoclonal 
antibody against human P53 protein (p53Ab1) identified its cognate epitope, a peptide 
containing the 5-mer ‘RHSVV’ and some other peptides containing the same 5-mer. LVS 
and VF exposed polyclonal sera had more non-specific binding to other pathogen 
peptides as compared to cognate pathogen peptides FTT or VF (highlighted with red 
boxes). The LVS serum is showing higher reactivity to Lassa, Guanarito and Machupo 
virus peptides as compared to FTT, cognate peptides. The VF infected individual’s serum 
is showing higher reactivity to FTT, Junin and Lassa virus peptides alongwith showing 
reactivity to VF cognate antigen peptides. 
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Figure 4- 1  The effect of incubation temperature on various samples tested on the 
pathogen array. 
The average signal intensities for peptides per pathogen proteins are represented using 
bar graphs with red bars representing signals from slides processed at 37°C and blue 
bars from slides processed at 23°C. Panel A shows the antibody reactivity from a F. 
tularensis LVS vaccinated individual on the PPP array with FTT peptide (cognate) 
signals highlighted in the red box. Panel B shows the antibody response from a VF 
infected individual with a red box highlighting VF specific peptide signals (cognate). 
Panel C shows the antibody reactivity from a Normal individual’s serum sample. Panel D 
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shows a monoclonal antibody (p53Ab1) binding its epitope peptide containing sequence 
‘RHSVV’ (red box) and few other peptides, containing the epitope sub-sequence. 
We observed statistically significant discrimination between cognate and non-
cognate peptide groups at 23°C, so further analysis was conducted at this temperature.  
Table 4- 5 summarizes the AUC obtained from this analysis.   
 
Table 4- 5 AUC derived from ROC summary of incubating samples on Aminosilane 
slides at varying temperatures, time of primary antibody incubation is held constant at 1 
hour. 
Surface: Aminosilane, Primary antibody incubated for 1 hour at 37°C 
Infection (No. of 
patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
Valley fever (1) 0.98 0.98 0.98 
LVS (1) 0.13 0.03 0.03 
p53Ab1 (1) 1.00 1.00 1.00 
    Surface: Aminosilane, Primary antibody incubated for 1 hour at 23°C 
Infection (No. of 
patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
Valley fever (1) 0.98 0.98 0.98 
LVS (1) 0.25 0.02 0.03 
p53Ab1 (1) 1.00 1.00 1.00 
 
In an effort to estimate cross-reactivity, well-characterized monoclonal antibodies 
(anti-FLAG and anti-p53Ab1) were processed on aminosilane arrays with and without 
the epitope peptides for the monoclonals being tested.  Figure 4-2 shows the signal 
intensities from binding observed on arrays at the end of 1 hour of primary incubation at 
23°C.  Even in the absence of the epitope peptide, the monoclonal antibodies bound 
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pathogen peptides that either naturally contained the partial monoclonal epitope or a 
mimotope of their cognate site.  The monoclonal antibodies show reduced binding to the 
non-cognate peptides when the epitope peptide was present suggesting higher affinity for 
the cognate sequence.   
 
Figure 4-2 Estimating cross-reactivity - Histograms displaying signal intensities from 
arrays with or without monoclonal antibody epitopes. 
The Y-axis shows the number of peptides at a given signal intensity displayed on the X-
axis in all four panels. Panels A and B display the binding of the FLAG tag monoclonal 
antibody on arrays without and with cognate epitope peptides respectively. Panels C and 
D display the binding of p53Ab1 monoclonal antibody on PPP arrays without and with 
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cognate epitope peptides respectively. Panels A and C show data from arrays without the 
monoclonal antibody epitope and panels B and D show data from arrays containing the 
monoclonal epitope. 
Reducing cross-reactivity on array by reducing peptide density on array surface 
To reduce non-cognate peptide binding due to high peptide density on the surface, 
we tested NanoSurface Biosciences [125] NSB-9 and NSB-27 slide surfaces.  The 
primary amine groups on these surfaces are spaced 3nm and 6nm apart, respectively, as 
compared to aminosilane slides where space between amine groups is approximately 
1nm.  In order to determine spot morphology on these alternate slide surfaces as 
compared to Aminosilane, peptides were biotinylated using NHS ester-coupled biotin 
from Thermo Scientific (Rockford, IL). This approach was designed to be used to semi-
quantitatively assess the quality of spotting within various slide print batches of a given 
Immunosignature array [126]. Free amine groups on the peptides were bound with biotin, 
and Alexafluor 647-conjugated streptavidin bound only biotinylated sites (Figure 4- 3).  
The NSB-9 slides show lower dynamic range of signal intensity of peptide compared to 
aminosilane, due to the higher distance between peptides than AS.  The higher distance of 
primary amine groups on NSB-27 slides contributed to lower dynamic range of signal 
than both NSB-9 and AS slides. The spot morphology of NSB-27 slides was not optimal 
and hence for the initial comparison with Aminosilane only NSB-9 slides were used.  
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Figure 4- 3 Biotinylation for comparing the spot morphology and dynamic range of 
signal from three slide surfaces, Aminosilane (AS), NSB-9 and NSB-27. 
The histograms display the binding of streptavidin conjugated Alexafluor 647 on the 
three different slide surfaces. The images inset are screen shots of the three surfaces 
showing spot morphology. 
Six monoclonal antibodies were processed for estimating binding specificity on 
NSB-9 slides for 1 hour at 23°C: anti-FLAG, anti-V5, anti-cMyc, anti-p53Ab1, anti-
p53ab8 and anti-Leu Enkephalin.  All antibodies other than anti-Leu-Enkephalin bound 
their cognate epitopes along with other peptides that partially contained the epitope sub-
sequence or mimics of it. (Supplementary Figure 4- 1) 
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Comparison 2: Slide surface  
A comparison was made between Aminosilane vs. NSB-9 slides to decide which slide 
surface to use for printed PPP arrays to test polyclonal infectious sera. The primary serum 
incubation time was held constant at 1 hour and 23°C and 1:500 dilution of primary.   
The samples processed for the previous comparison were now processed on NSB-9 slide 
surface. Table 4- 6 summarizes the results from comparing three samples on both 
Aminosilane and NSB-9 slides. A moderate improvement in ROC-AUC for detecting the 
LVS sample is observed on NSB-9 slides as compared to Aminosilane. This observation 
would need to be tested with additional samples for the two infection groups to be 
confirmed. 
Table 4- 6 ROC-AUC for comparing slide surfaces Aminosilane versus NSB-9 
Surface: Aminosilane, Primary antibody incubated for 1 hour at 23°C 
Infection (No. of patients) Mean Signal T-test p-value Pearson Correlation 
Valley fever (1) 0.98 0.98 0.98 
LVS (1) 0.19 0.02 0.04 
p53Ab1 (1) 1.00 1.00 1.00 
    Surface: NSB-9, Primary antibody incubated for 1 hour at 23°C 
Infection (No. of patients) Mean Signal T-test p-value Pearson Correlation 
Valley fever (1) 0.98 0.15 0.96 
LVS (1) 0.47 0.13 0.09 
p53Ab1 (1) 1.00 0.55 1.00 
 
Note: The normal sample from the previous comparison was excluded when re-
calculating the ROC-AUC for the previous set of AS slides and while calculating it for 
NSB-9 slides as a more relevant comparison would be between infectious groups. 
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In addition to the samples processed to match those used in comparison 1, the 
anti-FLAG tag antibody was processed under identical conditions for this comparison. 
Figure 4- 4 summarizes the box-plots from antibody binding distribution as observed on 
NSB-9 and Aminosilane slides. The top left panel showing anti-FLAG epitope specific 
monoclonal antibody reactivity show lesser non-cognate peptide reactivity on NSB-9 
slides as compared to on AS. The top right panel, showing anti-P53Ab1 antibody 
binding, displays higher cognate epitope binding observed on NSB-9 slides as compared 
to on AS. However, both bottom panels showing polyclonal exposure specific response 
from VF infected and LVS vaccinated individuals’ sera does not show significantly 
higher cognate pathogen peptide binding than that observed on other non-cognate 
pathogen peptides. The LVS sample processed on NSB-9 slides shows higher median 
binding of both cognate as well as non-cognate groups of pathogen peptides than that 
observed on AS slides. The VF sample tested shows moderately higher binding to 
cognate peptides as compared to non-cognate peptides on AS slides. 
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Figure 4- 4 Box-plots showing antibody binding distribution as observed on NSB-9 
versus Aminosilane (AS) slides.  
The top two panels show the binding observed on the array using two monoclonal 
antibodies, anti-FLAG tag and anti-P53Ab1. The bottom two panels show the antibody 
binding distribution to cognate pathogen versus non-cognate peptides for one exposed 
individual each from VF and F. Tularensis (LVS). The antibody binding distribution of 
peptides is plotted along the X-axis, while the Y-axis is discontinuous and compares 
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signal intensity data from NSB-9 versus AS for every sample processed. The antibody 
binding distribution from cognate pathogen peptides or monoclonal antibody epitope 
peptides are plotted as a separate distribution and highlighted in red next to the antibody 
binding observed from the remaining peptides on the array (blue dots). 
Additional sera from both these infectious groups would need to be processed to 
evaluate this antagonistic observation per infection. However, given that the monoclonal 
antibodies show better specificity on NSB-9 slides, they were used for all further 
comparisons. Figure 4- 5 supplements this observation by showing the exact position of 
cognate peptides (highlighted in black) within the overall antibody binding distribution 
observed on AS and NSB-9 slides for the same samples.  The LVS sample (top right 
panel) shows a significant change with higher cognate reactivity distribution on NSB-9 
slides as compared to AS. 
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Figure 4- 5 Histograms displaying cognate peptide reactivity on Aminosilane (AS) and 
NSB-9 slides. 
The X axis shows the number of peptides sorted based on signal intensities depicted on 
the Y-axis. The coloring is based on an arbitrary scale in Matlab. The cognate peptides 
for two monoclonal antibodies and one sample each of LVS and VF are highlighted in 
black.   
Three VF infected individuals and three F. tularensis (LVS) vaccinee sera were 
used to verify the previous observation of improvement in LVS cognate reactivity on 
NSB-9 slides.  The 37°C comparison is included to ensure the 23°C criterion established 
previously for AS is also valid for NSB-9 slides. Table 4- 7 summarizes the ROC-AUC 
of distinguishing VF vs. LVS on NSB9 slides at varying temperatures.   
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Table 4- 7 ROC-AUC obtained for 2 infections on NSB9 slide surface at varying 
temperatures  
Time of incubation held constant at 1 hour, temperature 23°C vs. 37°C 
Surface: NSB9, Primary incubated for 1 hour, 37°C 
Infection (No. of 
patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
VF(3) 0.90 0.10 0.66 
F. tularensis(3) 0.21 0.36 0.24 
         
Surface: NSB9, Primary incubated for 1 hour, 23°C 
Infection (No. of 
patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
VF(3) 0.85 0.10 0.73 
F. tularensis(3) 0.23 0.24 0.25 
 
The NSB-9 (Table 4- 7) slides show moderate improvement in detecting 
F.tularensis (LVS) exposure as compared to aminosilane slides (Table 4-5). Following 
this methodical analysis, we then tested the effect of incubation time of sera on the PPP 
array.  
Comparison 3: Time of Incubation of sera.  
Single antigen ELISA’s, show high specificity at capturing appropriate antibody 
reactivity. Longer times of incubation were tested to mimic ELISA like binding 
conditions (overnight incubation). Supplementary Figure 4- 2 demonstrates the change in 
binding over varying incubation times of a monoclonal antibody against TP53 to its 
cognate epitope peptide on the array.  Binding to a number of non-cognate peptides 
containing the identical ‘RHSVV’ recognition sequence of this monoclonal or other 
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mimics such as ‘RHSVI’ or ‘RHSII’ at the end of 1 hour of incubation is higher than that 
observed at the end of 36 hours.  It appears that by 16 hours the monoclonal antibody 
binding its cognate epitope peptide starts tending towards equilibrium. At 24 and 36 hour 
time points, the antibody likely degrades as observed through progressively lower signals 
for one of the two epitope peptides on the array. Additionally, three VF infected and LVS 
vaccinated patient sera were used as before to compare incubation of the antibody for 1 
hour versus 16 hours (factors held constant: slide surface-NSB-9, 23°C, 1:500 serum 
dilution) 
Figure 4-6 displays histograms for one LVS and VF exposed individual each out 
of the three tested per group, showing data from all peptides on NSB-9 slides colored by 
an arbitrary scale in Matlab. The cognate pathogen peptides FTT or VF are highlighted in 
black.  Incubating the primary antibody for a longer duration of 16 hours increases the 
overall binding observed on the assay (cognate and non-cognate). Higher cognate 
pathogen peptide reactivity is observed at 16 hour serum incubations for all six sera as 
depicted by data in Table 4-8.  
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Figure 4-6 Cognate pathogen peptide reactivity is enhanced at 16 hour in comparison to 
after 1 hour of serum incubation.  
Histograms displaying raw signal intensities on the Y-axis and number of peptides on the 
X-axis sorted based on signal intensity. The top panel displays one LVS and bottom panel 
displays one VF exposed individuals sera binding the PPP array after 1 hour and 16 
hour (red) respectively in paired panels next to each other. The distribution of cognate 
pathogen peptides (VF or LVS) is highlighted in black.  
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Table 4- 8 ROC-AUC during varying incubation times on NSB-9 surface 
Surface: NSB9, Primary incubated for 1 hour, 23°C (reproduced 
for comparison from Table 4-4) 
Infection (No. of 
patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
VF (3) 0.85 0.10 0.73 
F. tularensis (3) 0.23 0.24 0.25 
    Surface: NSB9, Primary incubated for 16 hour, 23°C 
Infection (No. of 
patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
VF (3) 0.89 0.16 0.84 
F. tularensis (3) 0.28 0.21 0.35 
 
From observing this moderate improvement in cognate peptide binding at 23°C after 16 
hours of incubation, we continued to process additional infectious sera on the PPP array 
under these conditions. 
Comparison 4: Spacing of peptides affecting polyclonal antibody capture.  
We tested the concentration of deposited peptide on the surface and the effect it had on 
antigen presentation and the specificity of antibody association on the array. To do this 
we used NSB-9 and NSB-27 slides along with serum incubation conditions optimized in 
the previous comparison. The incubation time for infectious sera was held constant at 16 
hours, 23°C with 1:500 serum dilution.   
Figure 4- 7 summarizes the ROC-AUC of detecting 6 different infections apart on 
both NSB-9 and NSB-27 slide surfaces at longer incubation times (16 hour) and 23°C.  
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NSB-9 slides showed greater detection accuracy for VF and Malaria samples as 
compared to NSB-27.  F tularensis (LVS) samples however were detected with greater 
accuracy using NSB-27 slides. 
 
Figure 4- 7 ROC curve AUC summarizing ability to distinguish one infection from 
another on the PPP array under longer incubation 
The NSB-27 slides showed inconsistent spot morphology and poorer replicate 
correlations due to the interaction between printing conditions (volume and peptide 
concentration held constant throughout) and the 6nm distant primary amines. We 
expected this higher distance between individual peptides to improve specificity on the 
assay. This higher spacing likely affected its reproducibility; therefore, NSB-27 slides 
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were excluded from further analysis except to test limiting conditions of antigen 
presentation and antibody dilution in the next comparison. A score combination approach 
which combined the scores for the eight statistical metrics obtained from NSB-9 (1:500) 
and NSB-27 (1:500) slides was also tested, but did not yield significantly higher accuracy 
as depicted in Table 4- 9 as compared to results in Figure 4- 7, panel A. This approach of 
combining multiple observations is typically utilized when analyzing Surface Plasmon 
Resonance (SPR) data. The NSB-9 and NSB-27 data were treated as replicates when 
completing this analysis. 
Table 4- 9 ROC-AUC after combining NSB9 and NSB-27 (1:500) data 
Infection (No. of patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
Valley fever(3) 0.82 0.14 0.84 
Francisella tularensis-LVS 
(3) 0.38 0.31 0.35 
ASFV (4) 0.97 0.60 1.00 
WNV (5) 0.51 0.99 0.77 
Vaccinia (5) 0.89 0.42 0.85 
Malaria (2) 0.05 0.04 0.02 
 
Comparison 5: Dilution of primary patient sera 1:5000 patient serum dilution 
In order to test the robustness of this system and estimate physical conditions 
under which it would fail to detect the appropriate pathogen infection, the assay was 
processed under limiting conditions of peptide antigen and antibody from 
infected/exposed sera. Doing this exercise gives us an estimate of likely assay conditions 
or sample related problems (degradation) to be tested in the event of failure. We used 
NSB-27 slides to test limiting conditions of antigen presentation for this assay and diluted 
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the serum 10 fold higher than is recommended for use on piezo-printed peptide glass 
microarray based Immunosignature platforms [11]. Table 4-10 summarizes the ROC-
AUC of distinguishing VF from LVS under these limiting conditions.  Processing patient 
sera under these conditions did not significantly reduce the detection ability of this assay 
using the pathogen mean signal metric as can be observed from comparing Figure 4- 7, 
Panel B and Table 4-10. The p-value score and Pearson Correlation scores however were 
significantly lower as compared to those observed from NSB-27 slides processed at 1:500 
serum dilution (Figure 4- 7, Panel B).  
Table 4-10 ROC-AUC of detection of 2 infections at limiting concentrations of antigen 
and antibody 
Surface: NSB27, Primary (1:5000) incubated for 16 hour, 
23°C 
 
Infection  
(# patients) 
Mean 
Signal 
T-test p-
value 
Pearson 
Correlation 
VF (3) 0.63 0.13 0.15 
F. 
tularensis(3) 0.51 0.55 0.76 
 
 
In summary, the information content obtained from such a multiplexed assay is 
dependent on several thermodynamic parameters and physical assay conditions tested 
above.  Figure 4- 8 demonstrates this concept by displaying the average signal intensities 
of peptides per pathogen groups of proteins between aminosilane (top panel) and NSB-9 
and NSB-27 slides (bottom panel).  One VF infected individuals’ serum is visualized 
under different thermodynamic conditions. Kinetic factors being tested here are amount 
of antigen presented on the surface (AS-dense, NSB9 and NSB27-less dense), 
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temperature (23°C vs. 37°C) and time of incubation of primary antibody (1 hour vs. 16 
hours).  Longer incubation times on the NSB9 surface at 23°C (blue bars, panel B) 
showed highest resolution of cognate VF peptide reactivity (highlighted with red box).  
The graph shows data for one Valley Fever-infected individual but is representative of 
the effect of optimizing these parameters for all infections studied in this work. 
 
Figure 4- 8  Effect of incubation time, temperature and slide surface on information 
content of array. 
Each bar represents the signal from peptides composing a given pathogen protein. Signal 
intensities to VF peptides averaged as proteins highlighted using a red box. Panel A 
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depicts the signal intensities as captured by pathogen peptides on the entire PPP 
microarray printed on Aminosilane slides. Panel B depicts the signal intensities as 
captured by pathogen peptides on the entire PPP microarray printed on NSB-9 and NSB-
27 slides. Blue bars represent one VF infected individual’s serum sample processed on 
Aminosilane or NSB-9 slide at 23°C. The red bars in Panel A represent this same VF 
infected individual’s serum sample binding PPP peptides at 37°C on Aminosilane slide 
surface. The red bars in Panel B represent this VF patient’s serum binding PPP array 
printed on NSB-27 slides.  
Discussion 
We have demonstrated that biochemical parameters associated with peptides 
spotted onto a glass microarray can be optimized to reduce the cross-reactivity observed 
in a multiplexed microarray.  A peptide array representing epitope peptides from 14 
priority pathogens was created and examined for accuracy of simultaneously 
distinguishing multiple exposures.  Three bioinformatic peptide selection strategies were 
explored but empirical evidence from other research groups [3,6,36] suggested it was 
ambiguous whether using bioinformatic selection would be beneficial only when testing 
single pathogen and not as useful when simultaneously detecting multiple pathogen 
exposures.  The hypothesis tested in this work was whether antigens previously shown to 
be immunoreactive would be sufficient to identify the infection among the pathogens 
represented on the peptide array.  To this effect we represented complete proteomes for 
smaller viruses and partial proteomes for larger pathogens.  The proteins tiled as peptides 
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for larger pathogens were immunodominant antigens from protein microarray 
experiments and those listed as B-cell epitopes in IEDB.  We used well -characterized 
monoclonal antibodies and ELISA or immunodiffusion characterized infectious sera to 
assess cross-reactivity on our multiplexed platform. 
Likely parameters that should affect antibody binding such as temperature, 
peptide spacing, and duration of incubation, were tested and optimized.  The selected 
parameters (23°C, 16 hour incubation, NSB-9 slide surface) were empirically determined 
based on improvement in the accuracy of simultaneous detection.  Additionally, eight 
statistical analyses were tested for their ability to distinguish infections.  The three most 
predictive analytical methods were average signal from groups of pathogen peptides, p-
value across pathogens (groups of peptide) and Pearson’s Correlation score (within and 
across pathogen peptide groups).  Four out of the six inefections/exposures tested 
resolved on one of these three statistical metrics with >90% ROC-AUC.  While no 
statistical method worked best for all infections, these four could be detected with greater 
than 80% ROC-AUC on the Pearson’s Correlation score metric.  Different infections 
resolved to a varying extent using the eight metrics tested.  VF, Fransicella (LVS) and 
ASFV resolved on the Mean signal pathogen scoring scale while WNV and Vaccinia 
resolved best on the P-value scale.  Malaria did not resolve well on any of the eight 
metrics tested.  
Temperature, longer patient serum incubation times and concentration of antigen 
presented on the surface had a significant impact on the information content obtained 
from the assay.  Prior work on antigen-antibody interactions using surface plasmon 
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resonance (SPR) demonstrates a reduction in the association and dissociation rate 
constants during antibody affinity maturation [127].  A longer incubation time should 
allow the binding to overcome mass transport limitations and approach equilibrium so 
that the binding observed better correlates with affinity [128].  The immune response to 
an infection/exposure has an initial natural antibody component and a latter adaptive 
(specific to the infection) component [129].  These natural antibodies are poly-reactive 
and often not high-affinity unlike those generated later in the infection post affinity 
maturation [103].  Longer incubations result in dissociation from non-cognate peptides 
and support association of slow on-rate or mass-action limited high affinity antibodies 
with cognate peptides.   
The statistical method by which different infections were detected may rely on the 
extent of peptide diversity required to accurately capture a given infection in the presence 
of other pathogen peptides. The P-value scale tends to resolve infections such as WNV, 
whose complete proteome is represented on the array in the form of 17-mer peptides.  
The probability of detecting the infection (e.g. WNV) improves with comprehensively 
mapping the entire proteome.  Exposures such as Vaccinia vaccination resolved on the P-
value scale suggesting that perhaps a minimum amount of proteome coverage is required 
(14.3% of Vaccinia proteome represented) for accurate detection.  Fransicella tularensis 
(LVS) vaccine (2.8% of proteome represented), VF (0.03%) and Malaria (0.31%) did not 
resolve on the P-value scale.  Additional testing using patient samples for pathogen 
proteomes completely represented on the array would be required to verify this trend. 
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ASFV and VF resolved on the average signal scale.  ASFV is a porcine infection 
with the potential for infecting humans [40].  The sera tested for ASFV was of swine 
origin and had overall higher reactivity as compared to human infection/exposure sera.  
Supplementary Figure 4- 3 displays the average signal intensity observed per individual 
per infection.  VF is a chronic infection and one of the largest pathogen proteomes 
represented on the assay.  The antibody response observed in all patients from VF 
infection is higher than other human infections or exposures tested on the platform, 
except one Vaccinia vaccinee as observed in Supplementary Figure 4- 3.  The Pearson 
Correlation score for WNV, Vaccinia, VF and ASFV is high suggesting more cognate 
pathogen peptides are responsible for the higher signal intensities on the array, which in 
turn influences the Pearson’s Correlation score. 
LVS and Malaria resolved with low accuracy on the average signal scale.  The 
Pearson correlation score was also low for these infections suggesting more cross-
reactivity observed to non-cognate peptides on the assay for LVS and Malaria.  One 
possible explanation might be low proteome representation on the array, 2.8% and 0.31% 
respectively, and also certain peculiarities of these infections.  Francisella is a gram-
negative bacteria and the majority of the host immune response is directed to the lipo-
polysaccharide (LPS) surrounding this pathogen [130] rather than to specific linear 
stretches of pathogen proteins.  Using a commercial antibody against Fransicella LPS 
and one against VEE we observed very little binding on the assay.  Supplementary Figure 
4- 4 demonstrates this, where only a handful of peptides show high reactivity for anti-
LPS antibody or anti-VEE antibody.  None of these peptides showing high antibody 
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binding are cognate peptides belonging to FTT or VEE peptide groups. Peptides 
belonging to the pathogen being compared are highlighted with arrows on the histogram 
and are marked in red.  Additionally, histograms of polyclonal sera generated by 
immunizing naïve special pathogen free mice with peptides are also depicted (FT03, 
Rco1, Rco2, Rco3 and Rco4).  Three out of five polyclonal sera recognized the cognate 
peptides used for immunization accurately with high signal intensity.  Two of these 
immunized peptides were not recognized but other peptides representing partial 
mimotopes (Supplementary Table 4-1) had higher signal intensities on the array than the 
cognate peptides demonstrating the possibility of generating cross-reactive antibodies 
even on immunizing with a 20-amino acid peptide. 
Plasmodium infected erythrocytes produce surface antigens to which IgG 
response is observed in infected individuals [131].  Additionally, pathogen specific 
antibody (IgG and IgM) may remain bound to circulating antigens [132-135] and the 
sample used to assess this reactivity on our assay is serum without the infected RBC’s.  
No additional pre-treatment to dissociate circulating immune-complexes from sera were 
applied in our protocol.  It is likely that for infections like malaria, that produce 
circulating immune complexes, pre-treatment of plasma from blood collected in anti-
coagulant tubes and treated with heat to dissociate circulating antigen and RBC bound 
antibodies might be necessary before separating the plasma for detecting anti-
Plasmodium antibodies [136].  From these data, to best ensure capturing cognate 
pathogen reactivity it would be optimal, to represent the complete pathogen proteome in 
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the form of peptides.  For representing larger pathogens this would mean generating an 
array containing up to 1 million peptides. 
The platform could be optimized to distinguish current versus prior exposure 
consistently based on measuring a quantitative increase in the immune response captured 
over time of exposure.  From studying the Vaccinia vaccination response on our array, 
we could predict more recent exposure versus vaccination received 4 years ago.  
Supplementary Figure 4- 5 demonstrates a proportionate increase in the response 
captured between current versus prior vaccination recipients.  Plots demonstrate the P-
value score on X-axis and pathogen ranking based on the score on Y-axis for individual 
vaccinees.  The two most recently vaccinated individuals show higher P-value score than 
the remaining three vaccinees.  This concept needs to be validated with additional 
samples and tested for consistency in different infections and on different print-batches of 
arrays.  
Additionally, optimizing the platform to distinguish closely related pathogens, 
such as various strains of Influenza or various Flaviviruses might prove beneficial.  The 
second leading cause of death in the world, 5.7 million deaths/year, are attributed to 
cerebrovascular disease [137].  Viral meningitis with estimated 434,000 hospitalizations 
(1988-1999)[138] is known to cause cerebrovascular complications [139].  Viral 
encephalitic meningitis infections such as those due to most NIAID priority pathogens do 
not have FDA approved diagnostics available that could readily be used in local 
laboratories for early detection of exposure.  Due to the severity of meningeal symptoms 
typically a spinal-tap procedure is performed for acquiring cerebrospinal fluid (CSF).  
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This CSF is then used for PCR-based direct detection of the pathogen.  To avoid these 
invasive procedures we recommend utilizing a pathogen proteome based peptide 
microarray, which would yield the infecting pathogen using as little as 1 µl of blood [66].  
Given that most encephalitis viral proteomes are small (2-12 proteins in proteome), it 
would be possible to represent all known encephalitis viruses on a higher density peptide 
array. 
Cross-reactivity on peptide microarray platforms such as the one presented is 
predominantly linear under the conditions optimized and easy to re-attribute to the 
original antigen.  Natural pathogen proteome specific peptide space is fairly conserved 
and redundant [140].  The cross-reactivity observed from monoclonal antibody binding 
can be re-attributed to either the partial epitope or a linear mimotope similar to the 
cognate epitope.  Similar analysis can be attempted on polyclonal patient sera to de-
convolute and re-attribute cross-reactivity to the cognate antigen responsible for 
infection/exposure. Although epitope-based peptide microarrays are of great utility, they 
also require physical optimization and rigorous bioinformatic analysis to reattribute 
cross-reactivity.  Based on the decreased monoclonal cross-reactivity when the epitope 
peptide is present on the array, we would expect including proteomes for commonly 
exposed pathogens might absorb antibodies from prior exposures to them and thus reduce 
non-cognate binding.  Given that complete medical histories and prior exposures for the 
patients tested are generally unknown, adding more pathogens might help 
comprehensively map the antibody response for individuals.   
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Supplementary Figures and Tables: 
 
Supplementary Figure 4- 1 Histograms displaying array data for 6 monoclonal 
antibodies on NSB-9 slides  
The X-axis demonstrates the signal intensity obtained from the assay and Y-axis 
represents the number of peptides displaying a given signal intensity. Every plot 
represents one monoclonal antibody’s reactivity as observed on the pathogen array. 
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Supplementary Figure 4- 2 Change in signal distribution and cognate versus non-
cognate reactivity of p53Ab1 monoclonal incubated on NSB-9 slides for 1, 16, 24 and 36 
hours respectively.   
The X-axis demonstrates the signal intensity obtained from the assay and Y-axis 
represents the number of peptides displaying a given signal intensity. Every plot displays 
the reactivity of p53Ab1 monoclonal antibody on the array under incremental times of 
incubation. The signal intensity of its cognate epitope is depicted on the histogram using 
an arrow to demarcate its position within the histogram of peptide signal intensities. 
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Supplementary Figure 4- 3 Average signal intensity observed for various infections on 
NSB-9 slides at 16 hour incubation, 23°C and serum dilution of 1:500  
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The X-axis represents number of patients tested per infection group and Y-axis displays 
average signal intensities. The Y-axis for ASFV control (un-infected) and infected groups 
is different as compared to that for human infections merely to display all data.  
 
Supplementary Figure 4- 4 Structural (anti-LPS, anti-VEE) and polyclonal antibodies 
(FT03, Rco1, Rco2, Rco3, Rco4) on array. 
The X-axis represents signal intensities observed on array, Y-axis represents the number 
of peptides displaying a given signal intensity. The position of cognate epitopes is 
highlighted in red on the histogram.  
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Supplementary Figure 4- 5 Capturing the memory immune response from exposure and 
distinguishing time of exposure – Vaccinia vaccination 
The X-axis depicts the p-value score for the cognate group of pathogen peptides (VACWR 
- Vaccinia) versus all other groups of pathogen peptides on the array. The Y-axis 
displays the ranks of pathogen groups basis p-values from top to bottom. The graph is 
colored on an arbitrary scale correlating to the range of p-values. The P-value score is 
calculated basis how significantly a group of pathogen peptides contributes to signal 
intensities observed on the array. 
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Supplementary Table 4- 1  Guitope match data (score cut=3) 
KANWFDFKTFNQMTQVWGSC 
FT03 
    ***** FORWARD PEPTIDES ***** 
   
SEQ 
SC
OR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WIND
OW 
PEP 
WIND
OW UniqueID 
CRHNIEASQLA
EVRSYCYHA 
5.5
21 10 11 8 
nQmtq
VwgsC 
sQlaeV
rsyC 
JEV[E](341-
357) 
CSGEQKLISEE
DLEQKLISE 
4.3
6 2 19 1 sc cs 
anti-cMyc 
(9E10) 
MMIFRNDFEW
LKIHKTRGSC 
6.1
76 8 13 13 
mtqvw
GSC 
ihktrGS
C 
FT04-
Control 
CRHDTLKNLQ
QDLHQYFKGK 
4.4
89 6 7 6 fKtfnQ lKnlqQ 
PVX_09768
0(1000-
1016) 
CRHMSQAIAA
VSQDRCKNIT 
3.9
29 4 12 3 qMtQ hMsQ 
FTT0083(10
3-119) 
CRHKAEECTC
NNGSCSLKTS 
6.1
19 3 18 13 GSC GSC 
ASFV132(4
5-61) 
        TIPAHNIFWILYFSIGTGSC 
Rco3 
    ***** FORWARD PEPTIDES ***** 
   
SEQ 
SC
OR
E 
ALIGN 
LENGT
H 
PRO 
POS 
PEP 
POS 
PRO 
WIND
OW 
PEP 
WIND
OW UniqueID 
CRHILLASKHD
LMKQKCLKG 
4.3
14 5 10 4 ILyfS ILlaS 
Lassa-
Lprot(352-
368) 
CSGKWDEPGN
NVYGCIKQMY 
4.3
6 2 19 1 sc cs 
CF-
VF_02795-
(97-113) 
CRHPTHRHLK
GEACPLPHKL 
3.4
54 3 3 4 PaH PtH 
Machupo-
Gly(456-
472) 
CRHWKAVEKS
VAMKHLTSFK 
4.7
54 4 11 16 Lyfs Ltsf 
JEV[C](69-
85) 
CRHIPHTIAGP
KSKHNRREG 
3.7
3 2 5 15 HN HN 
JEV[NS1](1
037-1053) 
CRHGRGEQQI
NHHWHKSGSS 
4.0
01 3 5 9 hni qin 
WNV-I-NY-
99[E](677-
693);WNV-
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II-
956[E](673-
689) 
CRHKKADITSK
VNHVKEKTS 
3.9
73 3 5 13 hni nhv 
PVX_09770
0(783-799) 
CRHGHPVSRG
TAKLRWLVER 
4.6
01 4 14 8 SiGT SrGT 
WNV-I-NY-
99[NS5](258
0-
2596);WNV-
II-
956[NS5](25
77-2593) 
CRHLLWGGFP
WVSLGYSQTE 
5.4
42 5 12 11 yfSiG wvSlG 
FTT0614(13
7-153) 
CRHALTFKAC
DHIMKSGDLK 
4.0
62 5 15 13 Igtgs Imksg 
VACWR148
(222-238) 
CRHVRHTHSK
HKYHCICPMK 
3.1
07 3 17 7 TgS ThS 
EEE[GP2](6
9-85) 
CRHYSSTWHQ
DANHPYRTWN 
5.4
55 3 4 12 Ahn Anh 
WNV-II-
956[NS5](28
15-2831) 
CRHPHFVQHS
YTVQCKCRST 
3.3
82 4 17 12 TgsC TvqC 
PVX_00099
5(341-357) 
CSGYGGFLYG
GFLYGGFLAA 
4.3
6 2 19 1 sc cs 
anti-Leu-
Enkaphalin 
clone 
1193/220  
CRHERSHPEIW
HHLSTLIKQ 
5.4
5 6 9 10 wilyfS iwhhlS 
Machupo-
Lprot(422-
438) 
CRHMDEYVQE
LKGLIRKHIP 
3.6
36 7 10 14 ilyfsIg lirkhIp 
Machupo-
Lprot(1-17) 
CSGYGGFYGG
FYGGFYGGFA 
4.3
6 2 19 1 sc cs Peptide 9449 
CRHVERCYLQ
ALSVCNKVKG 
3.6
22 2 11 8 ly yl 
Junin-
Lprot(322-
338) 
CRHIHAMTPER
VQRLKASRP 
3.5
82 2 4 5 ah ha 
VEE[GP2](1
599-1615) 
CRHTQEKFEM
GWKAWGKSIL 
4.3
48 4 13 8 FsiG FemG 
JEV[NS1](9
01-917) 
EFWDKEWHTR
ADWPVWDGS
6.1
19 3 18 18 GSC GSC 
Rco2-
Control 
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C 
CRHGVMVEGV
FHTLWHTTKG 
3.3
92 4 5 12 Hnif Htlw 
WNV-I-NY-
99[NS3](154
4-
1560);WNV-
II-
956[NS3](15
40-1556) 
CRHSESHSPQE
VCEKYCSWG 
4.9
75 5 12 16 YfSiG YcSwG 
ASFV006(1
27-143) 
CRHPSESDLEY
SWLNLAAHH 
5.0
76 4 2 16 ipAH laAH 
Lassa-
Lprot(1538-
1554) 
CRHILGFYHLK
HKPPKKKCK 
4.7
48 4 12 7 yfsi fyhl 
ASFV194(1
9-35) 
CRHYGRCTRT
RHSKRSRRSV 
3.6
98 3 18 5 GsC GrC 
JEV[preM(2
19);M(220)](
205-221) 
CRHVAKAEEA
KKEADNAKVA 
3.1
48 3 4 14 AhN AdN 
PVX_09768
0(647-663) 
CRHSLMHWDL
ETQAPKNSIN 
6.5
08 6 1 12 TipahN 
Tqapk
N 
FTT1775(47
7-493) 
CRHKGCTLKIE
GEYAYGWLR 
3.6
48 2 9 18 Wi Wl 
FTT0191(13
7-153) 
CRHTALHFLN
AMSKVRKDIQ 
3.2
06 3 11 6 LyF LhF 
JEV[RNAPo
l](3208-
3224) 
CRHCHQGINN
KLTAHEVKLQ 
5.2
43 6 2 12 ipAHni ltAHev 
Lassa-
Lprot(221-
237) 
CRHEIDRIYKTI
KQYHESRK 
3.9
97 5 11 8 lYfsI iYktI 
VACWR130
(222-238) 
 
Table displaying alignment matches of high signal intensity peptides with immunized 
cognate peptides (FT03, Rco3) using alignment program GuiTope [34]. Setting a low 
cut-off score = 3, so as to capture discontinuous and short epitope matches. 
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CHAPTER 5 
DE-CONVOLUTING ANTIBODY CROSS-REACTIVITY OBSERVED ON A 
PATHOGEN PROTEOME PEPTIDE MICROARRAY 
Abstract 
Multiplexed proteomic microarray platforms have been unsuccessful at 
distinguishing infections apart due to antigen-antibody cross-reactivity on the assay. 
Given the specificity of antigen antibody interactions and diagnostic success of single 
pathogen based ELISA assays, using epitope peptide microarrays might appear to be a 
logical transition. Previous studies have failed to address cross-reactivity observed on 
multiplexed pathogen proteome based microarrays. We developed a multiplexed, 
pathogen proteome peptide (PPP) microarray designed to distinguish four priority 
pathogens apart. Despite optimizing microarray processing conditions on the PPP array to 
reduce cross-reactivity, we observed non-obvious antibody binding between unrelated 
pathogen peptides. We investigated the underlying factors that impact specificity and 
report several biochemical and computational aspects that affect and, if resolved, could 
enhance the accuracy of multiplexed epitope microarrays. A confounding aspect in 
mapping infection is observing cross-reactivity on the array from identical 5-7 amino acid 
long sequences in common between unrelated pathogen peptides. Secondly, the presence 
of common pathogen epitopes, such as Influenza virus, reduces the specificity of the 
remaining non-influenza pathogen peptides on a multiplexed assay.  The primary goal of 
this work is to assess the limitations of the PPP array while simultaneously distinguishing  
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priority pathogen and common pathogen exposures. Third, to circumvent cross-reactivity 
we developed an alternative data analysis strategy which uses a pattern of common short-
sequence motifs in the cross-reactive response to accurately detect an infection.  We 
utilized peptide sequence identity on a 2-mer to 7-mer repetitive epitope level to analyze 
data and discern groups of peptide n-mer motifs that we refer to as an ‘umbrella of 
antibody reactivity’. We classified the original infection/exposure by reading a pattern of 
antibody reactivity after averaging the signal intensity for these individual n-mer 
umbrellas. In doing so, we attempt to mathematically re-appropriate antibody cross-
reactivity observed on the platform to the actual pathogen causing the infection. This 
approach could be applied to historical peptide microarray data, likely considered 
unusable due to cross-reactivity, thus rescuing a number of important research projects. 
Abbreviations 
ASFV, African Swine Fever Virus; BLAST, Basic local alignment search tool; CMG, 
Comparative microbial genomics; FIU, Fluorescence intensity units; HIV, Human 
Immunodeficiency Virus; HCV, Hepatitis C Virus; JEV, Japanese Encephalitis Virus; 
NIAID, National Institute of Allergy and Infectious Diseases; PPP, Pathogen proteome 
peptide; WNV, West Nile Virus. 
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Introduction 
Pathogen protein sequences are extremely conserved. While it may not be 
immediately apparent on the protein level, it definitely is on an n-mer (short-peptide) 
level [140]. A B-cell antibody epitope ranges from 4-12 amino acids in length [88].  
Mapping this level of n-mer commonality is crucial to understand cross-reactive 
observations when developing immunoassays. Previous work done by our group [141] 
explored the feasibility of using a life space peptide array representing epitopes for 14 
NIAID category A, B, C  priority pathogens to distinguish those infections on a single 
multiplexed platform. From six infectious sera tested on that platform, four infections 
were distinguished with >90% AUC-ROC (area under a receiver-operator characteristics 
curve) simultaneously. These four groups of infectious sera were from exposures to, 
Coccidioides spps. (Valley Fever), African Swine Fever Virus (ASFV), West Nile Virus 
(WNV) and Vaccinia, the smallpox vaccine. The platform failed to correctly distinguish 
Malaria and Francisella tularensis LVS-live vaccine strain sera.  In this paper, we 
examine the effect of a change in chemical diversity of the platform on the interaction 
and local competition between antibodies and peptides on the microarray. This work 
addresses the peptide-antibody cross-reactivity observed on a multiplexed assay using 
bioinformatic solutions to eliminate confounding effects of cross reactivity on pathogen 
identification. 
The humoral antibody response to an infection consists of multiple components 
including but not limited to natural antibodies, highly neutralizing antibodies specific to 
the infection or exposure, poly-reactive antibodies and cross-reactive antibodies [129]. 
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The persistent presence of cross-reactive antibodies has been documented through 
numerous studies in infections such as Influenza, Dengue, HIV, HCV and Malaria  [142]. 
The advent of advanced indirect (antibody based) pathogen surveillance assays, has 
resulted in discovering pre-existing reactivity to Influenza virus strains such as the swine-
origin H1N1 [143] and Japanese encephalitis virus (JEV) [144] in previously unexposed 
populations. Cross-reactivity is an inherent feature of all antigen-antibody reactions 
partly due to plausible conformational and structural reasons highlighted in literature 
[101]. In some instances cross-reactivity is beneficial, due to offering cross-protection for 
example, neutralization of the pandemic swine (2009 H1N1) and avian (1997, H5N1) 
origin influenza viruses due to a memory response from seasonal influenza vaccine 
strains [145-147]. When developing a single pathogen based diagnostic serological assay, 
explaining cross-reactivity captured on the assay from other unrelated pathogens is 
difficult. Ulrich et al [92] encountered this problem while developing a Yersinia pestis 
(gram-negative) specific proteome protein microarray. They observed cross-reactivity on 
Y.pestis proteins from rabbit sera experimentally infected with seven other genetically un-
related gram-negative bacteria and Bacillus anthracis a gram-positive. They used the 
signature pattern of cross-reactivity from other infections observed on their Y. pestis 
protein microarray to distinguish the cross-reactive pattern per pathogen.  
Cross-reactions are observed on serology based assays within genetically related 
strains of a given virus, for example, within Dengue strains 1, 2, 3 and 4 and also within 
viruses belonging to the same family, Flaviviridae- between Dengue and JEV [148,149]. 
Cross-reactivity has been documented on multiplexed diagnostic assays such as the 
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ToRCH assay that simultaneously measures antibodies from five vertically transmitted 
pathogens. The assay sensitivity when measuring antibodies against genetically distinct 
Toxoplasma gondii and Rubella versus Herpesviruses: Cytomegalovirus (CMV), Herpes 
Simplex virus 1 (HSV-1) and HSV-2 using ToRCH is variable per infection ranging from 
46-97% and specificity between 88-100% [37]. Cross-reactivity in antigen-antibody 
diagnostics could be explained as being observed due to short n-mer identity on a 5-mer 
to 11-mer amino acid level between unrelated pathogen proteomes. Based on this 
rationale, Kanduc and Kobinger et al. map the redundancy between pathogens and the 
human (host) proteome, for developing better pathogen targeted vaccines that could 
potentially generate lesser self-reactive antibodies [140,150,151].  
In this study, we tested how incrementally adding common exposure pathogen 
peptides on the PPP array affected its ability to discern priority infection antibody 
response. The original platform contained 12 pathogen epitopes (PPP-12) from either 
immunodominant antigens for larger pathogens or complete proteomes for smaller 
viruses. To test the effect of change in chemical diversity, we made two incremental sets 
of arrays, one in which we added ASFV and Vaccinia peptides (PPP-14) and another in 
which we added Influenza peptides (PPP-15). ASFV and Vaccinia viruses are both 
double stranded DNA viruses closely related to Herpes viruses. These pathogen peptide 
groups were added due to recent availability of sera and to measure the effect of adding 
peptides that are potentially capable of capturing Herpes virus cross-reactivity. The 
addition of ASFV and Vaccinia peptides did not have a detrimental effect on the PPP 
array’s ability to distinguish multiple infections. By adding influenza peptides, we 
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evaluate the effect of including a common exposure yet priority pathogen on the array. 
Due to the frequency of human exposures to various influenza strains [152], we expected 
to observe a distinct separation of memory influenza specific antibody response and 
priority pathogen reactivity, leading to more specific priority pathogen detection. The 
addition of influenza peptides on the array however, reduced the assay’s ability to 
distinguish priority pathogen infections. The most parsimonious explanation for this 
observation might be that the influenza peptides likely competed for antibody reactivity 
to other priority pathogen peptides. This competition reduced the pathogen specific 
response apparent on arrays without influenza peptides. This observed cross-reactivity to 
influenza peptides from all infectious sera led us to developing an improved 
bioinformatics approach to mathematically reattribute cross-reactivity. While doing so we 
used the cross-reactivity observed due to the addition of influenza peptides on the 
multiplexed assay to distinguish priority pathogen infections apart.  
Methods 
Serum samples and monoclonal antibodies used in this study 
Human patient serum samples from Influenza and Vaccinia vaccine recipients and 
healthy non-disease individuals were collected under the ASU IRB 0905004024, “Blood 
Collection for Immunological Studies”. Fransicella tularensis subsp. holarctica live 
vaccine strain (LVS) vaccinated individuals’ sera was received from Dr. Anders 
Sjöstedt’s laboratory at Umeå University, Sweden. They are part of a time course study; 
samples used were 28-30 days post-receiving the LVS vaccine. Valley fever infected 
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patient sera was received from Dr. John Galgiani at the University of Arizona (IRB# 
FWA00004218). Plasmodium vivax and West Nile virus infected sera was obtained from 
SeraCare Life Sciences (Milford, MA). All monoclonal antibodies used in this 
publication are listed in Supplementary Table 5- 1. 
Microarray production and processing 
Pathogen proteome peptide microarrays were produced as described in Chapter 4. 
Briefly, peptides were obtained from Sigma Genosys (St.Louis, MO) and printed on 
NSB-9 aminosilane slides from NSB Postech (Los Alamitos, CA). All slide surfaces were 
coated with sulfo-SMCC linker (Pierce, Rockford, IL) and peptides were conjugated to 
the surface using maleimide conjugation chemistry. Each peptide was printed twice on a 
two-up array by Applied Microarrays Inc. (Tempe, AZ) using piezo electric printing.  
The following pathogen peptides were represented on the PPP array: 
a.) PPP-12: Array representing 12 pathogens (3546 peptides) - Francisella tularesis 
[Tularemia-LVS], Coccicioides immitis [Valley fever], West nile virus (WNV) 
[strain: I & II], Japanese encephalitis virus (JEV), Plasmodium vivax [Malaria], 
Venezualan Equine Encephalitis, Eastern Equine Encephalitis, Bacillus anthracis, 
Machupo virus, Junin virus, Guanarito virus, Lassa virus and monoclonal 
antibody epitope peptide controls. 
b.) PPP-14: Array representing 14 pathogens (4337 peptides) - PPP(12) peptides + 
African swine fever virus [ASFV] and Vaccinia [strain: Western Reserve] 
peptides. 
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c.) PPP-15: Array representing 15 pathogens (4693 peptides) - PPP(14) + 283 
Influenza PR8 (H1N1) peptides 
Microarray slides were pre-washed with a solution containing 7.33% acetonitrile, 
33% isopropanol and 0.55% TFA to remove unbound peptides.  Slides were blocked in 
1X PBS, 3% BSA, 0.05% Tween 20, 0.014% β-mercaptohexanol for 1hr at 25oC.  Sera 
samples were diluted 1:500 in the Incubation buffer containing 3% BSA, 1X PBS, 0.05% 
Tween 20, and allowed to bind to the microarray for 16 hours at 23°C in 100 µl total 
volume per pathogen peptide array. The optimum thermodynamic parameters chosen for 
processing these pathogen arrays were based on empirical data from our previous work 
[141]. A Tecan 4800 Pro Hybridization Station (Tecan, Salzburg, Austria) was used for 
array incubation and primary sera was detected using Alexa Fluor-647 conjugated Goat 
anti-Human, IgG Fc (γ) fragment specific secondary antibody from Jackson 
ImmunoResearch (West Grove, PA).  
The slides were scanned using Agilent C scanner (Santa Clara, CA) at 635 nm 
excitation wavelength with 100% PMT and laser power at 10 µm image resolution. The 
16-bit TIFF images were aligned using GenePix 6.0 software (Axon Instruments, Union 
City, CA) and the data files imported into GeneSpring 7.3.1 (Agilent, Santa Clara, CA) 
and Matlab (Natick, MA) for further analysis. Every patient’s serum sample was 
processed in duplicate and since every peptide was printed twice within a sub-array, it 
gave 4 measurements from the same peptide upon combining both technical replicates. 
Any array with a Pearson Correlation Coefficient less than 0.85 across technical 
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replicates was re-processed. Upon meeting the quality criteria, all technical replicates for 
a given individual patient were averaged for further data analysis.  
Statistical analysis and software used 
The arrays were initially analyzed using Matlab (Natick, MA) code written from 
our previous work [141]. Short sub-sequence n-mer analysis was performed using a 
regular expression search program published in Richer et al. [153]. The algorithm was 
designed to find short identical sub-sequences in common within the peptides represented 
on a microarray. From a peptide sequence library, the algorithm divides all peptides into 
all possible subsequences within user input length ranges, 2-19 amino acids for a 20-mer 
peptide length array. The signal intensity associated with each one of these peptide sub-
sequences is extracted from the original peptide sequence they belong to and averaged 
together per sub-sequence, provided there are at least 2 replicates per sub-sequence full-
filling signal intensity criteria. These list of subsequences with signal intensities 
associated with them are ranked and sorted based on their signal intensity and 
subsequences below user input signal intensity cut-off (<500 FIU-Fluorescence intensity 
units) are excluded. This list of significant sub-sequences, are obtained per individual 
sample and the number of n-mers in common per infection and per individual are 
estimated using a custom python script. The mathematical pattern containing this 
information is used to classify the sample into an infectious group using leave one out 
cross-validated (LOOCV), Support Vector Machine (SVM) algorithm from the e1071 
library in R. The number of n-mer sub-sequences in common between individual serum 
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samples or individual pathogens was calculated using a custom python script. Using these 
numbers the Connectograms in Figures 2 and 3 are constructed using Circos online [154]. 
The pathogen proteome BLAST matrices are generated using CMG-biotools [155]. 
Influenza PR8 whole virus ELISA protocol 
Nunc Maxisorp microtiter ELISA plates were coated by incubating overnight at 
4°C with purified UV-inactivated Influenza H1N1 A/PR/8/34 (PR8) virus commercially 
available through Advanced Biotechnologies Inc. (Cat. No.: 10-2/3-500, Lot: 8J0006) at 
100 ng/well. Additional plates were coated with 5% non-fat milk in TBST (19.98mM 
Tris, 136mMNaCl, pH 7.4 with 0.05% Tween 20) as control for background binding and 
the same serum samples were processed on them simultaneously. The non-specific 
absorbance obtained from these plates was then subtracted from that obtained from PR8 
coated plates. As a positive control for secondary binding, 1:500 diluted pooled naïve 
mouse (C57BL6J) and uninfected pooled human sera was applied in 2 wells each, per 
plate. All control sera and antigens were diluted in the carbonate/bicarbonate buffer 
(15mM Na2CO3, 35mM NaHCO3). As a secondary antibody negative control, 3 wells per 
plate were coated overnight with the antigen and blocked to be detected directly with the 
anti-human secondary antibody and three with the anti-mouse secondary antibody per 
plate. These absorbance values were then averaged and subtracted from their respective 
human or mouse sera wells as background absorbance due to secondary antibody. All 
plates were washed between steps three times each using TBST. The plates were then 
blocked with 5% non-fat milk and incubated for 1 hour at 37°C. For the assay, serum 
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samples were serially twofold diluted in PBST and incubated on the plates for 1 hour at 
37°C starting at 1:50 dilution up to 1:800.  The bound serum antibodies were detected 
using the appropriate species specific secondary antibodies diluted 1:1000 in PBST. Anti-
mouse IgG (H+L)-HRP conjugated (Bethyl Laboratories, Montgomery, TX; Cat. 
No.:A90-216P) for mouse sera and anti-human IgG (H+L)-HRP conjugated (Vector 
laboratories, Burlingham, CA; Cat. No. PI-3000) for human sera, were incubated for 1 
hour at 37°C. Bound secondary antibody was detected by adding 100 µL of the substrate 
for HRP, ABTS (KPL, Gaithersburg, MD) and incubating for 30 minutes at 37°C. This 
colorimetric reaction was stopped using SDS (1%, 50 µL per well) and absorbance’s 
were read using the SpectraMax 190 absorbance microplate reader (Molecular Devices, 
Sunnyvale, CA) at 405nm.  
Results 
Redundancy observed within priority pathogen proteomes represented on PPP 
array 
We first sought to quantitatively measure the degree of sequence redundancy 
present in the pathogen proteomes.  Figure 5-1 is a BLAST (Basic local alignment search 
tool) matrix generated using the CMG-biotools [155] proteome comparison workbench. 
The figure represents 289 comparisons (17X17) of pathogen proteomes represented on 
the PPP array. Every cell of this BLAST matrix represents a summary of BLAST queries 
with a 50% homology restriction applied to between 2 (EEE and VEE proteomes) and 
10,454 proteins (Coccidioides immitis proteome) summarizing the results of 
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approximately 543 million BLAST searches between 23,311 total proteins. The epitope 
peptides used as positive control on the assay are intentionally included in this analysis to 
display no overlap at a stringent restriction of 50% identity in at least 50% alignment 
match of the two proteins being compared. As is expected Flaviviruses, WNV strains I 
and II and JEV are 76.9% homologous represented by bright green cells in the matrix. 
The Arenaviruses (Junin, Machupo, Lassa and Guanarito) are homologous amongst 
themselves as are the equine encephalitis viruses (EEE and VEE). The last row of this 
matrix depicts homology within the proteome and larger proteome pathogens such as 
Bacillus anthracis (Sterne) have up to 258 redundant homologous proteins within their 
proteome. In summary, on a proteome level, there is not much apparent homology 
between phylogenetically distant priority pathogens, at least under these criteria. 
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Figure 5- 1 BLAST matrix depicting homology between pathogens chosen to be 
represented on the pathogen proteome peptide (PPP) microarray.  
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A BLAST hit within this program is considered homologous (green) if at least 50% of the 
two protein sequences are aligned and 50% of the amino acids within the alignment are 
identical. The last row at the bottom of this matrix depicts homology within a given 
pathogen proteome under the strict homology criteria (gray to red scale). 
Redundancy observed within priority pathogen peptides represented on PPP array 
Homology calculated between full length proteins would be insufficient to explain 
the observed cross reactivity between evolutionarily distant priority pathogen proteomes.  
Therefore, we explored sequence identity on a finer scale, examining sequence motifs in 
the range of common epitope lengths.  The numbers of identical 5 to 10-mers in common 
between pathogen proteomes represented on the pathogen array and common pathogens 
such as Herpes and Influenza were calculated using a Python script from a suite of 
programs published in Richer et al. [153]. The overlap between pathogens based on 
shared sequence motifs is illustrated as a connectogram in Figure 5- 2.  
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Figure 5- 2  Pathogen space is extremely conserved on a 5-mer peptide motif level.   
Every pathogen has a unique color and the size of the ribbon is proportional to the level 
of overlap between those pathogens on either a 5 amino acid sequence (5-mer) or 10 
amino acid sequence (10-mer) levels. The extent of overlap appears to diminish as 
epitope length increases with 10-mers having the least overlap suggesting short sequence 
motifs might be responsible for driving cross-reactivity. The code for designations on the 
circle is given in a table on the left. 
Redundancy observed within peptides on the PPP array and pathogen proteomes 
Having established that a number of identical short motifs are conserved between 
unrelated pathogens, we sought to characterize the motifs present on the PPP array.  The 
implication from this analysis would be to a priori expect cross-reactivity to non-cognate 
pathogen peptides due to identical n-mers in common between the infecting pathogens 
proteome and several other pathogen peptides on the array. The peptides were selected 
for inclusion on the PPP so as not to represent any duplicate 16 & 17-mers. Any 
duplication in sequence between amino acid lengths 5 through 15 was noted so as to map 
possible cross-reactive binding between unrelated pathogen peptides. Distribution of 
common 5-mers between pathogen proteomes and peptides on the PPP is presented in 
Figure 5- 3 as a connectogram. The size of the ribbon between two groups is correlated 
to the extent of overlap between those groups.  A distinct pattern of common motifs 
radiates outward from each pathogen. This analysis indicates that multiple 5-mers are 
commonly present between complete pathogen proteomes and unrelated pathogen 
peptides on the array.  As depicted in Figure 5- 3, it may be possible using this 
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information to predict a priori cross reactivity between Valley Fever (Coccidioides 
immitis) infected individual’s serum antibodies to Francisella tularensis and Plasmodium 
vivax peptides on the PPP array.  Taken together this suggests that the unique pattern of 
potentially cross-reactive n-mers may be used to identify the priority pathogen exposure. 
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Figure 5- 3 Circular connectogram displaying 5-mer level overlap between peptides 
represented on the pathogen array and their respective proteomes 
Every pathogen has a unique color and the size of the ribbon is proportional to the level 
of overlap between those pathogens peptides and other pathogen proteomes on a 5 amino 
acid sequence (5-mer). The code for designations on the circle is given in a table on the 
left. 
Monoclonal antibody binding on the PPP array  
The sequence analysis indicates that common short motifs might be responsible 
for antibody cross-reactivity observed on the PPP array.  To test this hypothesis, we 
tested the binding of individual well characterized monoclonal antibodies on the 
platform. These monoclonals bound specifically to their cognate linear epitope peptide 
along with other peptides having amino acid sequence similarities as demonstrated in 
Figure 5- 4. As listed in the top panel of Figure 5- 4, the p53Ab1 monoclonal antibody 
recognizes the linear peptide sequence ‘RHSVV’ with high affinity (estimated kD 
<100pM) [2]. Additionally, on the array, it binds other unrelated peptides that either have 
the exact 5-mer epitope or have a structural analog of it such as, ‘RHSII’ and ‘RHSVI’ as 
listed in table. This group of antibody reactivity could thus be classified as one ‘umbrella 
of reactivity’ due to one antibody binding all these related peptides and will be referred to 
as such, throughout the Chapter. This result was verified with 4 other monoclonal 
antibodies namely, p53Ab8, cMyc, FLAG, V5-tag and support the hypothesis that the 
presence of short motifs in unrelated pathogen peptides might drive cross-reactivity.  
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Figure 5- 4 Monoclonal antibody binding observed on PPP-14 array (p53Ab1) 
The top panel lists the median signal intensity obtained for peptides binding the 
monoclonal antibody p53Ab1 alongside their sequence. The alignment of consensus 
sequence within these peptides is depicted in the last column. The bottom panel shows the 
amino acid structure and properties of a mimotope peptide within Lassa virus that has an 
analog of p53Ab1’s original recognition sequence ‘RHSVV’. 
Simultaneous detection of priority pathogen and common exposure pathogen 
signature 
Within a population, individuals are always exposed to common pathogens that 
may confound diagnosis of a priority pathogen through manifesting similar symptoms or 
increased lethality during co-infection [156].  For this reason, we sought to test the 
multiplexed PPP array’s ability to distinguish more than one infection/exposure in the 
same individual’s serum sample. The hypothesis was that the array would be capable of 
simultaneous detection of common pathogen signature (e.g. Influenza, Herpes) and 
priority pathogen signature. To test this concept we added 283 peptides representing 
100% of the Influenza-A/PuertoRico/8/1934 (H1N1) proteome. Given the high frequency 
of influenza exposures in human populations [157] and maintenance of long term 
memory responses to various influenza strains [54], we expected to be able to separate 
influenza and priority pathogen reactivity on the array simultaneously. Adding influenza 
peptides to the existing 14 pathogen peptides (PPP-14) reduced the specificity of the PPP 
array to distinguish between pathogens.  
 179 
 
 
Figure 5- 5 P-value score chart for 1 WNV infected individual’s sera on 3 different array 
platforms.  
The X-axis depicts the P-value score for group of pathogen peptides versus all other 
peptides on the array and the Y-axis displays the ranks of these pathogens based on the 
P-value score. The group labeled ‘Other’ represents signals from antibody binding to 
internal control monoclonal antibody epitopes peptides. The p-value cut-off for PPP-12 
is 0.0003 and that for PPP-14 and PPP-15 is 0.0002. The p-values of WNV group of 
peptides calculated on all 3 arrays are displayed within the graph. 
The addition of influenza peptides altered antibody binding to cognate infection 
pathogen peptides for all infections being tested. This can be observed in Figure 5- 5 
showing p-value score based pathogen rank plots. The 3 panels of Figure 5- 5 show 
change in antibody binding for one WNV virus infected individual on 3 different arrays, 
merely representing the trend observed in this dataset for all infectious samples tested. 
 180 
 
The first panel shows this WNV infected individual’s antibody binding as observed on an 
array representing peptides for 12 priority pathogens, not including Influenza, ASFV and 
Vaccinia. The p-value score of WNV group of peptides is 3.60 x 10-8, statistically 
significantly higher as compared to the p-value score of the remaining pathogen groups 
of peptides. The p-value score of Lassa (0.00014) and JEV (0.00012), other encephalitis 
viruses are above the p-value score cut-off = 0.0003 for this platform, displaying cross-
reactivity on the assay. These p-values however are much lower as compared to that of 
WNV showing a clear separation of WNV specific antibody reactivity. Panel 2 shows 
this same individuals’ antibody binding profile on an array that included ASFV and 
Vaccinia, but not influenza peptides. The addition of Vaccinia and ASFV peptides 
capable of capturing other poxvirus (such as Herpes) related antibody response, appears 
to improve the assay’s capability of detecting the priority pathogen antibody response. 
The p-value score of WNV group of peptides is 1.26 x 10-10, and while cross-reactivity to 
JEV (9.25 x 10-5) is retained and above p-value cut-off 0.0002, the p-value of WNV is 
significantly lower than that of JEV. Panel 3 displays how the change in antibody binding 
on the array after the addition of influenza peptides diminishes the platform’s ability to 
distinguish the WNV signature. The p-value score of WNV group of peptides is 0.05, 
with Vaccinia (VACWR) group of peptides being ranked highest at p-value 0.0005 below 
cut-off 0.0002. Using existing analysis techniques that involved ranking groups of 
pathogen peptides through eight statistical metrics did not resolve any of the priority 
pathogen signature responses including WNV on arrays containing influenza peptides.  A 
summary of results from all three versions of arrays is depicted in Table 5- 1 and all the 
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scoring metric transitions between these three array versions are summarized in Table 5- 
2. This observation warranted a bioinformatic intervention to re-appropriate cross-
reactivity observed on the assay regardless of change in the platforms’ chemical 
diversity.  
Table 5- 1 ROC summary displaying accuracy of diagnosing the cognate infection on 
three platforms 
Infection 
(No. of 
patients) 
PPP (12 
pathogens, 
no 
ASFV,VA
CWR,PR8
) 
Mean  
Sig. 
T-test  
p-val. 
Signal
*-
log(P-
val) 
Signal 
 to  
Noise 
Median  
Signal 
Mean  
Ranks 
Wilc
oxon 
Pearson  
Correlation 
Valley 
fever (6) 
0.94 0.24 0.41 0.43 0.77 0.38 0.20 0.80 
WNV (5) 0.58 0.95 0.86 0.44 0.63 0.87 0.95 0.69 
Malaria (3) 0.52 0.04 0.06 0.20 0.36 0.14 0.17 0.23 
LVS-
Francisella 
tularensis 
(5) 
0.37 0.48 0.41 0.15 0.23 0.37 0.47 0.57 
         Infection 
(No. of 
patients) 
PPP (14 
pathogens, 
added 
ASFV, 
VACWR) 
Mean  
Sig. 
T-test  
p-val. 
Signal
*-
log(P-
val) 
Signal 
 to  
Noise 
Median  
Signal 
Mean  
Ranks 
Wilc
oxon 
Pearson  
Correlation 
Valley 
fever (3) 
0.91 0.24 0.46 0.38 0.73 0.35 0.17 0.85 
ASFV (4) 0.96 0.46 0.89 0.90 0.96 0.73 0.92 0.98 
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WNV (6) 0.68 0.97 0.94 0.34 0.62 0.89 0.96 0.80 
Vaccinia 
(5) 
0.81 0.93 0.95 0.39 0.78 0.73 0.91 0.89 
Malaria (3) 0.37 0.35 0.11 0.41 0.08 0.38 0.44 0.54 
LVS-
Francisella 
tularensis 
(5) 
0.45 0.33 0.32 0.22 0.27 0.25 0.24 0.40 
         Infection 
(No. of 
patients) 
PPP (15 
pathogens, 
added 
PR8, 
ASFV, 
VACWR) 
Mean  
Sig. 
T-test  
p-val. 
Signal
*-
log(P-
val.) 
Signal 
 to  
Noise 
Median  
Signal 
Mean  
Ranks 
Wilc
oxon 
Pearson  
Correlation 
Valley 
fever (3) 
0.90 0.19 0.30 0.20 0.18 0.30 0.31 0.92 
ASFV (4) 0.99 0.64 0.96 0.69 0.98 0.94 0.84 0.99 
WNV (6) 0.57 0.59 0.61 0.47 0.61 0.49 0.38 0.57 
Vaccinia 
(5) 
0.89 0.36 0.56 0.67 0.88 0.63 0.44 0.80 
Malaria (3) 0.43 0.18 0.17 0.17 0.39 0.29 0.35 0.38 
LVS-
Francisella 
tularensis 
(3) 
0.29 0.58 0.46 0.25 0.19 0.49 0.46 0.54 
Influenza(5
) 
0.84 0.96 0.97 0.33 0.66 0.96 0.97 0.99 
 
Table 5- 2 Summary of the worst AUC-ROC changes between array iterations, after the 
addition of Influenza peptides in PPP (15), PPP (no. of pathogens represented as 
peptides on array). 
Infection (no. of patients) 
PPP 
(12) 
PPP 
(14) 
PPP 
(15) Statistical metric 
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Valley fever (3) 0.94 0.91 0.90 Mean Signal 
WNV (6) 0.95 0.97 0.59 T-test p-value 
Vaccinia (5) NA* 0.93 0.36 T-test p-value 
Francisella tularensis 
(LVS) (6) 0.37 0.45 0.29 Mean Signal 
Malaria (3) 0.23 0.54 0.38 
Pearson 
Correlation 
 
Cross-reactivity observed on pathogen peptide array from evolutionarily related 
pathogen exposures 
Cross-reactivity is not limited to the inclusion of influenza peptides. Two out of 
the five tested Vaccinia vaccinees showed reactivity to both ASFV and Vaccinia 
peptides. Given that both these pathogens are double stranded DNA viruses and belong to 
evolutionarily related viral families, Asfarviridae and Poxviridae, one might expect 
significant commonality in peptide motifs. Cross-reactivity is also observed between 
Herpes virus infected individuals (human sera) and ASFV/Vaccinia peptides as 
demonstrated in Figure 5-6. 
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Figure 5- 6 Cross-reactivity displayed on three versions of PPP arrays from one HSV-2 
infected individual’s sera.  
 185 
 
The Y-axis shows the scale of non-normalized signal intensity from averaging signal of 
peptides per pathogen protein (X-axis). The green bars display signal from peptides 
averaged per protein from the 12 pathogen peptide array. Blue bars represent signal 
from the 14 pathogen peptide array and Red bars represent signal intensities from the 15 
pathogen peptide array containing influenza peptides. 
ASFV is a swine infection and has currently not been documented as being 
transmitted to humans. Though ASFV-like genetic sequences have been isolated from 
febrile patient’s sera in the Middle East and several sewage sources [40]. It is highly 
unlikely the sera we tested represents past exposure to ASFV. Therefore the reactivity on 
ASFV peptides is almost assuredly due to cross-reactivity. The prior exposure and 
vaccination history of both Vaccinia vaccines and herpes virus infected sera is 
unavailable. It is therefore, not possible to exclude prior Vaccinia vaccination in Herpes 
infected sera or Herpes exposure in Vaccinia vaccines. To test whether antibody cross-
reactivity between related pathogens poses a significant diagnostic problem, we tested 
four Herpes virus infected patient sera on the arrays which do not have herpes virus 
peptides represented. We observed cross-reactivity to ASFV and Vaccinia peptides 
(Figure 5-6) which was expected given that they are both dsDNA viruses like Herpes 
[40]. 
Simulating an artificial infection using multiple monoclonal antibodies 
In order to de-convolute cross-reactivity observed from infected sera on PPP-15 
arrays containing influenza peptides a mix of monoclonal antibodies was processed on all 
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three versions and array signals obtained. The monoclonal antibody mix experiment was 
done to mimic a polyclonal infection specific immune response, except where the linear 
epitope peptides expected to capture those antibodies were known a priori. The 
experiment included eight pre-characterized linear epitope binding monoclonal antibodies 
as listed in Supplementary Table 5- 1. In addition to the eight monoclonals, three 
influenza polyclonals against immunodominant antigens hemagglutinin (HA), 
neuraminidase (NA) and nucleoprotein (NP) were added in samples denoted as ‘with 
Influenza (INF)’ to study the effect of having a memory influenza antibody component 
within non-influenza infectious sera. Figure 5- 7 illustrates the median signal intensity 
for three peptide groups on three array versions with or without the influenza antibody 
component.  
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Figure 5- 7 Median signal intensities on a log10 scale for 8 monoclonal antibody 
epitopes (blue bars) versus signals from all other peptides on the array (green bars) and 
PR8 influenza peptides (red bars). Error bars represent standard error, P-value cut-off = 
0.125. 
* Significant between arrays with and without influenza peptides for monoclonal 
antibody mix experiment without an influenza antibody component on a one-tailed, 
paired t-test (p-value=0.02) 
* Significant between arrays with and without influenza peptides for monoclonal 
antibody mix experiment with an influenza antibody component on a one-tailed, paired t-
test (p-value=0.02) 
The blue bars represent the binding observed on the eight linear monoclonal antibody 
epitope peptides. Signals from all the remaining peptides on the array are represented by 
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green bars and influenza PR8 peptides on PPP-15 array containing them are represented 
by red bars.  
The remaining peptides (non-monoclonal pathogen epitopes) on the array (green 
bars) have 19%, 3-mers in common with the immunogens used to generate the 8 
monoclonal antibodies. These 3-mers might represent potential antibody contact points 
which explains the cross-reactivity observed on some non-monoclonal epitope peptides 
on each version of the array (green-bars). This number of n-mers in common between the 
remaining peptides and monoclonal antibody immunogens reduces as expected to 1.8% 
in common when searching for 4-mers. Despite the addition of influenza polyclonal 
antibodies within the monoclonal antibody mix, a clear bifurcation of influenza specific 
and monoclonal specific antibody responses can be measured on PPP-15 array. A 
surprising observation, during this analysis was the binding observed on influenza 
peptides from monoclonal antibodies despite no influenza polyclonals added with the 
monoclonal antibody mix (PPP-15, MAbMix_NoINF). This as well could be partially 
explained by the number of 3-mers in common between influenza peptides and 
monoclonal antibody immunogens (22%). Additionally, the amount of antibody 
reactivity captured from monoclonal antibodies on PPP-15 was statistically significantly 
lower as compared to that observed on PPP-14. This observable change in median signal 
intensities corresponds to a significant change in antibody binding distribution on the 
three array versions as observed from the antibody binding histograms of this data in 
Figure 5-8. The peptides for each monoclonal antibody are highlighted using arrows 
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demarcating their position within the histograms. This suggests cross-reactivity occurs on 
a short n-mer amino acid level to partial epitopes within unrelated peptides. 
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Figure 5- 8 Monoclonal antibody mix on pathogen arrays.  
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Histograms showing the distribution of signal intensities due to monoclonal antibodies 
binding peptides on three PPP arrays. The Y-axis shows the number of peptides at a 
given signal intensity (red=high signal, blue=low signal) whose range is displayed on the 
X-axis. The positions within these histograms showing cognate monoclonal antibody 
binding epitope peptides, is highlighted with arrows. (PPP-12 has 12 pathogen peptides 
excluding Influenza, ASFV and Vaccinia peptides; PPP-14 has 14 pathogen peptides 
excluding influenza peptides; PPP-15 has 15 pathogen peptides including influenza). 
Influenza antibody reactivity observed in individuals responding to non-influenza 
virus exposures 
Due to a high level of homology among all influenza virus proteomes, 
representing the Influenza PR8 proteome in the form of peptides, inadvertently also 
represents multiple human vaccine strains. Figure 5- 9 summarizes the analysis 
performed to de-convolute influenza peptide related cross-reactivity observed on the PPP 
array. 
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Figure 5- 9 Influenza reactivity observed in individuals with non-influenza exposures.  
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A. Influenza PR8 proteome homology with other human influenza vaccine virus 
proteomes (60 to 100% homologous) B. Box-Cox plot displaying pre-existing reactivity 
observed in special pathogen free naïve mice (D0) Influenza Pre (blue) versus 40 days 
(D40) post infection (red) on 283 influenza PR8 peptides from pathogen proteome 
peptide array. The line in the center of the box represents the median signal intensity. C. 
PR8 ELISA (blue bars), a measure of antibody reactivity observed in naïve mice (D0 = 
Day 0) along with reactivity from same sera on day 40 (red bars). D. Reactivity of serum 
antibodies in a whole virus (PR8) ELISA for some human donors whose serum antibodies 
strongly bound PR8 epitope peptides on the pathogen array (green bars). Averaged 
values from 3 replicates per ELISA measurement are shown and error bars in panels B 
and D represent standard deviation. The Y axes represent relative fluorescence on array 
in panel B and absorbance at 405 nm in panels C & D. The data reported in panels C 
and D is from 1:50 serum dilution for both mouse and human sera. 
Figure 5- 9, Panel A is a BLAST matrix obtained through CMG-biotools 
representing the extent of proteome overlap between Influenza PR8 and human vaccine 
strains. The matrix represents 49 comparisons (7X7) of pathogen proteomes. Every cell 
of the BLAST matrix represents BLAST queries with a 50% homology cut-off between a 
total of 72 proteins summarizing the results of 4,418 BLAST searches. The 2006-2009 
human influenza vaccine strains were 60%-100% homologous with PR8. In order to 
determine if influenza peptides could compete for non-influenza infection specific 
antibody response, some patient sera with sufficient volumes available were tested for 
cross-reactivity using a whole PR8 virus ELISA. We hypothesize that the change in 
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antibody binding observed from non-influenza infections might be due to competition for 
antibodies between influenza peptides and cognate priority pathogen’s peptides. To test 
this hypothesis without potentially confounding vaccination history from human sera, 
specific pathogen free (SPF) Naïve mouse sera were collected before and 40 days after 
PR8 infection and their antibody response was measured on both the PPP-15 microarray 
(Figure 5- 9, Panel B) and PR8 ELISA (Figure 5- 9, Panel C). All mice tested including 
Naïve, showed pre-PR8 exposure antibody cross-reactivity to Influenza PR8 in the 
ELISA and on the pathogen proteome array. Using Gnotobiotic mice instead of SPF mice 
might show lesser PR8 reactivity pre-exposure; however, this does not exclude the ability 
of influenza peptides to non-specifically capture antibody reactivity not related to PR8 
exposure. 
Figure 5- 9, Panel D shows antibody cross-reactivity as measured by an ELISA 
from infected human sera (green bars) having non-influenza pathogen exposures. The 
blue bars represent un-infected pre and post-vaccine sera from one 2006-2007 seasonal 
influenza vaccinee (ND43) and one Francisella tularensis Live vaccine strain (LVS) 
recipient sera collected in 2009 (LVS93). The probability that LVS93 might have either 
received or been exposed to the strains in 2006-2007 seasonal Influenza vaccine cannot 
be excluded. The Influenza vaccine (ND43) pre and post-vaccine serum was included to 
demonstrate the specificity of the PR8 ELISA. This individual had received the 2006-
2007 seasonal influenza vaccine which included another H1N1-like virus A/New 
Caledonia/20/99 strain, 90.9% homologous to the PR8 strain. ND43’s pre and post-
vaccine sera did not show significant antibody reactivity on the A/Puerto Rico/8/1934 
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H1N1 ELISA. This was not an end-point ELISA because it was performed as an 
alternative measurement of the cross-reactivity observed from non-influenza infection on 
the PPP array. Average absorbance values were calculated for the most descriptive 
dilution. The remaining dilutions till 1:800 were processed to observe a linear trend in 
data so as to verify the observations from 1:50 diluted sera. The sensitivity of a peptide 
microarray is higher as compared to that of an ELISA [158]. Therefore, the 1:50 dilution 
was more informative on an ELISA as compared to the 1:500 used for the peptide 
microarray. Additionally, arrays were processed using 1:50 and 1:100 serum dilution to 
estimate if concentrating the serum amount would overcome the influenza peptide 
directed cross-reactivity. The assumption was that increasing the concentration of sera 
would saturate the influenza peptides sufficiently to reduce competition, thereby, 
allowing priority pathogen specific antibodies to bind their appropriate target peptides. 
The two serum concentrations tested, 1:50 and 1:100, however were not sufficient to 
improve the ability of priority pathogen peptides to capture additional reactivity. Figure 
5- 10 shows two WNV infected individuals sera in panels A and B at the default standard 
1:500 serum dilution versus 1:50 and 1:100. The arrays were processed under 
thermodynamic conditions previously optimized for this platform to reduce cross-
reactivity, primary sera incubated for 16 hours at 23°C. At both higher concentrations the 
average antibody reactivity captured by influenza peptides and several other non-cognate 
infection pathogen groups is higher than the average antibody reactivity captured by 
cognate WNV peptides. A similar experiment was repeated using arrays without 
influenza peptides to observe the antibody reactivity at varying concentrations of serum 
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dilution. The average signal response from pathogen groups of peptides for three VF 
infected individuals is depicted in panels A, B, and C of Figure 5- 11 at the standard 
1:500 versus 1:50 and 1:100 serum dilution. As depicted in the figure at 1:500 serum 
dilution, two out of three individuals’ VF reactivity is higher than that of other pathogen 
groups of peptides. This suggests that the 1:500 serum dilution as previously optimized 
for this assay is appropriate to allow cognate pathogen antibodies to bind their target 
pathogen peptides under thermodynamic conditions optimized for this assay. 
 
Figure 5- 10  WNV Patients sera processed at three dilutions on PPP-15. 
The average signal per pathogen groups of peptides is plotted on the Y-axis. Two WNV 
infected individuals sera at varying antibody dilutions are presented in panels A and B. 
The average signal per pathogen groups of peptides is plotted with WNV group antibody 
signal highlighted in red and Influenza PR8 group antibody signal highlighted in green. 
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Figure 5- 11 VF Patient sera processed at three dilutions on PPP-14.  
Three VF infected individuals at varying antibody dilutions as listed in the figure are 
plotted in panels A, B and C. The average signal per pathogen group of peptides is 
plotted on the Y-axis with signal from 83 VF epitope peptides averaged together and 
highlighted in red.  
Taken together these observations indicate that, increasing the concentration of 
serum on the platform is not sufficient to retrieve cognate infection reactivity from 
competing influenza peptides. Including influenza peptides might compete for the 
antibody response captured by priority pathogen peptides on the PPP array. Antibody 
binding data obtained from arrays containing influenza peptides would be impossible to 
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re-attribute to the original infection using the eight statistical metrics developed for data 
analysis likely requiring bioinformatic intervention.  
Defining the umbrella of antibody reactivity observed on the pathogen array 
Using standard statistical metrics previously designed for this assay, the pathogen 
peptide ranking system failed to classify priority pathogen infection on an array including 
influenza peptides. The cross-reactivity observed on this assay might be likely 
attributable to short, identical amino acid sequences in common between influenza 
peptides and other priority pathogen peptides. As attempted earlier by Ulrich et al. [92], 
we utilized the pattern of cross-reactivity due to short, identical amino acid sequences in 
common between unrelated pathogens to re-attribute cross-reactivity observed towards 
influenza peptides. A regular expression search algorithm developed by Richer et al. 
[153] was used to select the most statistically significant n-mers per individual patient 
based on averaging signal intensities above background (>500 FIU).  
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Table 5- 3 displays the results from using the pattern of number of 2-7mer 
epitopes in common between individual patients classified using SVM with leave one out 
cross-validation (LOOCV). The classification method is applied to all three versions of 
the array. Panel C shows the recovery from cross-reactivity and incorrect infection 
assignment when using SVM to classify samples based on n-mer commonality. 
  
 200 
 
Table 5- 3 SVM (LOOCV) results from PPP-15 using the n-mer analysis for 
classification 
A.) Infections tested on 
PPP-12 
Total 
samples 
No. correctly 
classified 
%Correctly 
classified 
Malaria 3 0 0 
ASFV NA 
Not 
processed, no 
peptides NA 
WNV 5 4 80 
LVS 5 1 20 
Vaccinia NA 
Not 
processed, no 
peptides NA 
VF 6 6 100 
    B.) Infections tested on 
PPP-14 
Total 
samples 
No. correctly 
classified 
%Correctly 
classified 
Malaria 2 0 0 
ASFV 4 4 100 
WNV 6 6 100 
LVS 5 1 20 
Vaccinia 5 4 80 
VF 3 2 67 
 
 
C.) Infections tested on 
PPP-15 
Total 
samples 
tested 
No. correctly 
classified 
%Correctly 
classified 
Malaria 3 1 33 
ASFV 4 4 100 
WNV 6 5 83 
LVS 3 1 33 
Vaccinia 5 5 100 
VF 3 3 100 
Influenza 5 5 100 
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Due to comparing the count of unique 2-mers, 3-mers through 7-mers in common 
within individual patients, the fundamental assumption of independence among features 
required for using machine learning algorithms like SVM is not violated. The n-mers in 
one individual are compared to the n-mers in another completely independent individual. 
Using n-mer umbrella classification arrays containing influenza virus peptides, PPP-15, 
showed 100% correct classification for ASFV, Vaccinia, VF and Influenza samples. This 
method was able to partially recover the accuracy of this assay to detect WNV, 5/6 sera 
correctly detected 83% correct. The WNV infected patient serum set contained one 
patient whose sera was part of a longitudinal seroconversion panel from SeraCare (PWN-
901) [159]. On day 0 time point of this panel when the patient was still sero-negative on 2 
different standard WNV EIA tests (Focus IgG, IgM and PANBIO IgG, IgM) for IgG & 
IgM and the Taqman RNA was <30 copies/ml, it was accurately detected on the PPP-15 
array as having WNV using n-mer umbrella classification.  This demonstrates the utility 
of such an n-mer approach in sensitively classifying disease. LVS and Malaria sera tested 
however could not be accurately detected (1/3 sera correctly classified).  
Discussion 
My goal in this study was to increase the accuracy of the multiplexed PPP array 
and test its limitations. For de-convoluting whether or not the addition of common 
exposure pathogen peptides on PPP array improves the accuracy of detection of the 
priority pathogen, three versions of arrays were made with incremental addition of 
common exposure pathogen peptides. Initially we created a pathogen proteome peptide 
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array representing 12 priority NIAID categories A, B, C pathogens (PPP-12) and tested 
sera from 4 exposures (VF, WNV, Malaria and F. tularensis LVS) to discern the 
predictive potential of such a system. VF and WNV out of the four exposures tested 
could be successfully distinguished using cognate peptides from those pathogens. We 
added ASFV and Vaccinia peptides to this existing array (PPP-14) and re-tested its 
accuracy at discerning 6 exposures apart. VF, ASFV, WNV, and Vaccinia could be 
distinguished with AUC-ROC >90%. There was moderate improvement in the AUC for 
F. tularensis and Malaria exposures as compared to the previous 12 pathogen peptide 
platform. It was estimated that the addition of Vaccinia and ASFV pathogen peptides 
represented sufficient double stranded DNA virus related peptides to be able to capture 
Herpes virus related reactivity. The hypothesis was that the addition of common pathogen 
peptides might improve the accuracy of distinguishing priority pathogen exposure. This 
was tested by processing Herpes virus infected patient sera on the array to observe cross-
reactivity with ASFV and Vaccinia and several other pathogen peptides on the array 
despite not directly representing any Herpes virus specific peptides. To test this concept 
further, PR8 influenza peptides were added to this 14 pathogen array (PPP-15) given that 
the H1N1 PR8 strain overlaps significantly with other human influenza virus vaccine 
strains. The addition of influenza peptides significantly reduced the ROC-AUC of 
detecting priority pathogen specific antibody response on the multiplexed PPP array.  
The arrays without influenza peptides showed the best ROC-AUC classification 
accuracy. The addition of influenza peptides to the array resulted in adversely affecting 
the detection capability of the platform for exposures such as WNV, Vaccinia, F. 
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tularensis and Malaria. VF, ASFV and Influenza reactivity was not adversely affected by 
the addition of Influenza peptides. Cross-reactivity to influenza within VF, WNV, LVS 
exposure patient sera was confirmed on a PR8 ELISA. Several special pathogen free 
naïve mice also showed PR8 cross-reactive antibodies in an ELISA before being 
experimentally infected with PR8. Since antibodies cross-reactive to influenza were 
found to be present in un-related pathogen exposures, it was deemed best to avoid 
including influenza peptides within a priority pathogen array so as to maintain its ability 
to discern multiple priority pathogen infections apart. One strategy to improve the assay’s 
detection ability was to remove cross-reacting common pathogen representing peptides. 
An alternative strategy would be to develop a bioinformatic analysis pipeline that would 
discern the appropriate cognate infection while circumventing the cross-reactivity 
observed on the assay. 
In order to delineate whether or not changing the peptide diversity on the array 
lead to significantly different antibody binding, an artificial infection sera, including eight 
well-characterized monoclonal antibodies, was processed on each array. Change in 
peptide diversity significantly altered the binding pattern observed on the platform 
between PPP-12, 14 and 15 as depicted by Figure 5-8 panels A, C and E. Monoclonal 
antibodies to linear peptide epitopes not directly related to influenza epitopes appeared to 
bind influenza PR8 peptides. The presence or absence of influenza polyclonal antibody 
component within the mix of 8 monoclonal antibodies did not have a statistically 
significant contribution to directing the binding observed on the assay in contrast to the 
effect observed by adding or removing influenza peptides.  
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One explanation for the observed change in binding after adding influenza 
peptides could be that on an amino acid frequency level, influenza, unlike any other 
pathogen represented on the assay has a greater frequency of the negatively charged, 
glutamic acid within their proteome. And while this difference in amino acid frequencies 
might not be significantly high, it appears to be enough to redirect other pathogen 
antibody reactivity and even unrelated monoclonal antibodies to influenza peptides. The 
charge on an antigen is known to increase non-specific cross-reactive binding in 
immunoassays [160]. Herpes viruses, for example, have more Arginine’s (positively 
charged amino acid) in their proteome as compared to any other priority pathogen tested 
on this array. For the purpose of this study though, it is empirically evident that exclusion 
of influenza peptides from a multiplexed assay designed to distinguish multiple priority 
pathogen infections might be an appropriate strategy to accurately detect priority 
pathogen infection. 
A bioinformatic strategy was implemented to trace the original groups of 
antibodies generating the signature response on the array, thereby de-convoluting the 
cross-reactivity observed. We ignored existing peptide annotations obtained from amino 
acid position within pathogen proteomes and instead re-analyzed the datasets based on 
signal intensities of ‘umbrellas of antibody reactivity’. The ultimate goal was to generate 
an algorithm capable of bioinformatically discerning the umbrellas of antibody reactivity 
observed on the assay despite apparent cross-reactivity allowing distinction of the correct 
infection/antigen (exposure) regardless of changes in the platforms peptide diversity. This 
strategy aims to delineate the antibody n-mer umbrella of reactivity per infection, 
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measuring how many n-mers overlap within individual patients and using those set of 
infection specific umbrella patterns to de-convolute the original infection. This strategy 
of counting the number of occurrences of a given n-mer or string to create a mathematical 
signature which could then be used to classify data is typically used in natural language 
processing for example, when creating e-mail spam-filters [161]. The signature response 
represents the number of n-mers in common per patient with a given infection versus all 
other infections. All individuals having a given infection have a specific pattern of 
overlapping n-mers in common with individuals having other infections and thus based 
on the extent of overlapping n-mers, get classified into a specific infection group. The 
antibodies from infected individuals and therefore, high signal intensity peptides they 
bind on PPP array as well as n-mer umbrellas observed within individuals sera having a 
given exposure are not always the same for all individuals having that exposure. This 
individual variation in immune response for one infection could be explained by the 
observation that immunizing animals experimentally with the same antigen yields 
antibodies reacting to different epitopes within that antigen per individual animal within 
the group [162].  
Representing the complete proteome of a pathogen ensures accurate detection on 
the assay. While this trend has been observed for small viruses such as WNV and 
Influenza on PPP array, it is yet to be tested for larger pathogens in a multiplexed format. 
The assay has tremendous utility if all known encephalitis viruses are represented on it, 
as it would reduce the need for central nervous system infection diagnosis requiring 
invasive procedures such as lumbar puncture. Given the limited diagnostic algorithms 
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applied to this data, it might be best to avoid inclusion of common pathogens such as 
influenza alongside priority pathogens. In conclusion, the addition of influenza virus 
peptides, to the PPP array does not improve its diagnostic ability.  
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Supplementary Information 
Supplementary Table 5- 1 Monoclonal and polyclonal antibodies used on PPP array 
Antib
ody 
Name 
Protein 
Target 
Ab 
Clon
e 
Epitope Epit
ope 
Len
gth 
(aa) 
Sourc
e  
Cat # Hos
t 
Spe
cies 
Isoty
pe 
Monoclonal antibodies to linear epitopes 
FLAG 
KAX71_P
ANIM 
Potassium 
channel 
toxin 
alpha-KTx 
7.1 
F-
tag-
01 DYKDDDDK 8 
Novus 
Biolog
icals 
NB500
-554 
Mou
se IgG1 
P53Ab
1 
P53_HUM
AN 
Cellular 
tumor 
antigen 
p53  
pAb2
40 RHSVV 5 
Millip
ore 
CBL40
4 
Mou
se IgG1 
[Leu5]
-
Enkep
halin 
PDYN_H
UMAN 
Proenkeph
alin-B  
1193/
220 YGGFL 5 
AbD 
Serote
c 
4140-
0159 
Mou
se IgG1 
P53Ab
8 
P53_HUM
AN 
Cellular 
tumor 
antigen 
p53  
P53A
b8 SDLWKL 6 
Therm
o 
MA1-
19055 
Mou
se 
IgG2
b 
DM1
A 
TBA1A_H
UMAN 
Tubulin 
alpha-1A 
chain 
DM1
A AALEKD 6 
Millip
ore 05-829 
Mou
se 
IgG1
kapp
a 
Biotin 
BiotinMim
ic - 
SGGGPCHPQ
FPRCYA 15 
Santa
Cruz 
Biotec
h 
sc-
101339 
Mou
se IgG1 
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cMyc 
MYC_HU
MAN Myc 
proto-
oncogene 
protein 
9E-
10 
EQKLISEED
L 10 
AbD 
Serote
c 
MCA2
200G 
Mou
se IgG1 
V5 
V_SV5 
Non-
structural 
protein V  
SV5-
Pk2 
GKPIPNPLL
GLDST 14 
AbD 
Serote
c 
MCA2
892 
Mou
se IgG1 
         Influenza polyclonal antibodies 
HA 
Influenza 
A 
PR8(H1N1
) HA 
IC5-
4F8 native HA 565 
BEI 
Resou
rces 
NR454
2 
Mou
se 
IgG3
.k 
NA 
Influenza 
A 
PR8(H1N1
) NA 
NA2-
1C1 NA-tetramer 454 
BEI 
Resou
rces 
NR454
0 
Mou
se 
IgG1
.k 
NP 
Influenza 
A 
Okada(H2
N2) 
nucleoprot
ein C43 
nucleoprotein 
498 
Abca
m 
ab1281
93 
Mou
se 
IgG2
a 
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CHAPTER 6 
CONCLUSION 
Coccidioidomycosis 
The first cases of Valley Fever (VF) were observed in agricultural workers from 
central California in 1890’s. In 1892, a physician named Alejandro Posada, diagnosed the 
cutaneous inflammation in an Argentinian soldier originally misdiagnosed as cancer as 
instead emanating from an infectious source, Coccidioides [163,164]. The infection 
initiates post exposure of hosts to spores namely, Arthoconidia. The weaponization 
potential of Coccidioides (Lethal Dose LD50, 300 arthroconidia in non-human primates) 
is greater than that of Bacillus anthracis (LD50, 8000 spores in monkeys), which was 
why it was included in the NIAID Priority pathogen list [165]. Johnson et al. [63] 
estimated that a single arthroconidia was sufficient to cause in infection in mice. Between 
1 to 10, arthroconidia are sufficient to establish infection in humans [166]. Once infected 
the arthroconidia convert into spherules with sizes ranging from 3 µm [167-169] to 200 
µm [170] with the largest recorded at 262 µm [171]. The size of the spherule depends on 
the immune status of the host, with observable differences in C57BL/6 VF susceptible 
mice versus resistant mice to Coccidioides, Swiss-Webster [169]. Galgiani et al. 
documented that spherules sizes observed in-vitro (80-100 µm) were smaller than those 
observed in vivo [172]. The size of B and T cells typically ranges between 7-10 µm in 
diameter and that of antigen presenting cells such as dendritic cells and macrophages is 
between 10-22 µm [173] rendering them partially ineffective when responding to larger 
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spherules. Given that the immune machinery of hosts is severely overwhelmed by this 
pathogen, early detection of disease is crucial to facilitate appropriate anti-fungal 
treatment. Newer drugs like Nikkomycin Z have shown promising results in murine 
models by eradicating infections if given 5 days post-exposure [174] and also in dogs 
[175].  
The recovery rate of this fungus from blood unlike Mycobacterium tuberculosis is 
very low, 0.4% i.e. 20 out of a total of 5,026 samples (6-year retrospective study); 
making direct pathogen detection based diagnostics less sensitive [65]. To date, 
depending on the site of primary infection and symptoms manifested due to this disease, 
the presumptive differential diagnosis can include everything on the spectrum from 
cancer (fungal granuloma/swollen lymph nodes), arthritis (joint pain), community 
acquired pneumonias such as tuberculosis (lung nodule/patch, respiratory distress), 
psychological distress/ depression (meningitis) to chronic fatigue syndrome (chronic 
muscular pain). Early detection of VF infection would also help obviate unnecessary 
costs associated with incorrect differential diagnosis.  
Development of a microarray diagnostic that exceeds existing diagnostic standards 
Developing higher sensitivity assays often comes at the cost of specificity. After 
selecting random peptide features for the valley fever diagnostic sub-array, we learnt that 
using as broad a training dataset representing as many confounding conditions during 
feature selection was crucial to maintaining high assay specificity. The ‘VF-diagnostic’ 
sub-array (Chapter 2) is a 100% sensitive diagnostic and could be used in combination 
 211 
 
with the higher specificity immunodiffusion (IDCF) and enzyme immunoassays (EIA) 
for differential diagnosis of disease [164]. The comparison of natural epitopes to non-
natural mimotopes has been reviewed on multiple occasions both structurally and 
informatically [31,89,176]. Chapter 3 shows an empirical comparison of life-space 
epitopes versus non-natural sequence peptides in the context of a diagnostic assay. Life-
space VF epitope peptides show higher specificity when distinguishing VF from LVS and 
normal, but random peptides show higher sensitivity. An interesting aspect of this work 
was the di-peptide modulation suggested to improve the accuracy of the Smith-Waterman 
[33] local alignment algorithm in a sequence alignment program, GuiTope [34]. This 
observation was made when de-convoluting why random VF predictor peptides 
performed with higher sensitivity than VF epitope peptides. GuiTope found several short 
sequence motifs in common between random peptides and VF antigens. The frequencies 
of di-peptides within a given protein, have been used to classify them into functional 
protein families [85], for designing tumor homing peptides, anti-cancer peptides 
[177,178] and designing cell penetrating peptides [179]. Rubenstein et al. [180] and Sun 
et al. [89] while characterizing epitopes noticed cooperativeness of certain di-peptide 
pairs as being observed at a higher frequency within epitopes as compared to non-epitope 
regions on antigens. Inverse-docking also known as ‘target fishing’ has been 
informatically viable when applied in molecular docking software for searching ‘target-
like’ structures [181]. The high binding associated with short sequences having di-peptide 
inversions in common between life-space VF antigens and VF-predictor random peptides 
is empirical proof of the viability of the inverse-docking approach.   
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Bioinformatic analysis of pathogen proteomes toward the development of a 
multiplexed life-space peptide microarray diagnostic 
While creating a multiplexed pathogen proteome peptide array (Chapter 4), our 
work assessed the various informatics strategies applied for epitope mapping. A T-cell 
epitope typically ranges in length from 8-12 amino acids [182] and  linear B-cell epitopes 
range from 4-12 amino acids [88]. A conformational B-cell epitope is estimated to 
contain 3-mer (60%) to 5-mer (85%) linear stretches involved in epitope-paratope 
binding [99]. While selecting the epitopes to be represented on the multiplexed PPP 
array, for larger pathogens we represented protein antigens predicted to be surface 
proteins (ASFV) or empirically documented to be immunodominant (IEDB). For some 
small viruses such as WNV, we represented the whole viral proteome. Given that the 
human population has >3000 different MHC alleles [183], it might be prudent to 
represent every pathogen using their whole proteome to enable accurately capturing 
individual variance in antibody response to an infection. Whole proteome based protein 
microarray experiments performed by Felgner et al. document that a small portion of the 
pathogen’s proteome is immunoreactive (~26%, Vaccinia) [109]. Due to the fine 
resolution obtained when using peptide microarrays as compared to using protein 
microarrays, it is very likely that no a priori selection of immunodominant or surface 
antigens was necessary. This concept however might need additional testing using larger 
patient serum sets and pathogen peptide groups to specifically compare whole proteomes 
peptides versus partial proteome peptides ability to capture infection specific immune 
response in a side by side comparison. In our comparison, the immunodominant antigen 
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peptides (partial proteome) were sufficient and capable of capturing and distinguishing 
infection specific response from other pathogen peptides. The multiplexed pathogen 
proteome array was capable of distinguishing 4 priority pathogen infections (VF, WNV, 
Vaccinia, and ASFV) apart simultaneously despite moderate cross-reactivity with greater 
than 90% ROC- AUC accuracy. 
Designing a multiplexed pathogen proteome peptide microarray – Future directions 
Although there was substantial measurable (and in many cases predictable) cross-
reactivity between host antibodies and peptide antigens, there were a number of non-
obvious causes for this observation on the PPP array.  Given the amount of cross-
reactivity observed, the discussion addresses a number of methods, both bioinformatic 
and biochemical, to ameliorate this seemingly intractable specificity problem.  Antigen-
antibody interactions observed on a multiplexed PPP array are a function of both the 
human patient sample being tested as well as the extensive overlap between natural 
pathogen sequences. The workarounds illustrate some important and quite fundamental 
aspects of physical characteristics of peptides, their presentation on the assay, and the 
intricate ways in which antibodies interact with them. 
While creating the multiplexed pathogen proteome peptide (PPP) array we printed 
the 15 pathogen peptides in no specific physical order together in a single array (Chapter 
4). Under thermodynamically optimized conditions to reduce cross-reactivity the array 
functioned with greater than 90% ROC-AUC at distinguishing 4 infections apart (VF, 
WNV, Vaccinia, and ASFV) simultaneously while it had 14 pathogen peptides. Upon 
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adding influenza peptides, the array’s ability to distinguish between influenza versus 
priority pathogen infection diminished. From this experience we concluded that creating 
multiplexed assays using pathogen epitope peptides and circumventing the cross-
reactivity observed to common pathogen peptides would require bioinformatic 
intervention in array design as depicted in Figure 6- 1.  
 
Figure 6- 1 Schema for designing a multiplexed pathogen proteome peptide microarray 
Initially, a pathogen proteome level comparison between all pathogens of interest 
to be included on the array would be necessary to estimate an obvious overlap based on 
protein sequences within phylogenetically related and unrelated pathogens (BLAST). 
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Using such an analysis, the cross-reactivity observed in Japanese, Dengue virus infected 
individuals to JEV could be explained [149]. Figure 6- 2 is a blast matrix generated by 
comparing the proteomes of various Flaviviruses using CMG-biotools [155]. 7 proteomes 
(7 X 7=49 comparisons, 96 total proteins) are compared through 7,886 BLAST searches 
using the 50% identity and 50% length match between compared fragments homology 
criteria. Between Japanese encephalitis virus, West Nile virus and Dengue viruses there is 
a significant proteome level overlap ranging from 12% to 100% and this might explain 
some of the cross-reactivity observed on immunoassays between these Flaviviruses 
[148]. 
 
Figure 6- 2 Blast matrix depicting proteome level overlap between the four main races of 
Dengue virus (reference proteomes) and WNV-I and II and JEV 
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A BLAST hit within the CMG-biotools program is considered significant (green) if at 
least 50% of the two protein sequences being compared are aligned and 50% of amino 
acids within the alignment are identical. The last row at the bottom of this matrix depicts 
homology within a given pathogen proteome under the strict BLAST search match 
criteria (grey to red scale).  
If significant overlap is observed between pathogen proteomes, those pathogen 
peptides could either be excluded from being multiplexed together or they could be 
printed on a physically separate sub-array such as that depicted in the 24-sub array format 
in Figure 6- 1. Additionally, each individual pathogen’s peptides could be printed 
separately within a sub-array on a single glass slide representing up to 24 pathogen 
proteomes. Alternatively, multiple pathogen peptides could be multiplexed together 
based on lack of obvious proteome level overlap allowing representation of more than 24 
pathogens on a single chip. In summary, when detecting Flaviviruses using pathogen 
epitope peptides, it might be advisable to print them on separate sub-arrays and process 
patient sera on them separately. 
Another example where a proteome level overlap analysis would be sufficient to 
explain lower specificity (46 - 97%) observed on an immunoassay is on the ToRCH assay 
[37].  
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Figure 6- 3  Blastmatrix showing ToRCH assay pathogen proteome overlap. 
Proteomes included: Toxoplasma gondii, Rubella, Chlamydia trachomatis, HSV-1, HSV-
2, HSV-3 and CMV. A BLAST hit within the CMG-biotools program is considered 
significant (green) if at least 50% of the two protein sequences being compared are 
aligned and 50% of amino acids within the alignment are identical. The last row at the 
bottom of this matrix depicts homology within a given pathogen proteome under the strict 
BLAST search match criteria (grey to red scale). 
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Figure 6- 3 summarizes 86 million BLAST searches generated from pathogen 
proteomes represented on the ToRCH assay using the Blastmatrix program in CMG-
biotools [155]. The figure summarizes a BLAST comparison of 9275 total proteins in 7 
proteomes (7x7=49 comparisons). From this comparison given that HSV-1 and HSV-2 
show greater than 94.7% proteome level overlap (50% identity, 50% length match 
criteria), it might be prudent to include them on separate sub-arrays to avoid cross-
reactivity. Despite printing pathogen proteomes showing a high level of proteome level 
overlap on separate sub-arrays, it is likely that infected individual’s sera might still 
display cross-reactivity to both sub-arrays. While they may still display cross-reactivity, 
the peptides of one pathogen will not be able to compete for reactivity from antibodies 
generated against another pathogen sharing multiple identical short peptides. A new data 
analysis pipeline would need to be developed from training on well-characterized serum 
samples to evaluate the extent of expected cross-reactivity. A probabilistic model based 
on log-odds ratios might need to be developed as has been done for the LLMDA 
(Lawrence Livermore Microbial detection array) [47,184] to estimate which infection, 
HSV-1 or HSV-2 or both is more likely based on prior empirical observations from sera 
for both infections respectively and co-infections processed on such an array. 
If there is no obvious overlap observed through a BLAST matrix analysis then an 
n-mer level analysis of overlap should be conducted on both a peptide level and between 
peptides and pathogen proteomes if representing partial proteomes. Given that B-cell 
linear epitopes range from 4-12 amino acids in length and a conformational epitope 
shows 3-mer to 5-mer contiguous contact points within the antibody paratope as 
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ascertained in structural studies, it might be appropriate to note the 3-12 mer overlap and 
exclude pathogens showing significant overlap or print their peptides on a separate sub-
array. A peptide to peptide comparison will allow a priori estimation of 3-mers to 12-
mers in common between genetically unrelated pathogens and expected cross-reactivity 
attributable to these short motifs.  
An example of the benefit of such n-mer short sequence level analysis can be 
provided using data from Andresen  et al [36]. They developed a 900 peptide microarray 
representing peptides from closely related Herpes viruses (HSV-1, HSV-2, CMV, EBV) 
and Hepatitis C virus. They observed specific reactivity to CMV and EBV peptides from 
infected sera tested for those infections. However they were unsuccessful at 
distinguishing these Herpes viruses apart from Hepatitis C infected sera due to broad 
cross-reactivity observed from HCV infected sera towards Herpes virus peptides. Figure 
6- 4 summarizes 173K BLAST searches generated using CMG-biotools representing 
pathogen proteomes from the Andresen et al. study. It represents a comparison of 416 
total proteins in 5 proteomes (5x5=25 comparisons). On a proteome level, there is no 
obvious overlap under stringent BLAST search criteria between HCV and the herpes 
viruses. However, on a 5-amino acid short sequence (n-mer) level, the extent of overlap 
between these proteomes is obvious as summarized in Table 6- 1, Panel A. As expected 
this 5-mer overlap diminishes when searching for identical 9-mers between these 
proteomes (Table 6- 1, Panel B). 
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Figure 6- 4 Pathogen proteome level overlap for pathogens represented in a multiplexed 
900 peptide microarray showing cross-reactivity in Andresen et al (2009).  
The pathogen proteomes included in this comparison are HSV-1, HSV-2, CMV, EBV and 
Hepatitis C. A BLAST hit within the CMG-biotools program is considered significant 
(green) if at least 50% of the two protein sequences being compared are aligned and 
50% of amino acids within the alignment are identical. The last row at the bottom of this 
matrix depicts homology within a given pathogen proteome under the strict BLAST 
search match criteria (grey to red scale). 
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Table 6- 1 Unique 5-mers and 9-mers in-common between pathogens tested on the 
Andresen assay 
A.) Unique 5-mers in 
common HSV2 EBV 
CMV-
HSV5 Hepatitis C  HSV1 
HSV2 36488 2212 2795 173 18833 
EBV 2212 38977 2556 144 2116 
CMV-HSV5 2795 2556 58960 169 2703 
Hepatitis C  173 144 169 3151 167 
HSV1 18833 2116 2703 167 36444 
 
B.) Unique 9-mers in 
common HSV2 EBV 
CMV-
HSV5 Hepatitis C  HSV1 
HSV2 38159 26 15 0 12186 
EBV 26 39939 11 0 24 
CMV-HSV5 15 11 60809 0 15 
Hepatitis C  0 0 0 3154 0 
HSV1 12186 24 15 0 37715 
 
From our own pathogen proteome peptide (PPP) array data, we observed cross-
reactivity to ASFV and Vaccinia peptides from Herpes virus infected individuals 
(Chapter 5). We also noted ASFV peptide cross-reactivity from Vaccinia vaccine 
recipient sera. This cross-reactivity to ASFV and Vaccinia peptides from herpes virus 
infections could not be explained on a proteome level overlap as depicted in Figure 6- 5. 
The Blastmatrix generated using CMG-biotools [155] compares proteomes of the 8 
known variants of herpes simplex virus with Vaccinia and ASFV representing 1294 total 
proteins comparisons (11X11) summarizing 1.49 million BLAST searches. The stringent 
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homology cut-off of 50% identity and 50% length match between query sequences was 
applied. HSV-1 and 2 showed 94.7% identity, HSV-3 showed 4.9% and 4.2% identity 
with HSV-1 and 2 respectively. The two HSV-6 strains showed 65.4% identity among 
themselves and HSV-6 and HSV-7 showed 28.3% (HSV-6 strain: U1102) and 32.6% 
(HSV-6 strain: Z29) identity. On a pathogen proteome protein level there is no overlap 
between ASFV and Vaccinia proteomes with Herpes virus proteomes.  
 
Figure 6- 5 Blast matrix depicting proteome level overlap between Herpes viruses 
(Herpesviridae) and other pox-viruses ASFV (Asfarviridae) and Vaccinia 
(Orthopoxviridae) 
A BLAST hit within the CMG-biotools program is considered significant (green) if at 
least 50% of the two protein sequences being compared are aligned and 50% of amino 
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acids within the alignment are identical. The last row at the bottom of this matrix depicts 
homology within a given pathogen proteome under the strict BLAST search match 
criteria (grey to red scale). 
This cross-reactivity could however be explained by annotating the high number 
of 5-mers in common between these double stranded DNA viruses belonging to distinct 
viral families. Table 6- 2 summarizes the number of 5-mer identical epitopes in common 
between ASFV, Vaccinia and all eight Herpes virus strains. Cells in the table are colored 
with red if the value is greater than 1000 identical 5-mers in common. On a 5 amino acid 
peptide motif level the number of identical unique 5-mers in common between all herpes 
viruses and ASFV ranged from 1,043 to 1,716. There are 1,140 to 1,846 identical 5-mers 
in common between Vaccinia and herpes viruses. Between ASFV and Vaccinia there are 
2,161 identical 5-mers in common. This implies that the probability of humoral 
antibodies generated against one herpes virus infection showing cross-reactivity with an 
identical 5-mer epitope within an ASFV or Vaccinia peptides is plausible. 
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Table 6- 2 Five mers in common between ASFV and Vaccinia proteomes (orange) and 
several Herpes viruses (yellow). 
 
Noting the peptide to pathogen proteome commonality is recommended because 
pathogen proteome space is extremely conserved resulting in overlaps within distinct 
pathogens. To assess if the extent of overlap between life-space pathogens versus those 
randomly generated, is greater than that possible by chance, pathogen proteomes 
matching the original size of the priority pathogens represented on the PPP array were 
generated in-silico using a custom script written in R. The amino acid frequency of 
priority and common pathogen proteomes was calculated using MEGA5 [185]. This 
amino acid frequency observed in life space pathogen proteomes, depicted in Table 6- 3 
was intentionally ignored while generating the random proteomes. The Blast matrix 
program within the CMG-biotools environment was used as before to assess the extent of 
overlap between pathogens due to random chance. There was no overlap observed within 
any of the randomly generated proteomes indicating that amino acid bias is essential for 
inter-pathogen overlap. 
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Table 6- 3 Amino acid frequencies in proteomes of priority pathogens and common 
pathogens 
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 When representing partial proteomes for larger pathogens, while certain peptide 
sequences may be excluded from the array they might be represented through another 
unrelated pathogen’s peptides. If an infected individuals sera shows antibody reactivity 
against these excluded motifs due to them being presented by the pathogen to their 
immune system, that might result in cross-reactivity. For antibody association on peptide 
microarrays short sequence identities are sufficient, but so is the context of presentation 
(surrounding sequence). The surrounding context within a peptide might be inhibitory to 
antibody association. If the context is not inhibitory, then from our experience with 
monoclonal antibody binding (e.g. p53Ab1) we have observed non-cognate reactivity. An 
analysis to estimate commonality between the peptides chosen to be represented on the 
assay and all pathogen proteomes of interest for the assay can help decide whether that 
pathogen’s peptides might need to be presented in a separate sub-array to avoid 
competition between peptides for antibodies. 
Cross-reactivity attributable to common exposures and vaccinations: 
Certain pathogen proteomes might have to be excluded when multiplexing 
priority pathogens on an epitope peptide microarray format to avoid observing residual 
memory antibodies from vaccinations or common infections. Miller  et al. [54] have 
demonstrated through their longitudinal study characterizing Influenza A and 
Cytomegalovirus (CMV) serum antibody in 40 individuals for 20 years that influenza 
antibodies capable of neutralizing the virus increase during the lifetime of an individual. 
CMV antibody titers on the other hand remained stable in the 15 out of 40 individuals 
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that tested positive for CMV in the first assessment. The duration of circulating 
antibodies to common exposure pathogens such as Varicella and Epstein Barr virus 
(EBV) or common vaccinations such as Measles, Mumps, Rubella (MMR vaccine), 
Vaccinia (small-pox vaccine), Clostridium tetani (Tetanus) and Corynebacterium 
diphtheriae (Diphtheria) measured by Slifka and colleagues [53] ranged with half-lives 
from 50 to 200 years and were short-lived for Tetanus (11 years) and Diphtheria (19 
years). Herpes simplex viruses are ubiquitous human pathogens that have a worldwide 
sero-prevalence in the population of up to 90% [186-188].  
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Figure 6- 6 Commonality on a 5-mer sequence level between priority pathogen 
proteomes and common pathogen proteomes such as Herpes viruses and influenza 
vaccine proteomes (highlighted in the legend in yellow).  
In context to the priority pathogens represented on the PPP array, Figure 6- 6 
represents the number of unique 5-mer sequences in common between the priority 
pathogen peptides and common pathogens. The common pathogen proteomes included 
for this analysis were eight herpes viruses and influenza vaccine strains (2006-2009) not 
intentionally represented on the array. The connectogram was generated using an online 
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tool, Circos [154]. The size of the ribbon represents the number of 5-mer sequences in 
common between peptides represented on the array and pathogen proteomes of priority 
and common pathogens. While the extent of overlap between common pathogens 
apparent on a 5-mer level is less in comparison to that observed between some unrelated 
priority pathogens it might be sufficient to drive competition on the assay. 
Thus, when developing extremely sensitive multiplexed pathogen specific assays 
the contribution and presence of these circulating antibodies to persistent common 
pathogens; common vaccinations and homologous pathogens cannot be neglected. To 
summarize this with respect to a multiplexed peptide microarray platform, the antibody 
response observed post exposure to a new priority pathogen could potentially have 3 
primary components. An adaptive immune response specific to the priority pathogen, a 
component representing specific reactivity to epitopes not represented on the array and a 
component representing non-specific, residual reactivity from prior exposure to a 
homologous or unrelated pathogen either part of a vaccination or persistent chronic 
infection. 
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APPENDIX I  
COCCIDIOIDES SPHERULES IN SERA  
INTERFERENCE IN MICROARRAYS – SUPPLEMENTAL FIGURES AND TABLES 
FOR CHAPTER 2  
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The recovery of culturable Coccidioides spherules from blood is 0.4% (n=5,026; 
0.4% = 20 samples) as per a retrospective study from processing 55,788 samples in a 
diagnostic lab in Phoenix (endemic for Coccidioides) [77]. The highest recovery rate of 
this pathogen through culturing techniques is directly from the primary site of infection, 
i.e. respiratory tract specimens is 8.3% (n=10,372; 8.3% = 861 samples).  Coccidioidal 
antigenemia to galactomannan [136] or coccidiodes specific antigens [189,190] has been 
detected in patient sera through ELISA’s for antigens and DNA using PCR [191].  
Fungemia [192] is a common feature of several fungal infections, but only observed in 
the disseminated form of Coccidioidomycosis [193].  The prognosis of these patients is 
poor with mortality rates up to 73% [194] Till date, 113 cases showing fungemia have 
been reported in literature as reviewed by Blair et al. in 2010 [195]. The detection of 
fungemia in Coccidioidomycosis is impeded due to physician’s not ordering the fungal 
blood culture assay or the assay not being performed in clinical laboratories with 
modifications providing higher recovery rates from blood [193]. One such modification is 
the lysis centrifugation system whereby, whole blood is lysed and centrifuged so that the 
microorganisms are released from polymorphonuclear leukocytes and the sediment is 
cultured on appropriate fungal culture media [193]. 
The spherules of Coccidioides range in size from 3 µm to the largest recorded in 
literature from a patient, 262 µm [171]. The following observation is the first report on 
Coccidioidal spherules-like objects observed in Valley Fever (VF) infected patient sera 
and the probable interference they might impose on antibody detecting peptide 
microarrays. Coccidioidal antigenemia in sera is reported to interfere with antigen 
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detection based assays yielding lower true positives. For example, in the MiraVista 
Diagnostic Coccidioidal anti-galactomannan antibodies were used to detect antigenemia 
in EDTA and heat treated sera (73.1% positive) versus untreated sera (28.6% true 
positives detected). In context to the peptide microarray, if Coccidioidal spherules 
capture VF infected individuals antibody, a protocol change allowing dissociation of 
circulating antigen-antibody complexes without degrading antibodies from VF infected 
sera might enhance detection of antibodies on our assay. 
I noted the presence of brightly fluorescent spherule-like globular objects when 
processing patient sera from VF infected individuals (Figure A1- 1, Figure A1- 2).  A 
summary of these incidental observations is presented in Table A1- 1.  The diameter of 
these N=15 spherule-like globules observed from 12 patient sera falls within the range 
observed in clinical samples with the exception of the larger spherules (290 to 
486µm).The size of these objects made it unlikely that they were T or B cells (7-10µm), 
Dendritic cells or Macrophages (10-22µm) Neutrophils (8-15µm) and Eosinophils (10-
12µm) [173] or auto-fluorescent human skin cells [196] from the stratum-corneum (34-
44µm) [197].  The spherule-like objects likely showed high fluorescence in both red 
(IgM-Median fluorescence intensity units (FIU) range: 6,237.5 to 50,358) and green 
channels (IgG-Median FIU range: 1,040 to 11,711).  These images were obtained during 
routine scanning of 1:500 diluted patient sera which was incubated on the VF diagnostic 
peptide sub-array and detected using anti-human secondary antibodies.  Such globular 
objects were not observed on slides when processing any other infected sera (West Nile 
Virus (WNV) infected human sera, F.tularensis Live Vaccine Strain (LVS) vaccinated 
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human sera, Normal human sera, African Swine Fever Virus (ASFV) infected swine sera, 
Influenza PR8 strain infected mouse sera, Vaccinia-Western Reserve strain vaccinated 
human sera) under similar microarray processing conditions.  
 
Figure A1- 1 A screenshot of a spherule-like object (Slide No. CNS00209) as captured 
using GenePix Pro on the VF diagnostic sub-array (slide surface: Aminosilane). 
The distribution of signal in fluorescence intensity (FIU) within the encircled area 
selected is depicted at a wavelength of 649 nm. 
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Figure A1- 2 A screenshot of a spherule-like object (Slide No. CNS00209) as captured 
within GenePix on the VF diagnostic sub-array (slide surface: Aminosilane) 
The distribution of signal in fluorescence intensity units (FIU) within the encircled area 
selected is depicted at a wavelength of 549 nm. 
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Table A1- 1 Summary of Spherules-like objects observed in VF infected individuals sera 
when incubated on aminosilane surface VF diagnostic sub-arrays.  
Signals depicted in Fluorescence intensity units (FIU). 
No. 
Patient 
No. 
Slide 
Num
ber 
Area-
GenePix 
estimate(
µm2) 
GenePix 
estimated 
Diameter 
(µm) 
Mean 
Signal 
FIU 
(649nm) 
Mean 
Signal 
FIU 
(549nm) 
Spherule-
like 
objects 
1 BL55  
(0-407) 
CNS0
0206 
78400 316 
39527 3184 
 
2 
32-555 
CNS0
0146 
21800 167 
13817 3016 
 
3 BL58  
(1-412) 
CNS0
0208 
44000 237 
31604 3842 
 
4 BL58  
(1-412) 
CNS0
0208 
21800 167 
21461 3034 
 
5 BL57  
(0-412) 
CNS0
0209 
96400 350 
47544 11011 
 
6 BL58  
(1-412) 
CNS0
0209 
29200 193 
26146 2568 
 
7 BL61  
(0-413) 
CNS0
0210 
29200 193 
22687 2814 
 
8 BL62  
(0-413) 
CNS0
0213 
73600 306 
25863 3040 
 
9 BL68  
(0-472) 
CNS0
0216 
166100 460 
25608 2690 
 
10 32-
1280 
CNS0
0149 
53600 261 
16971 2935 
 
11 BL49  
(0-391) 
CNS0
0201 
151700 440 
34247 6707 
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12 BL49  
(0-391) 
CNS0
0201 
185600 486 
24104 11521 
 
13 
2-7 
CNS0
0123 
35200 212 
11996 1602 
 
14 
64-607 
CNS0
0152 
66400 291 
25537 3474 
 
15 BL52  
(0-401) 
CNS0
0205 
38500 221 
32862 13208 
 
 
Several aspects of processing peptide microarrays are identical to pre-processing 
conditions applied in Immunohistochemistry (IHC).  For example, the peptide microarray 
slide surface used in this analysis was Aminosilane activated with SMCC (primary 
amines present on surface at a density of one free primary amine group ~ per 1nm).  In 
IHC cytospin protocols, cells are fixed on silanated glass slides [198].  The patient sera in 
this assay was diluted 1:500 in the standard microarray incubation buffer and incubated 
on the array at 37°C for 1 hour using the Tecan Pro automated hybridization station.  In 
IHC a short fixing protocol involves fixing the cellular material on plain glass slides for 
30 minutes to 1 hour at room temperature [198,199] or on a 37°C slide warmer.  
Fluorescent dye labeled anti-pathogen antibodies have been used for direct detection and 
differentiation of Coccidioides from other fungal pathogens in microscopy and IHC 
techniques [200].  The direct detection technique involves fixing the pathogen on a glass 
slide and detecting the pathogen with fluorescent dye labeled anti-pathogen serum.  The 
indirect detection technique involves fixing the pathogen on a glass slide, incubating 
patient serum on it and detecting the pathogen bound patient serum using an anti-host 
fluorescently labeled antibody.  The peptide microarray slides were scanned on a Perkin 
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Elmer ProScan Array HT microarray scanner (Melville, NY) in two channels, 633 nm 
(Red wavelength) and 543 nm (Green wavelength) at 10µm resolution.  This scanner 
scans slides from the top, slide-facing surface. The secondary anti-host (human) IgM and 
IgG antibodies are conjugated to fluorescent dyes, Dylight 649 and Dylight 549 
respectively. The microarray images included in this Appendix are from the PerkinElmer 
scanner, but were also scanned using the Agilent ‘C’ scanner (Santa Clara, CA).  The 
Agilent microarray scanner scans the back of the slide with excitation at 633 nm (Red) 
and 532 nm (Green) with 10µm resolution. 
Hypothesis 
In the red and green wavelength, we might be detecting fluorescence from the 
secondary anti-human IgM (5µ) and anti-human IgG (Fcɣ) antibody detecting the Fc 
portion of pre-bound IgM and IgG antibodies from the patient’s serum, on the spherule-
like object.  The fluorescence intensity estimated by GenePix in both red and green 
wavelengths is much higher than background fluorescence observed from these slides. 
This hypothesis could be tested by either culturing the pathogen from patient sera 
listed in Table A1- 1 or checking for fungal auto-fluorescence using UV illumination in 
fluorescence microscopy (serum sediment).  Fungi including Coccidioides spherules are 
known to auto-fluoresce upon UV illumination in the green wavelength [201,202].  This 
fungal auto-fluorescence has been used for diagnosis with a sensitivity of 97.8% and 
specificity of 100% (n=64) to distinguish Aspergillus, Candida and Zygomycetes cases  
in Hematoxylin and Eosin stained tissue sections from several tissue sites by Rao et al 
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[203].  A more sensitive confirmation could be made utilizing PCR to confirm the 
presence of DNA from Coccidioides in centrifuged patient serum sediment [191]  Given 
the paucity of accurate VF diagnostics and variability of symptoms, any approach 
enabling direct detection of VF is useful and is therefore documented in this report. 
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APPENDIX II 
SUPPLEMENTAL DATA FOR CHAPTER 3 – VALLEY FEVER EPITOPE 
PEPTIDES 
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The raw IgG and IgM antibody reactivities in FIU (Y-axis) captured by 83 life 
space epitope peptides representing 4 Valley Fever (VF) immuno-dominant antigens is 
plotted per peptide (X-axis) in these graphs. The 4 antigens were chitinase F (CF) [81], 
Expression Library Immunization Eli-Ag1 [83], Antigen 2 [82] and Coccidioides specific 
antigen (CSA) [84]. These data show the trend (bright red line) in humoral immune 
responses at various stages of Valley Fever infection from CF-Titer=0 (primary) to CF-
titer=256 (dissemination). The advantage of using peptide microarrays is their ability to 
separate each component of the humoral immune response to an infection/exposure. This 
high resolution is advantageous while evaluating whether or not certain VF proteins offer 
protection and could potentially be used as vaccine candidates against VF. For example, 
the signal sequence of Ag2 (amino acids 1-18) is known to be protective in BALBc (VF 
susceptible) mice upon immunization and challenge [204]. In our data as well, some VF 
patients display a high IgG antibody response to Ag2 peptides at the same amino acid 
positions (1-17, 13-29 and 25-41) in primary infection (CF-titer = 1, Figure A2-3). 
At all CF-titers (0, 1, 2, 4, 8, 16, 32, 64, 128, 256) the IgM graphs show higher 
binding than IgG data at multiple epitope sites displaying the breadth of IgM response. 
The IgM response might also be broad because IgM is a much larger molecule (36nm x 
4nm- planar disk) [205] as compared to IgG (20-40nm) [206,207] and is reactive to many 
VF epitope peptides in this solid phase assay (antigen peptide attached to solid slide 
surface). From our own experimental data however, we know that the specificity when 
using IgM data is lower than that obtained using IgG data for distinguishing VF versus 
normal (Table 3-2, Panel A) or VF versus non-VF (normal and LVS, Table 3-2, Panel B). 
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Thus it would be unlikely that IgM array data alone might be sufficient for diagnosis. 
This concept would need to be tested on a larger peptide microarray (>96 peptides). 
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Figure A2-1 IgG antibody reactivity captured on VF epitope peptides (83) from false-
negative CF-titer=0 patients sera (N=54).Each line on the graph represents antibody 
response from one VF sample. 
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Figure A2-2 IgM antibody reactivity captured on VF epitope peptides (83) from false-
negative CF-titer=0 patients sera (N=54) Each line on the graph represents antibody 
response from one VF sample. 
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Figure A2-3 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=1 patients sera (N=9). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-4 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=1 patients sera (N=9). Each line on the graph represents antibody response from 
one VF sample.  
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Figure A2-5 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=2 patients sera (N=15). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-6 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=2 patients sera (N=15). Each line on the graph represents antibody response from 
one VF sample.  
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Figure A2-7 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=4 patients sera (N=8). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-8 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=4 patients sera (N=8). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-9 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=8 patients sera (N=4). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-10 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=8 patients sera (N=4). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-11 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=16 patients sera (N=10). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-12 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=16 patients sera (N=10). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-13 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=32 patients sera (N=12). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-14 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=32 patients sera (N=12). Each line on the graph represents antibody response from 
one VF sample.  
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Figure A2-15 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=64 patients sera (N=5). Each line on the graph represents antibody response from 
one VF sample. 
 282 
 
 
 
Figure A2-16 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=64 patients sera (N=5). Each line on the graph represents antibody response from 
one VF sample.  
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Figure A2-17 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=128 patients sera (N=3). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-18 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=128 patients sera (N=3). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-19 IgG antibody reactivity captured on VF epitope peptides (83) from CF-
titer=256 patients sera (N=2). Each line on the graph represents antibody response from 
one VF sample. 
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Figure A2-20 IgM antibody reactivity captured on VF epitope peptides (83) from CF-
titer=256 patients sera (N=2). Each line on the graph represents antibody response from 
one VF sample. 
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SUPPLEMENTAL DATA FOR CHAPTER 4 
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1.) F. tularensis Vaccine Project: Overcoming ELISA limitations using the pathogen proteome 
peptide (PPP) array 
The pathogen proteome peptide (PPP) array was used to discern the antibody response 
generated from Francisella tularensis vaccinated rat sera. The study involved serum samples 
from the following 4 groups of immunized rats provided by our collaborators at the University of 
New Mexico as part of their Tularemia vaccine development consortium (TVDC) project: 
 Group 1 – Naïve rats 
 Group 2 – Francisella tularensis Live Vaccine Strain (LVS) vaccinated  
 Group 3 – O-Antigen mutant Francisella tularensis SchuS4 strain vaccinated 
 Group 4 – Immunized with 23 SchuS4 Proteins [Only 1 protein out of these 23 was 
represented on the PPP array, in the form of 30 non-contiguous peptides. The PPP array 
carried 862 Francisella tularensis SchuS4 peptides in total]. 
We anticipated significant differences in the antibody responses among these 4 groups 
based on observations through similar studies [208]. However, this serum set did not show 
statistically significant difference between Naïve (Group1) versus Vaccinated (Groups 2, 3, 4) 
when tested by ELISA. The limit of detection (LOD) of antibodies on peptide microarrays is 
between 0.5 to 2ng/ml, many-fold lower than an ELISA’s LOD, 7ng/ml [158,209]. Therefore, I 
attempted to use a more sensitive technology to be able to measure subtle differences in immune 
responses between these 4 different groups. I hypothesized that pathogen specific peptides fixed 
in a microarray format, such as the PPP array, would enable smaller differences in the immune 
response to be detected. As a proof of concept, Figure A3- 1 shows the antibody response 
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generated by individual rats within the 4 groups as captured using 862 F. tularensis (SchuS4) 
peptides on the PPP array.  
 
Figure A3- 1 Box plots of immune response from individual rats per group (X-axis) as captured 
on 862 F. tularensis (SchuS4) peptides printed on an array. The raw (un-normalized) 
fluorescence intensity units (FIU) are plotted on the Y-axis on a log scale. The line at the center 
of every box represents the median signal intensity for that individual rat. 
When these antibodies were measured by ELISA, all animal sera in each group were 
pooled.  However, here on the PPP array, Rat 1 in the Naïve set shows a higher antibody 
response as compared to other rats within the Naïve group. This disparity in immune response 
within animals belonging to the same group has been observed in other studies [162]. It is thus 
obvious through the use of a more sensitive technology such as the pathogen proteome peptide 
microarray that Rat 1 from the Naïve set might bias the observation in a pooled ELISA leading 
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to non-observable differences between the 4 groups. This assay could thus be used to trace 
underlying reasons for lower statistical differences between groups when pooling sera due to 
single outliers such as Naïve Rat 1 from Group 1. An appropriate analysis to estimate whether or 
not the response from the treated group is indeed statistically significantly different due to the 
treatment (vaccination or genetic immunization) as compared to Naïve would be to calculate the 
statistical differences between the mean responses of Naïve versus treated both with and without 
the outlier. Table A3- 1 summarizes the statistical differences between Naïve versus the 3 
immunization groups using data from PPP array FTT peptides. As expected, the whole pathogen 
vaccine LVS shows the most significant difference when compared to Naïve. However the 
average antibody response observed on vaccinating with the O antigen mutant SchuS4 strain 
(group 3) was lower than that of Naïve rats. In comparison the 23 protein immunization also 
shows a significant p-value over Naïve above cut-off 0.001. Protection data post-challenge might 
be more indicative of the impact of these three vaccination strategies on these groups of animals. 
Table A3- 1 Difference between immunization groups and Naïve sera using PPP array data 
Groups 
Mean 
Signal 
(FIU) 
Standard 
Deviation Variance 
p-value (single 
tailed, two-
sample 
unequal 
variance) 
Group 1 - Naïve 300 227 51565   
Group 2 - LVS Vaccine 701 694 481871 6.61E-305 
Group 3 - O Ag 
Mutant SchuS4 207 245 60038 7.08E-89 
Group 4 - 23 protein 
immunization 419 596 355696 8.57E-41 
 
p-value cut off = 1/n = 1/862 FTT peptides = 0.00116 
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A more informative set of peptides for completing this comparison should be ones 
representing the whole proteome of F. tularensis (SchuS4 and LVS). This would allow a 
comparison of antibody responses from individual animals vaccinated with the complete 
pathogens (LVS-Group2 or SchuS4-Group3) versus those that were immunized using 23 
proteins from F. tularensis (SchuS4)-Group4. These peptides should be printed on an array by 
themselves instead of within the context of other pathogen peptides. This would reduce 
competition on the array from other unrelated pathogen peptides for capturing Francisella 
specific antibodies as observed from the addition of influenza peptides to the PPP array in 
Chapter 5. 
Conclusion: The pathogen proteome peptide microarray can be used to segregate minor 
differences in the immune response generated from individuals within the same group. 
Additionally it also allows for more sensitive differences in antibody response between 
immunization groups beyond those observable through an ELISA. 
 
2.) ASFV Vaccine project: Mapping humoral response from genetic immunization using the 
PPP array 
The African Swine fever virus (ASFV) is a double stranded DNA virus from the family 
Asfarviridae. The disease infects wart-hogs, bush-pigs, domesticated pigs and ticks. 
Phylogenetically it is very closely related to the human infection causing viruses from 
Herpesviridae and Poxviridae (Variola-smallpox) families [40]. The swine sera were obtained 
from Dr. Linda Dixon at the Institute of Animal Health (IAH), Pirbright, UK and the primary 
goal of that project was to create a vaccine protective in domestic pigs against ASFV. It is a 
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priority pathogen of interest on the U.S Department of Agriculture (USDA) list [39] due to its 
ability to potentially infect humans [40].  
The following double vaccinia boosted, sera from 4 groups of six inbred pigs/group was 
obtained from IAH, Pirbright as follows:  
Group 1: Randomly selected antigens 1-20 + Vp30, Vp72 
Group 2: Randomly selected antigens 21-40 + Vp30, Vp72 
Group 3: 12 known surface antigens (including Vp30, Vp72) 
Group 4: Vp30, Vp72 
The above sera are part of a Genetic Immunization Screen (#2) to optimize the expression 
library immunization (ELI) [210] protocol for pigs. These animals were not challenged with the 
virulent strain of ASFV post-genetic immunization. Vp30 and Vp72 proteins in group 4 are 
immunodominant antigens of ASFV, as established by conventional ELISA and Western blot 
assays [107,211]. Immunization with these antigens produces neutralizing antibodies against the 
virus [108]. These proteins were included in every group as a genetic immunization control and 
their reactivity was measured in all sera by ELISA.  
We selected 299 peptides to print on the PPP array that represent antigens from group 3 
and group 4. Peptides representing all proteins in group 1 and group 2 would comprise 1000 
additional peptides required to complete this analysis. As an initial proof of concept that the 
peptide microarray is capable of accurately capturing ASFV specific antibody responses post-
genetic immunization, Figure A3- 2 displays the range of immune responses per individual 
animal using Box-Cox plots. Data for groups 1 through 4 immunized animals in comparison to 
one Day 0 sera from group 1 and the special pathogen free (SPF) out-bred ASFV infected and 
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uninfected pigs within the French cohort is plotted. The immune response mounted in all 4 
groups of genetically immunized animals as captured by 299 peptides is equivalent to that 
mounted in a real infection (French cohort) and captured by the antigens in group 3. All 4 groups 
were immunized using Vp30 and Vp72 which were included as peptides on the array, in addition 
to 20 other antigens in groups 1 and 2 and 12 additional antigens in group 3. 
 
Figure A3- 2 A simultaneous comparison of infectious (French cohort) versus genetic-
immunization (UK cohort) antibody responses as captured by 299 ASFV peptides on PPP array. 
The box-plot depicts raw (un-normalized) fluorescence intensity units (FIU) plotted per 
individual animal on the Y-axis using a log scale. The French cohort represents a separate 
experiment involving ASFV infected and uninfected out-bred pigs. One day zero (D0), pre-
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immunization sample and all day final – post-immunization (DF) samples from the UK cohort 
are presented on the X-axis.  
The Day 0 sample from swine no. 393 of group 1 had a higher antibody response even 
pre-immunization as expected than that of the 2 uninfected negative control SPF pigs in the 
French cohort. It was processed on the array to test whether it would be worthwhile to subtract 
the pre-immunization response of individual out-bred pigs (UK cohort) from their post-
immunized samples. The medians of antibody responses capture by the 299 ASFV peptides from 
group 3 and 4 protein immunized animals were comparably higher (except Day Final-DF pig 421 
from group 4) than the immune response observed from an infection (French cohort). 
Apart from Vp30 and Vp72, none of the 20 distinct antigens of group 1 or 2 were 
represented on the PPP array. As mentioned in Chapter 4, Supplementary Figure 4-3, the overall 
reactivity captured on PPP arrays from ASFV sera despite dilution (1:500) was much higher than 
that observed from any of the human exposures tested (VF, WNV, LVS, Vaccinia). Figure A3- 3 
shows a similar trend when using genetically immunized sera from groups 1 through 4.  The 
average signal obtained per individual swine sera in all 4 groups on the PPP array seems roughly 
proportional to the number of antigens they were exposed to per genetic immunization group (22 
constructs each in groups 1 & 2, 14 constructs in group 3 and 2 in group 4). The extent of cross-
reactivity observed from this assay to non-ASFV peptides was high due to the total antibody 
response captured despite processing these arrays under optimized thermodynamic conditions to 
reduce cross-reactivity (incubating sera for 16 hours at 23°C). 
 296 
 
 
Figure A3- 3 Average signal captured by PPP array for 4 groups of ASFV genetic immunization 
are depicted with every animal’s antibody response represented per bar on the X-axis.  
The background subtracted average raw (un-normalized) signal intensity data is plotted on the 
Y-axis. One Day 0 – pre-immunization (D0_393) and all Day Final – post-genetic immunization 
(DF) pig sera are depicted in these bar graphs.  
Once conditions for the genetic immunization of pigs were established through this 
experiment, and it was confirmed that the immunization led to both T-cell (Pirbright) and B-cell 
responses (ELISAs, PPP array-CIM), they were applied to the next two immunization regimes. 
Both immunization protocols contained a boosting step using recombinant Vaccinia viruses 
(rVV), each expressing an ASFV gene. A group of such recombinant Vaccinia viruses were then 
combined into a single inoculum and delivered to the animals 2 and 3 weeks post the gene gun 
immunization. Each recombinant Vaccinia virus containing one ASFV antigen was present at 
109pfu/dose. Each pig received 2 x 109 pfu/100µL dose of rVV. A summary of the steps involved 
in these genetic immunization regimes are as follows: 
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1. Day 0 & 2/3: Double prime + CPG adjuvant (left & right ear-5 gene gun shots) 
2. 2 Weeks later: DNA Boost + CPG adjuvant (left & right ear-5 gene gun shots) 
3. 3 Weeks later: 1st recombinant vaccinia boost (intra-dermal) 
4. 2 Weeks later: 2nd recombinant vaccinia boost (intra-dermal) 
Immunization Protocol # AR000158:  
Although Vp30 and Vp72 are immunodominant antigens for ASFV, there are 
confounding reports on whether or not groups of neutralizing antibodies generated against these 
antigens are sufficient to protect against challenge with a virulent ASFV strain. Barderas et al. 
have shown that immunization of pigs with a chimeric protein combining Vp30 and Vp54 
proteins was sufficient to protect them against a virulent ASFV isolate E75 challenge [106]. 
Neilan et al. immunized pigs with baculovirus expressed ASFV-pr4 isolate Vp30, Vp72, Vp54 
and Vp22 antigens and found that they did not survive post-challenge with the pr4 strain [108]. 
An experiment was conducted to isolate the effect of adding Vp30 along with the bin of antigens 
in all Groups. The rationale for this experiment was to test if Vp30 alone or in combination with 
Vp72 was responsible for the non-protective immune response as observed by Neilan et al. [108] 
Group A: all antigens from previous Groups 1, 2 and 3 [= 37 antigens including Vp30] (6 pigs) 
Group B: all antigens except Vp30 (6 pigs) 
Group C: no ASFV antigens, irrelevant antigens for challenge control-HA, AAT, gp160 (3 pigs) 
Post vaccination, pigs were intramuscularly challenged with 104 (50% hemadsorbing 
doses) HAD50/ml ASFV strain Georgia 2007/1 (Genotype-II).  None of these animals survived 
the challenge and had to be humanely euthanized on day 6 and 7 post-challenge. Collaborators 
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from IAH sent information on viral load estimated via PCR from blood and tissues (spleen, 
tonsil, mesenteric & gastro-hepatic lymph nodes) on the third day post-challenge. They also sent 
other clinical parameters such as weight gain in kg, temperature per individual and clinical 
scores based on the severity of disease symptoms manifested. Group A pigs showed moderately 
higher viraemia in blood on day 3 as compared to pigs from group B. Group C pigs showed 
higher viraemia as expected in comparison to groups A and B. All individual pigs in group A, 
showed higher weight loss as compared to weight gain observed in 4 out of 6 pigs in group B 
and 4 out 6 group C pigs. Normal body temperature in pigs is 38-39°C, and temperature of 
febrile pigs in the immunized groups A and B raised to greater than 40.5 two days post-challenge 
where as that of group C pigs became febrile three days post-challenge (except pig C5, febrile on 
day 2). A clear bifurcation in the distribution of viraemia in blood was observed between 
individual animals in all three groups. The sera for two pigs showing higher viraemia and two 
showing lower viraemia in blood per group were processed on the PPP array and data presented 
in Figure A3- 4.  
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Figure A3- 4 Humoral immune response as measured on PPP array from Group A, B, C pigs 
sera post-challenge with ASFV 
Average signal intensities in FIU (Y-axis) from animals in groups A, B and C (X-axis) as 
measured using ASFV (red bars) and Vaccinia (blue bars) peptides on the pathogen proteome 
peptide (PPP) microarray. The error bars represent standard error. 
Figure A3- 4 represents the average signal intensities from ASFV as well as Vaccinia 
(rVV boost) peptides as measured from capturing antibodies from individual pig sera. Pigs A5 
and A6 had lower viraemia as compared to pigs A1 and A2 and this seems to correlate with 
observing a marginally higher relative antibody response in pig A5 and a significantly higher 
response in pig A6 as compared to A1 and A2. Pigs B4 and B6 had lower viremia as compared 
to pigs B2 and B3 but the antibody response captured on the PPP array does not reflect a clear 
correlation between viraemia and antibody response. 
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Figure A3- 5 Signal intensities from ASFV peptides averaged per ASFV protein as measured on 
the PPP array from group A, B and C samples post-ASFV challenge.  
Figure A3- 5 represents the signal averaged for peptides per ASFV protein from 
individual animals in groups A, B and C. The control group C animals were not genetically 
immunized with ASFV antigens and still mounted a strong antibody response to challenge 
infection especially pig C1. Additional comparisons might be necessary to establish whether the 
PPP array platform can be used to correlate protection post-challenge. 
The Immunosignature non-natural sequence peptide microarray has been used to 
distinguish the outcome from different vaccine regimens [75]. The pathogen proteome peptide 
microarray could be potentially used for similar studies. Figure A3- 6 displays an individual 
pigs’ antibody response as captured by the PPP array from group A before immunization, after 
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immunization and post-challenge. Panel B displays an individual pig’s antibody response from a 
separate experiment, before and after immunization with an attenuated ASFV vaccine strain and 
post-challenge with ASFV Georgia/2007 strain. In both cases the antibody immune response to 
the challenge was lower as compared to that observed post-immunization. In Panel B, the 
recombinant vaccinia vector containing ASFV antigens was not used for boosting the immune 
response from the immunization and yet the peptide microarray captures cross-reactivity to 
Vaccinia peptides. Ideally, for mapping the protective response post-immunization and challenge 
the peptides for the complete ASFV viral proteome should be printed on a separate microarray 
by themselves and not within the context of other pathogen peptides as done here on the PPP 
array. 
 
Figure A3- 6 Average signal intensities in FIU (Y-axis) from various stages (X-axis) in two 
separate immunization and challenge regimes.  
Panel A displays the antibody response as captured by PPP array peptides representing ASFV 
(red bars) and Vaccinia (blue bars) peptides and Panel B displays the antibody response from 
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another pig immunized with the ASFV OURT88/3, attenuated vaccine strain. Both pigs were 
challenged with ASFV Georgia/2007 virulent strain. The error bars represent standard error. 
Despite the observable cross-reactivity when printing multiple pathogen peptides on a 
single assay, an advantage of using the PPP microarray is its ability to resolve linear antibody 
epitope within immunodominant antigens despite significant competition from several other 
unrelated pathogen peptides. Figure A3- 7 displays the significant epitopes within the 
hierarchical clustering map of Vp30. Figure A3- 8 displays Vp72 with a high resolution mapping 
of exactly which linear peptide segments the individual pigs were responding to post-challenge. 
 
Figure A3- 7 Peptides tiling Vp30 (ASFV127) an immunodominant antigen of ASFV displaying 
individual (X-axis) responses from sera on PPP array.  
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Every column represents one individual pig and every row represents one peptide within the 
ASFV127 protein. The coloring within this heatmap is based on median normalized signal 
intensities obtained from the microarray. Blue squares represent no antibody binding whereas 
yellow to orange represent moderate-high binding of antibody to those peptides on a relative 
scale as colored in GeneSpring GX 7.3.1 (legend on right). 
 
Figure A3- 8 Peptides tiling Vp72 (ASFV113) an immunodominant antigen of ASFV, displaying 
individual (X-axis) responses from sera on PPP array.  
Every column represents one individual pig and every row represents one peptide within the 
ASFV113 protein. The coloring within this heatmap is based on median normalized signal 
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intensities obtained from the microarray. Blue squares represent no antibody binding whereas 
yellow to red represent high binding of antibody to those peptides on a relative scale as colored 
in GeneSpring GX 7.3.1 (legend on right). 
Table A3- 2 summarizes the T-test p-value results reflecting statistical significance of 
groups A and B over control non-ASFV genetic immunization (group C) sera.  The p-value was 
calculated using antibody signal intensities captured using ASFV and Vaccinia peptides on the 
PPP array between groups A and B versus group C. Both groups A and B are statistically 
significantly different as compared to the control group (p-value cut-off = 0.001155). The mean 
antibody response post-challenge in group B is statistically significantly lower as compared to 
the control group C. The addition of Vp30 in group A resulted in statistically significantly higher 
mean antibody response as compared to animals in group C post-challenge.  
Table A3- 2 Summary of statistical differences between groups A, B and control group C post-
ASFV challenge. 
Groups Mean 
Standard 
Deviation Variance 
p-value 
(single 
tailed, 
paired) 
A 15718 16037 257172615 5.00099E-63 
B 7254 5173 26764966 1.0717E-106 
C 10370 7875 62020663   
p-value cut off = 1/no. of ASFV + Vaccinia peptides = 1/866 = 
0.001155 
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The protective ability of Vp30 however could not be assessed using this immunization 
regime as all pig’s perished post-challenge. It was estimated that the immune system of pigs in 
group’s A and B was likely overwhelmed due to the amount of DNA injected from 37 and 36 
ASFV genes respectively. An alternate protocol was therefore attempted with a balanced and 
reduced DNA load in immunization protocol # AR000302. 
Immunization Protocol # AR000302: 
Group A: 21 antigens (contains Vp30) 
Group B: 16 antigens approximately equivalent in DNA size to 21 antigens in group A. This was 
done so as to roughly normalize for the amount of genetic material used for immunization 
between Groups 1 and 2. 
Group C: no ASFV antigens, irrelevant antigens for genetic-immunization control-HA, AAT, 
gp160. 
None of the pigs survived post-challenge. Our collaborators from IAH sent us in-vitro T-
cell response to virus as measured by an IFN-ɣ ELIspot assay pre-challenge and post-
immunization and boost from Day 70. Pigs from group A (A3, A4 and A5) showed a higher T-
cell response as compared to those from groups B and C. This observation correlates with our 
antibody measurement using PPP array as summarized in Table A3- 3. Group A had a 
significantly higher mean antibody response as compared to the immunization control group C. 
The antibody response as measured in group B was not significant at the p-value cut-off of 
0.001.  
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Table A3- 3 T-test p-value from samples on Day 70 post-immunization and boost, pre-challenge 
as captured using ASFV and Vaccinia peptides on PPP array 
Groups  Mean 
Standard 
Deviation Variance 
p-value 
(single tailed, 
two-sample, 
unequal 
variance) 
A 22723 13140 172649302 1.74057E-42 
B 18316 11988 143704928 0.017567 
C 17575 15348 235549616   
 
p-value cut-off: 1/n = 1/866 = 0.001155 
 
Figure A3- 9 summarizes the results from measuring the antibody response on the PPP 
array. Day 70 is after the second live vaccinia-ASFV construct boost and one day before 
challenge. Day 76/77 is a time point post-challenge before these animals were humanely 
euthanized. The immediately observable trend from this data is that of lower signals on Day 
76/77 and this might be because these samples were severely hemolyzed and coagulated, making 
them unusable for this comparison.  
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Figure A3- 9 Signal intensities averaged per ASFV protein (N=12) tested in the form of peptides 
on the PPP microarray.  
Day 70 (post-immunization and one day pre-ASFV challenge) and Day 76 (post-ASFV 
challenge) sera per pig are depicted on the X-axis. The Y-axis displays the average raw (non-
normalized) signal intensities from background subtracted microarray data in FIU. 
In summary, the antibody response obtained from group A, pigs A1 and A3 were higher 
post-immunization and boost as compared to that obtained from group B pigs, not immunized 
with Vp30, except pig B5, and group C control pigs (except pig C3). Given that neither of these 
animals survived post-challenge, the protective effect of including Vp30 could not be isolated. 
Conclusion: The PPP microarray can be used to distinguish the immune response generated 
during various modulations of an immunization regime using genetic-immunization. Additional 
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sera need to be processed to compare if quantifiable differences in the immune response due to 
vaccination using an attenuated virus versus genetic-immunization could be accurately 
distinguished using the PPP array. 
3.) IVTT bead protein array–Rapid screening of immunogenic/immunodominant proteins 
The IVTT bead protein array is part of the MPID (Membrane proteins in Infectious 
diseases) grant. Performing in-vitro translation of proteins in the presence of uncoupled (without 
protein anti-tag antibody) tosyl-activated magnetic beads, results in binding of the membrane 
proteins to the beads. This is an irreversible hydrophobic interaction which allows the membrane 
protein to stabilize on the tosyl-activated bead surface. The beads containing proteins are printed 
onto aminosilane glass surface using sonication printing technology developed by Matt Greving. 
All proteins printed on the slide have the folding reporter green fluorescent protein (frGFP) 
construct integrated within their expression cassette. The frGFP construct was included to allow 
a quick quality control over the spotting and appropriate folding and presentation of these 
proteins by measuring the fluorescence from frGFP [excitation 490nm, emission 510nm [212]] 
under the blue wavelength (488 nm) on the Perkin Elmer ProScan Array HT microarray scanner 
(Melville, NY).  
Sonication printing protocols 
Three different print protocols were used for printing in the first print run so as to be able 
to optimize for the best printing conditions going forward. The array was initially printed with 13 
reagents, some proteins being captured on Dynabeads MyOne-1 µm diameter bead versus some 
on M280-2.8 µm beads from Life Technologies (Grand Island, NY) as listed: 
1.) frGFP LEE (Linear Expression Element) [213] #1 - MyOne 
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2.) frGFP LEE#2 - MyOne 
3.) ASFV113-F1 - MyOne 
4.) ASFV113-F2 - MyOne 
5.) FTT0583-frGFP - MyOne 
6.) FTT1258-frGFP - MyOne 
7.) GFP-HA in pET 32 - MyOne 
8.) Mock IVT (no template) – Negative control 
9.) My one beads – clean (no protein bound) – Negative control 
10.) frGFP LEE#1 – M280 
11.) frGFP LEE#2 - M280 
12.) ASFV113F1 - M280 
13.) GFP-HA in pET 32 - M280 
Out of the 13 reagents mentioned above, only proteins 3, 5, 6, 7, 12 and 13 were 
expressed and observed on a protein gel during pre-printing quality control. Reagents numbered 
8 and 9 are negative controls to allow estimation of background fluorescence from spots due to 
either the beads themselves or the IVT reagent mixture. All proteins represented on the array 
have the folding reporter GFP tag on them. The same calibration file was used for all 13 
solutions.  However sample 9 did not print consistently with these conditions in initial tests.  It 
was removed from the map and printed afterwards with a slight increase in energy onto the same 
slide. 
Slide 1: 400787 
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5µL of each bead-PBS buffer solution were placed in a 1536 well plate.  Each sample 
was laid out in a square pattern of 4 replicates. A dot pitch of 0.5mm was used, which is the 
distance between IVTT bead protein spots on array.  The samples were printed in a randomized 
manner with each well ejecting 10 times and hitting 10 different blocks of 4 in order to ensure 
even drying on the surface.  The rapid cycling through the sets of 13 samples was an attempt to 
ensure that the beads remained in suspension in the solution over the entire time of the print (~20 
minutes.) Slide 3 (400931) was printed using this same protocol. 
Slide 2: 400940 
The print plate from slide 1 was used for slide 2 and a pitch of 0.5mm was used for 
printing the slide.  However, in order to test the quality of the suspension over time, each sample 
was printed completely (~350 prints) before moving on to the next sample.  Additionally, each 
well was primed onto a disposable surface between each print on the final slide.  Visually this 
produced worse alignment of reagents on the slide as compared to slide 1. This might perhaps be 
due to the loading and unloading of the target plate. The plate map for the 0.5mm pitch is 
included in Figure A3- 10. 
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Figure A3- 10 Plate map for 0.5 mm pitch sonication printing protocol.  
The red and white squares in a ‘Z’ pattern show location of proteins expressed in IVTT on the 
array, green show the location of negative control and un-expressed proteins.  
Slide 4: 400941 
The slide was printed with a pitch of 0.75mm.  The printing was done with 5 prints from 
each source well.  Sample 9 printed slightly off target alignment but within register from the rest 
of samples.  This is most likely due to the unloading of the target for priming. The plate map for 
the 0.75mm pitch is included in Figure A3- 11. 
 312 
 
 
Figure A3- 11 Plate map for 0.75 mm pitch sonication printing protocol.  
The red and white squares in a number ‘1’ pattern show location of proteins expressed in IVTT 
on the array, green show the location of negative control and un-expressed proteins. 
For quality control, the arrays were screened using a polyclonal Rabbit anti-frGFP 
primary antibody and appropriate reactivity detected using a secondary Alexa Fluor 647 
conjugated antibody as seen in Figure A3-12, Panels A, B and C. In all four panels, the green 
spots are from bead-protein mixtures where the protein were not expressed and therefore the 
folding reporter GFP could not be detected with the anti-frGFP antibody. The orange-red 
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fluorescence is from the polyclonal rabbit anti-GFP antibody binding the GFP protein tag, 
detected using an Alexa Fluor 647 labeled anti-rabbit secondary antibody in panels A, B and C. 
In panel D the faint orange fluorescence from certain spots highlighted with white dotted lines is 
from the anti-mouse Alexa Fluor 647 labeled secondary antibody detecting mouse antibodies to 
cognate antigens used in immunization. The spot margins are much more regular at 0.75 mm 
pitch (Slide 4) instead of the 0.5 mm pitch (Slide 1, 2 and 3) The printing protocol used for Slide 
2 produced some brighter spots due to the same protein being printed on the whole slide (~350 
prints) first and then resuming other proteins sequentially. But the positioning of these spots was 
extremely irregular making alignment using the GenePix Pro (Molecular Dynamics, Sunnyvale, 
CA) program difficult. The signal intensities obtained from testing these 4 slides are represented 
in Table A3- 4 (Section A-D). 
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Figure A3-12  Anti-GFP antibody reactivity captured from translated proteins on IVTT bead 
protein array. 
Panels A, B and C show orange dots representing anti-GFP antibody recognizing the GFP tag 
on IVTT proteins on beads being detected by an Alexa Fluor 647 labeled secondary antibody. 
Panel D shows the anti-FTT583 protein polyclonal mouse sera detected using an anti-mouse 
secondary binding cognate bead-protein spots (highlighted using grey dotted squares).  
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Table A3- 4 Signal captured from slides included in the printing protocol comparison in 
Fluorescence intensity units (FIU).  
The count N represents the number of replicates printed & measured per reagent on a given 
slide.  
A.) Rabbit anti-GFP (polyclonal) - 5nM (Slide 1-400787, pitch=0.5 mm) 
Reagent 
No. Reagent 
Protein 
Expression Count(N) 
Min 
(FIU) 
Max 
(FIU) 
Mean 
(FIU) 
Median 
(FIU) 
1 
rGFP_LEE#1 
(MyOne) -ve 167 98 220 137 132 
2 
rGFP_LEE#2 
(MyOne) -ve 169 112 263 147 141 
3 
ASFV113-F1 
(MyOne) +ve 170 236 9952 2656 1721 
4 
ASFV113-F2 
(MyOne) -ve 176 104 268 138 136 
5 
FTT0583 in 
GFP 
(MyOne) +ve 171 859 18593 4142 3290 
6 
FTT1258 in 
GFP 
(MyOne) +ve 171 152 6416 1661 1032 
7 
GFP-HA-in 
pET32 
(MyOne) +ve 168 378 5045 1352 1111 
8 
Mock IVT 
(IVT 
reaction/no 
template) 
(MyOne) -ve 174 112 296 168 166 
9 
MyOne 
beads clean -ve 170 99 165 121 119 
10 
rGFP_LEE#1 
(M280) -ve 166 107 228 147 143 
11 
rGFP_LEE#2 
(M280) -ve 167 104 237 131 127 
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12 
ASFV113-F1 
(M280) +ve 174 139 4277 2096 1978 
13 
GFP-HA-in 
pET32 
(M280) +ve 172 203 1553 431 379 
        B.) Rabbit anti-GFP (polyclonal) - 5nM  (Slide 2-400940, pitch=0.5 mm) 
Reagent 
No. Reagent 
Protein 
Expression Count(N) 
Min 
(FIU) 
Max 
(FIU) 
Mean 
(FIU) 
Median 
(FIU) 
1 
rGFP_LEE#1 
(MyOne) -ve 305 123 378 203 201 
2 
rGFP_LEE#2 
(MyOne) -ve 312 132 405 201 200 
3 
ASFV113-F1 
(MyOne) +ve 312 518 16820 2812 1403 
4 
ASFV113-F2 
(MyOne) -ve 307 119 371 174 170 
5 
FTT0583 in 
GFP 
(MyOne) +ve 312 238 6064 2170 1637 
6 
FTT1258 in 
GFP 
(MyOne) +ve 312 331 8450 1702 1016 
7 
GFP-HA-in 
pET32 
(MyOne) +ve 312 342 8017 2123 1614 
8 
Mock IVT 
(IVT 
reaction/no 
template) 
(MyOne) -ve 305 127 338 171 166 
9 
MyOne 
beads clean -ve 300 111 318 197 197 
10 
rGFP_LEE#1 
(M280) -ve 308 135 290 204 203 
11 
rGFP_LEE#2 
(M280) -ve 313 0 376 204 200 
12 
ASFV113-F1 
(M280) +ve 312 741 41258 6338 4710 
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13 
GFP-HA-in 
pET32 
(M280) +ve 312 352 14723 2654 1658 
        C.) Rabbit anti-GFP (polyclonal) - 5nM  (Slide 4-400941, pitch=0.75 mm) 
Reagent 
No. Reagent 
Protein 
Expression Count(N) 
Min 
(FIU) 
Max 
(FIU) 
Mean 
(FIU) 
Median 
(FIU) 
1 
rGFP_LEE#1 
(MyOne) -ve 164 76 224 149 157 
2 
rGFP_LEE#2 
(MyOne) -ve 166 79 237 143 140 
3 
ASFV113-F1 
(MyOne) +ve 164 181 13491 2080 1632 
4 
ASFV113-F2 
(MyOne) -ve 164 76 208 139 143 
5 
FTT0583 in 
GFP 
(MyOne) +ve 164 217 18515 2623 1701 
6 
FTT1258 in 
GFP 
(MyOne) +ve 166 140 6143 1484 1391 
7 
GFP-HA-in 
pET32 
(MyOne) +ve 164 110 2657 673 561 
8 
Mock IVT 
(IVT 
reaction/no 
template) 
(MyOne) -ve 164 92 225 172 184 
9 
MyOne 
beads clean -ve 166 66 229 137 138 
10 
rGFP_LEE#1 
(M280) -ve 164 72 251 152 161 
11 
rGFP_LEE#2 
(M280) -ve 164 75 218 141 144 
12 
ASFV113-F1 
(M280) +ve 166 178 10222 2645 2383 
13 
GFP-HA-in 
pET32 
(M280) +ve 162 89 1777 434 344 
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D.) Polyclonal mouse anti-FTT0583 sera (1:500 diluted) - (Slide 3-400931, 
pitch=0.5mm) 
Reagent 
No. Reagent 
Protein 
Expression Count 
Min 
(FIU) 
Max 
(FIU) 
Mean 
(FIU) 
Median 
(FIU) 
5 
FTT0583 in 
GFP 
(MyOne) +ve 168 108 505 190 156 
 
On slide 1-400787 (Table A3- 4, Section A), from the maximum signal captured, MyOne 
bead-proteins showed higher signal as compared to M280 for 2 antigens ASFV113-F1 and 
Hemagglutinin (HA). This is an unexpected result given that M280 beads have a larger surface 
area as compared to MyOne beads. One reason why this might have happened could be due to 
lesser retention of M280 (larger) beads on the aminosilane surface as compared to MyOne beads 
during slide processing. Bead run-off before and after microarray processing would be difficult 
to estimate. Alternatively, the suspension time of beads in buffer during printing might be more 
important for M280 (heavier) beads. The effect of suspension time on beads is tested in Section 
B on slide 2-400940 whereby one reagent is printed on the complete slide before moving onto 
the second reagent. Here as expected M280 bead-proteins show higher signal intensity as 
compared to MyOne for both proteins ASFV113-F1 and HA. The quality of suspension 
decreases over time as observed when comparing intensities obtained from these two proteins 
between Section A and B. Higher sonication energy was used to deposit beads in slide 4 – 
400941 (Table A3- 4, Section C) to estimate if doing so would equalize the amount of deposited 
bead-proteins regardless of the bead diameter. Increase in sonication energy was sufficient to 
overcome the difference in spotting between M280 and MyOne bead-proteins and resulted in 
better spot morphology as compared to Slides 1 and 2. 
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We also probed the array with polyclonal sera from mice immunized with protein # 5 
(FTT0583) and protein # 6 (FTT1258). The overall signal obtained from polyclonal sera was low 
and very close to background as depicted in Figure A3-12, Panel D and Table A3- 4, Section D. 
This observation might be because polyclonal sera takes longer to equilibrate as observed from 
the pathogen proteome peptide (PPP) microarray in Chapter 4 and we only incubated the primary 
polyclonal sera for 1 hour during our initial test. Going forward, we would be testing polyclonal 
sera reactivity observed after 16 hours of incubation, which is recommended for protein 
microarrays [214].  
For the next set of experiments, I would recommend testing different slide surfaces and 
using the print protocol that was approved in this first round of comparison. Again quality 
control testing should be repeated using the polyclonal anti-tag antibody so as to decide which 
slide surface provides maximum retention of beads. This technology could potentially be used 
for screening proteins from a pathogen whose epitope peptides have not been empirically 
mapped in literature or the Immune Epitope DataBase (IEDB) to rapidly identify both 
immunoreactive and immunodominant antigens.  
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